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Abstract 
Acute inflammation is the innate immune defence against environmental disturbances. 
Macrophages are one of the central immune cells that react to infections and maintain 
tissue homeostasis, and they exhibit their functions via numerous inflammatory 
signalling regulators. In addition to previously identified immune mediators, novel 
proteins involved in inflammation continue to emerge. 
 
A previous cDNA functional screening in murine macrophages has identified a novel 
protein named transmembrane protein 203 (Tmem203) displaying pro-inflammatory 
characteristics. Tmem203-promoted inflammatory activities were found to be TLR 
independent but dependent on STING, a cytosolic innate immune adaptor for DNA 
detection. STING responds to upstream DNA sensors and microbial cyclic 
dinucleotides, and instigates type I interferon response via TBK1-IRF3 axis.  
 
The work in this thesis investigated the function of TMEM203 in STING-dependent 
type I interferon responses. TMEM203 has been found to colocalise, interact and 
migrate with STING. Further studies revealed a critical role for TMEM203 in STING-
dependent type I interferon response in both human and mouse primary macrophages. 
We showed that TMEM203-STING association was highly dependent on STING’s N-
terminal transmembrane domains. Finally, TMEM203 showed a distinct regulation of 
STING-interferon signalling between stimulation by natural and synthetic STING 
ligands, and this difference was also reflected in TMEM203-STING interaction. Thus, 
this novel mechanism of TMEM203-dependent STING regulation has brought new 
insights to better understand critical regulators of pathogen infections and interferon-
associated autoimmune diseases.   
 
Additionally, a brief research was conducted to explore STING regulation in flavivirus 
infected primary macrophages. Flaviviruses Dengue virus and Zika virus infect 
humans to cause global pandemics. Dengue virus is known to specifically and potently 
interrupt STING-interferon pathway. The emerging flavivirus Zika virus is genetically-
16 
 
closely related to Dengue virus and thus it has been hypothesised to adopt similar 
strategies in STING antagonism. We have investigated Dengue and Zika virus-
induced type I interferon stimulated ISG response in the M-CSF differentiated primary 
macrophage model, and tested the role of STING in such conditions. Contradictory to 
previous report, our experiments showed a potent and persistent ISG induction in 
virus-infected macrophages. Prior virus infections were unable to intercept ISG 
induction cause by STING ligands, whereas the downregulation of STING dampens 
virus-induced ISG response. Therefore, this primary macrophage model highlights 
alternative regulatory mechanisms via STING in response to Dengue and Zika virus.  
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Chapter 1: Introduction  
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1.1 Inflammation  
Inflammation is the response of the immune system to a variety of physiological 
disturbances, such as metabolic stress, damage, pathogen invasions, and 
senescence-associated cell and tissue failure. Our understanding of inflammation 
evolves with the discovery of novel diseases and the manifestations associated with 
them. Although inflammatory responses often result in irritations such as heat, pain, 
swelling, and sometimes the loss of mobility, it nonetheless has crucial roles in 
detecting, acting and restoring host immune homeostasis. The process of 
inflammation is evolved for two major functions, one is to limit infection by pathogens, 
predominantly bacteria and viruses, and another is to facilitate wound healing. The 
dysregulation of inflammatory response in diseases helped us to identify cellular and 
molecular components that composed the immune system and to understand how 
they are coordinated during disorders. Not only that the immune cells are capable of 
inflammatory activation, a variety of somatic cells are also able to respond to innate 
immune stimuli, including for instance endothelial and epithelial cells [1, 2]. 
 
The immune system can mount both the immediate innate response against stimuli 
encountered for the first time and the adaptive response to a recurrent challenge, both 
have been extensively reviewed in the past [3–6]. In comparison to adaptive immunity 
which protects host from a specific recurrent stimulus, innate immunity acts on a wide 
spectrum of antigens and the response is rapid and dynamic. Therefore, cells and 
molecules involved in an inflammatory response are diverse. 
 
Myeloid cells are important regulators of inflammation, amongst which the neutrophils, 
monocytes, dendritic cells and macrophages, are the most predominant contributors. 
Not only do they express and secrete inflammatory signals (mostly cytokines) during 
the response, their responses also help alerting the surrounding tissue and cells when 
danger and damage appears. Some myeloid cells are specialised in certain 
environment or a period of inflammation, such as the immediate and short-lasting 
action of neutrophils to early infections, but macrophages are present throughout most 
inflammatory activities. These cells can engulf invading bacteria, present antigens to 
cytotoxic effector cells, release cytokines to induce or suppress further inflammatory 
19 
 
responses, and even regulate lipid and nutrients metabolism to adapt to the changing 
environment [7, 8]. Thus, comprehending the role of macrophages in vivo enables us 
to study a number of human pathologies and to develop novel therapeutics. 
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1.2 Macrophages 
 
1.2.1 Macrophage Lineages 
The macrophage is a cell of complex origins. Contrary to the traditional view that 
macrophages combat infections in situ and therefore are supplied from the 
differentiating monocytes in the circulation, recent observations showed that there are 
two lineages of macrophages. One adopts the known mechanism of replenishing “old” 
macrophages from monocytes produced from the bone marrow, while some 
macrophages emerged with the tissue during embryonic development and their 
survival is independent of monocyte-derived macrophages [9, 10]. Tissue-resident 
macrophages adapt to the niche-specific environment and predominantly respond to 
on-site infections and the homeostasis of the tissue [7, 11]. For instance, the central 
nerve system macrophage microglia combat infections in the brain and are actively 
involved in neuroinflammation and the removal of degenerated or damaged neurons 
[12, 13]. A summary of macrophage development is shown in Figure 1. 
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Figure 1. Macrophage development.  
Macrophages are categorised as monocyte-derived macrophages (yellow box) or tissue 
resident macrophages (green box). A pool of replenishing macrophages arises from precursor 
monocytes generated from human bone marrows. During embryonic development, a pool of 
progenitor cells in tissues and organs have committed into macrophage development and 
become tissue resident.  
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Although microglia are a particular example to indicate the importance of tissue-
resident macrophages as the blood-brain barrier protects against acute inflammation 
and leukocyte infiltration, other tissue resident macrophages also acquired specific 
characteristics during evolution in the tissue environment. The skin macrophage 
Langerhans cell (LC) forms a “web of immunity” across the epidermis of the skin and 
connects the lymph nodes. Their functions include but are not limited to the 
surveillance and defence against pathogen invasions, immediate recruitment of 
immune cells, priming and differentiation of lymphocytes at the lymph nodes, and most 
importantly antigen uptake via LC migration between keratinocytes and the lymph 
node has been described [14–16]. Furthermore, the most abundant tissue-resident 
macrophage Kupffer cells in the liver sinusoids are highly responsive to release 
proinflammatory factors against infections in the digestive tract and have acquired a 
unique role in liver regeneration and scavenging malformed haemoglobin [17]. Other 
tissue-resident macrophages such as Osteoclasts in the bone and alveolar 
macrophages have additional functions in bone remodelling and surfactant clearance, 
respectively [18, 19]. Contributed by these resident macrophages, our tissues and 
organs can respond to danger signals rapidly and appropriately in physiological 
conditions. 
 
Apart from the well-portrayed tissue-resident macrophages, there are the type of 
“replenishing” macrophages which act in need and throughout human body. These 
macrophages are originated from the bone marrow –derived precursor monocytes in 
the blood circulation, which were differentiated into macrophages near the site of 
infection or injury. Human monocyte subsets are classified by their variation of CD14 
and CD16 expressions, as the classical type is CD14 positive CD16 negative 
(CD14++CD16-), intermediate is CD14++CD16+, and non-classical is 
CD14dimCD16++ [20]. In mouse, monocyte subpopulations are divided upon the 
expression of Ly6C (Lymphocyte antigen 6C) and CD43 (leukosialin), equivalent to 
the human markers CD14 and CD16 [21]. The population orthologues are the classical 
LyC6++CD43-, the intermediate LyC6+CD43++, and the non-classical LyC6+CD43++. 
Although all these monocytes can be differentiated into macrophages, the classical 
monocytes, comprise the large majority of total population (87%), are mainly 
responsible for replenishing macrophages in rapid response to inflammation and injury 
23 
 
[22–25], while the intermediate monocytes facilitate later inflammatory responses, and 
the CD16-high nonclassical monocytes aid immune surveillance [26].  
 
Whilst monocyte/macrophage development is affected by a mixture of stimulating 
factors, this transition predominantly relies on the presence of macrophage colony-
stimulating factor (M-CSF, also known as CSF-1) that is secreted by the blood/tissue 
stromal cells [27]. In contrast to the alternative method of GM-CSF macrophage 
differentiation which renders cells ability to activate the inflammasome complex and 
release interleukins and other proinflammatory cytokines [28], M-CSF differentiation 
method is widely applied in vitro for its advantage of yielding a consistent population 
of resting macrophages that uniformly express type I interferons to viral challenges 
[29]. Upon M-CSF -induced cell fate commitment, a negative feedback loop is initiated 
to reduce CSF receptor expression and the consequent cell proliferation [30–32]. 
However, macrophage proliferation is not completely abolished and its aberrancy is 
often associate with pathologies. A typical example of this is the chronic inflammatory 
disease atherosclerosis, where monocyte-derived macrophages (MDM) recruited to 
the damaged endothelial site continue to proliferate, uptake oxidised lipids and 
become foam cells in the atherosclerotic plagues [33–35]. 
 
Similar to human cells, mouse macrophages maintain the two lineages. While the 
tissue-resident macrophages arise during embryonic development, the circulating 
macrophages are differentiated from bone marrow -released monocyte-macrophage 
progenitor cells upon exposure to murine M-CSF. The Fibroblast L929 cells are a 
widely-applied model to produce M-CSF –containing medium for bone marrow-
macrophage differentiation in the laboratory [36].   
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1.2.2 Macrophage Phenotypes 
Independent of monocyte differentiation, macrophages also display pleiotropic 
functions during their activities in tissue homeostasis and are thus further categorised 
into physiological subsets or phenotypes. In a broader classification method, 
macrophages are either a cytotoxic/killing character (M1) or a repairing/growth 
character (M2) [37]. This “Fight or Fix” switch is achieved predominantly by metabolic 
modulation of arginine, where the inducible nitric oxide synthase (iNOS) is more active 
in M1 phenotype and arginase is more active in M2 (at least in murine models), 
therefore promoting the respective Th1 and Th2 inflammatory response [38]. While 
the metabolic pathway of M1/M2 transition discussed in reviews helps to identify the 
nature of macrophage [38–41], it is the associated gene expression profile that is most 
critical to our study of pathology. 
 
In the Th1 or “Fight” response, M1 macrophages respond to interferon-gamma (IFN-
γ), lipopolysaccharide (LPS), tumour necrotic factor-α (TNF), viral nucleic acids, and 
promote iNOS-dependent NO production and proinflammatory activation [42]. 
Establishment of M1 phenotype is indicated by the enhanced expression of cell 
surface receptors CD86, CD80, CD68, major histocompatibility complex II (MHC II), 
TLR2 and TLR4 [43]. In addition to these stimulants, M1 phenotype is mostly induced 
by microbial infections and aberrant cell death as a defence mechanism for biological 
threats. A wide spectrum of pattern-recognition receptors expressed by macrophages 
detect pathogen or danger –associated molecular patterns named PAMPs or DAMPs. 
Cellular dysfunction may give rise to DAMP signals by releasing intracellular 
molecules such as ATP and DNA which are detected by purinergic receptors on 
macrophage surface [44], or are internalised and recognised by cytoplasmic receptors 
such us Stimulator for Interferon Genes (STING) [45]. In terms of pathogens, a variety 
of macrophage PRRs detects pathogenic proteins, lipoproteins, nucleic acids, as well 
as antibody/complement-labelled or opsonised bacteria to intercept infections. From 
the literature, M1 macrophages are significantly affected and activated by the well-
known microbial infections including Mycobacterium tuberculosis, Listeria 
monocytogenes, Salmonella typhimurium, Staphylococcus aureus, Influenza virus, 
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Herpes simplex virus and Dengue virus [46–52], and their functions have recently 
been addressed in Zika virus pandemic [53, 54].  
 
Alternatively, the Th2 or “Fix” phenotype of M2 macrophages is responsible for 
repairing tissue damage and resolution of inflammation. Despite the debate on M2 
sub-classifications based on their functional statues, there are 4 agreed subtypes of 
M2 as group according to their gene expression profiles. M2a is stimulated by 
interleukin-4 (IL-4) and IL-13 (M2a), M2b is induced by IL-1 receptor ligands, immune 
complex and LPS, M2c is induced by glucocorticoids, IL-10 and transforming growth 
factor-β (TGF-β), and M2d is induced by IL-6 and adenosine [42, 55, 56]. These 
reviews have summarised the current findings on M2 phenotypes and the associated 
regulatory and anti-inflammatory mediators and responses, amongst which IL-10, 
TGF-β and mannose receptor CD206 are ubiquitously expressed. 
 
The current classification of macrophage phenotypes by protein marker expression is 
still incomplete. An advanced approach is by RNA-seq (RNA sequencing) analysis of 
transcriptomic signatures of polarised macrophages to identify significantly induce or 
repressed genes. At this resolution, phenotypes can be associated with additional 
gene regulation mechanisms such as promoter activities, alternate transcription 
splicing, and untranslated region (UTR) regulation [57, 58]. To note, gene profiles of 
different phenotypes are constantly changing according to the microenvironment. For 
instance, while the classic M1 and M2 macrophages maintain their specific gene 
expression profiles, in atherosclerotic plaques, a rich signal of oxidised phospholipids 
is added to these cells which can induce additional transcription of antioxidant 
enzymes that helps limiting lipid accumulation [59]. Transcriptomic analysis of 
macrophage phenotypes more accurately reflects the change of environmental 
adaptations of different sub-populations, and it is an advanced tool with considerable 
clinical potential to diagnose and predict macrophage-associated pathologies [60]. 
 
Although it has been a general understanding that the naïve macrophages can switch 
between the major M1 and M2 phenotypes based on signalling transduction, and such 
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M1/M2 counteraction is a safety mechanism to prevent chronic inflammation and 
immunosuppression exhibited by each phenotype. However, the complexity of 
macrophage phenotypes has been built up throughout research, with the addition of 
numerous sub-phenotypes. The interplay between signalling pathways gives 
macrophages the plasticity to readily alter between phenotypes, and this certainly 
reflects the flexibility and broadness of macrophage response to modulate host 
immunity [61, 62].  Therefore, phenotypes may not be the most accurate method to 
describe the role of macrophages, their responses to the immune challenge are more 
essential to determine the phenotype in a specific condition. 
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1.2.3 Macrophage Functions  
Macrophages exhibit two critical immune functions: phagocytosis and antigen 
presentation. Phagocytosis is a process employed by macrophages to scavenge 
“biological waste or stimuli”. By recognition of targets via cell surface Fc receptors, 
complement receptors, mannose receptors, scavenger receptors and lectin receptors, 
targets including apoptotic and necrotic cell debris, excessive proteins and lipids and 
incoming microorganisms which are vesicle-enwrapped and engulfed by 
macrophages [63–66]. Although most pathogens are digested by the acidic and 
enzymatic environment of phago-lysosomes, this antimicrobial exercise can 
sometimes be resisted. These evasion mechanisms are exemplified by internalised 
Mycobacteria which have evolved an anti-digestive cell wall and the ability to inhibit 
the vacuolar proton-ATPases to protect against phagolysosomal breakdown, so that 
it can persist until a chance for escape [67–69]. While phagocytosis is beneficial to 
restoring host physiology, it also contributes to pathogenesis when an excessive 
amount of waste is scavenged. One example is the generation of atherosclerotic 
plaques where macrophages are recruited to the site of lipid accumulation in the wall 
of blood vessels and later become the proinflammatory and pro-atherogenic “Foam 
cells” when their scavenging limits are exceeded [34, 35]. This process can be viewed 
as a double-edged sword, protecting the host from infections and biological wastes 
but becoming pathogenic once their functions are overwhelmed by stimuli. Thus, 
precise control of macrophage function is critical and is achieved via a tight regulation 
of intracellular inflammatory signalling networks. 
 
Macrophages also act as professional antigen presenting cells (APC) together with 
dendritic cells and B cells [70]. Macrophages process the engulfed pathogens or 
cellular breakdown products to antigens which are complex with surface expressed 
major histocompatibility complex class II molecules (MHC II) to be presented to T cells. 
This helps to activate naïve T cells to become either CD8 positive cytotoxic T cells or 
CD4 positive helper T cells. Macrophages requires IFN-γ signal from memory T 
lymphocytes to express MHC II molecules [71]. MHC II complex were not expressed 
on the plasma membrane at abundance until immune challenge occurs. In Listeria 
monocytogenes-infected macrophages, they were initially found in lysosomes and 
were rapidly induced to the surface with bacterial antigens [72] where T cell receptors 
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can recognise and respond. The crosstalk between macrophages and the adaptive 
immunity critically underlies a sustained and secondary inflammatory response that 
secures the elimination of pathogens. 
 
To orchestrate macrophage functions, a number of inflammatory proteins and 
signalling pathways have been studied to enable such precise actions at the 
appropriate time and duration.  
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1.3 Inflammatory signalling 
Macrophages and dendritic cells are the critical players in host innate immunity while 
other immune cells support and compensate their functions at different stages and in 
different immune environments. Innate immunity predominantly contributes to the 
acute inflammatory response against physiological disturbances, during which cells 
frequently communicate via molecular signals named cytokines [73]. Post cellular 
interaction and PRR recognition, a complex network of signalling cascades is activated 
to facilitate the generation of correct and corresponding cytokine response 
downstream of PRRs. While the canonical PRRs such as TLRs, C-type Lectin 
receptors (CLRs), NLRs and the Retinoic acid-inducible gene (RIG)-I-like receptors 
(RLRs) have been well studied in the past [74], a number of novel inflammatory 
regulators have been characterised in the recent years and have demonstrated 
indispensable roles in regulating host immunity.  
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1.3.1 Canonical inflammatory regulators 
TLR family receptors form the most well-established PRR system in innate immunity. 
Similar to the plasma membrane receptors of the CLR family including Dectin, 
MINCLE and mannose receptors [75], most TLRs are exposed on plasma membranes 
yet some are also present in endo-lysosomal structures [76]. For a wide spectrum of 
antigen recognition, each TLR detects a specific ligand and their signalling pathways 
crosstalk to respond to infections. The cell surface receptor TLR2 recognises microbial 
lipoproteins and TLR4 recognises bacteria endotoxin LPS, endosomal receptor TLR3 
recognises viral double-stranded (ds)RNA and TLR7 recognise single-stranded 
(ss)RNA from microorganisms [77]. Activation of TLRs ignites the signalling 
transduction from the major adaptor proteins MyD88 and its accessory facilitators 
TRAM, TIRAP, Mal, and finally induces the proinflammatory pathways via mitogen-
activated protein kinase (MAPK) / activator protein-1 (AP-1) and IKK (IκB kinase) / 
nuclear factor kappa-light-chain-enhancer of B cells (NF-κB). These two transcription 
factors coordinate the secretion of proinflammatory cytokines and chemokines such 
as IL-1, IL-6, IL-8, CCL3 and TNF-α [74, 78]. Alternatively, endosomal receptor TLR3 
and the “late signalling” events of internalised TLR4 induce the TRIF/TRAM mediated 
response and activates interferon regulatory factor 3 (IRF3) [74, 79]. IRF3-dependent 
action elicits the type I interferon response which is antiviral, immune regulatory, pro-
haematopoietic regeneration, and pro-apoptotic for infected and damaged cells [80, 
81]. Dysregulation of type I interferons is associated with chronic inflammation and 
autoimmune diseases. Amongst all PRR ligands, LPS is capable of activating multiple 
inflammatory pathways and thus is a model immune stimulus for exploring novel 
inflammatory mediators involved in both the direct and late-signalling activation (Figure 
2).   
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Figure 2. Overview of LPS activated TLR4 pathways.  
Bacterial endotoxin LPS is recognised by TLR4 and the co-receptors CD14, LBP and MD-2 at 
the plasma membrane surface. TLR4 receptor couples to TIRAP and Mal and induces MyD88-
dependent signalling through the IRAK-TRAF6-TAK axis, which then signals to IKKs and 
MAPK for activation of transcription factors NF-κB and AP-1, respectively. This results in the 
expression of classical proinflammatory cytokines. Alternatively, “late signalling” events cause 
LPS-bound TLR4 internalisation and activate TRAM/TRIF –dependent induction of TRAF3 
and TBK1, which finally induces the transcription factor IRF3. TRAM/TRIF activation 
additionally induces the common signalling through TRAF6-TAK, and together with the 
product NF-κB, IRF3 upregulation of type I interferon expression. Abbreviations: LPS= 
lipopolysaccharide; TLR4= Toll-like receptor; LBP= LPS binding protein; TIRAP= 
Toll/interleukin-1 receptor domain-containing adaptor protein; Mal= MyD88 associated protein; 
MyD88= myeloid differentiation primary response 88; IRAK= interleukin-1 receptor-associated 
kinase 1; TRAF= tumour necrosis factor (TNF) receptor-associated factor; TAK1= 
transforming growth factor (TGF) beta-activated kinase 1; TAB= TGF-beta activated kinase; 
MAPK= mitogen-activated protein kinase; AP-1= activator protein 1; IKKs= IκB kinase; TRIF= 
TIR-domain-containing adaptor-inducing interferon-β; TRAM= translocating chain-associated 
membrane protein 2; TBK1= Tank-binding kinase; IRF3= interferon regulatory factor 3.  
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Pathogen induced proinflammatory cytokine production also instigates a positive 
feedback loop which leads to further cytokine amplification. For instance, NF-κB 
mediated cytokine expression can be enhanced by TNF and its receptor through a 
TRAF2-containing adaptor cascade [82]. Particularly, IL-1 secretion induced by the 
TLR4 recognition of LPS promotes further inflammation through a signalling cascade 
that highly resembles LPS-TLR4 signalling. Upon induction, IL-1 precursors are post-
translationally processed by proteases (mostly calpain and granzyme B) or caspase-
1 to release the mature IL-1α and IL-1β, respectively. The activation of receptor dimer 
by IL-1 proteins assembles intracellular adaptors including MyD88 and IRAK4, and 
these in turn initiate the IRAK1/TRAF6-dependent signalling to both NF-κB and AP-1 
transcription factors which enhance proinflammatory cytokine production [Reviewed 
in [83]]. These feedback mechanisms can be beneficial to sustain inflammatory 
response throughout infections and immune regulations; however, it can also be 
associated with chronic inflammation and autoimmune diseases. Rheumatoid arthritis 
(RA) is a typical autoimmune disease resulted from chronic release of IL-1 and TNF-
α (amongst other proinflammatory cytokines such as IL-17, IL-18 and RANKL) in an 
unresolved joint inflammation [84, 85]. Not only that chronic inflammation affects the 
local region, in recently identified cases of RA, patients were also found with cognitive 
impairment which was likely caused by the reduced life quality associated with disease 
management (use of glucocorticoid, income, mobility and other social aspects) [86]. 
Therefore, the feedback mechanism must also be exhibited in a tightly controlled 
manner to prevent adverse effects on immune resolution. 
 
A limitation for the functioning of cell membrane-embedded receptors is the lack of 
surveillance in the cytoplasm. Molecules such as nucleic acids and proteins originating 
from microorganisms and cellular stress can bypass membrane PRR recognition, and 
thus necessitate the additional defence provided by the cytoplasmic PRR families 
NLRs and RLRs. NLR-mediated activities involve inflammasome formation and 
caspase activation and recruitment domain (CARD)-dependent activation of caspase-
1 and IL-1β/ IL-18 processing [87, 88]. The well-studied members of NLR family NOD-
1 and NOD-2 respond to peptidoglycan in the cytosol as a result of microbial 
breakdown or division [89]. As a result of cytosolic detection, NLR pathways commonly 
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crosstalk with other PRR families such as TLR and RLR, such as the TLR4 / NF-κB 
activation priming NLRP3 inflammasome assembly [90]. 
 
It is well appreciated that RNA and DNA molecules are potent immune stimulants. In 
addition to the NLR, another family of cytoplasmic receptors RLRs are responsible for 
detecting virus-released RNA [91]. These receptors were identified when the loss of 
TLR3, -7, -8 and -9 was unable to abolish type I interferon response upon certain viral 
infections [92–94]. RLRs receptors include the RNA helicases RIG-I and melanoma 
differentiation associated factor 5 (MDA5), which recognise 5’ triphosphate-tagged 
ssRNA and dsRNA molecules released by viruses such as Rotavirus, West Nile 
viruses and Dengue virus [95–98]. A third RLR member named laboratory of genetics 
and physiology 2 (LGP2) lacks the RLR signature CARD domain yet it still recognises 
dsRNA termini, and has regulatory functions for RIG-I and MDA5 –dependent antiviral 
activities [99–102]. RIG-I and MDA5 signal through the intracellular adaptor 
mitochondrial antiviral signalling protein (MAVS) which induces NF-κB and IRF3-
dependent type I interferon response [98, 103].  
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1.3.2 Non-canonical inflammatory regulators 
Further to these categorised PRRs, several non-canonical immune sensing pathways 
have been described. Pathogen-derived nucleic acids are detected by additional 
cytosolic proteins including RNA sensors RNase L, protein kinase R (PKR) and 
oligoadenylate synthase (OAS) family proteins [104–106]. Although these sensors 
lead to type I interferon response upon encountering cytoplasmic RNA, their 
interferon-inducing events are independent of TRIF and MAVS. For instance, RNase 
L and OAS are nucleases that inhibit infections by cleaving ssRNA and dsRNA, 
respectively, into smaller products which subsequently induce RIG-I/MDA5/MAVS 
axis for interferon augmentation [106, 107]. Type I interferon signalling also induce 
further inflammatory gene expression including OAS as a positive feedback 
mechanism to maximise antiviral response. Distinct from these nucleases, PKR is a 
dsRNA-recognising kinase that phosphorylates and inactivates translation factor 
eIF2α when it has been hijacked for microbial protein expression [105, 108, 109]. PKR 
is also involved in the regulation of IFN-α/-β mRNA integrity, where the loss of PKR 
functionality did not impair type I interferon expression but caused the absence of 
terminal polyadenylation of mRNA which prevents transcription degradation [110, 111].  
 
Additionally, absence in melanoma 2 (AIM2), DEAD-Box helicase 41 (DDX41), cyclic 
di-GMP-AMP synthase (cGAS), interferon (IFN)-gamma inducible protein 16 (IFI16) 
[112–115] and the endonucleases such as TREX1 and MUS81 act as DNA sensors 
in the cytoplasm [116, 117]. DNA molecules are confined in the host nucleus and 
mitochondria unless cellular stress induces DNA leakage or pathogens introduce their 
genes into the cytoplasm. Therefore, cytoplasmic dsDNA are potent immune 
activators. Despite that AIM2 is activated by dsDNA to induce caspase-1 
inflammasome assembly [112], all the other described DNA nucleases and sensors 
signal though an endoplasmic reticulum (ER) adapter protein Stimulator of Interferon 
Genes (STING), which has been reviewed by Barber [118] and later in Chapter 1.5 
[119].  STING signalling not only forms a cytosolic DNA defence mechanism, its 
dysregulation is highly associated with autoimmune diseases [120–122], and its value 
as antiviral and anti-tumour adjuvant is a prominent focus in clinical laboratories [123–
127].  
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1.3.3 Summary of inflammatory regulators 
Immune cells, most importantly macrophages, exhibit inflammatory stimuli through the 
activation of the innate immune receptors PRRs which recognise PAMP and DAMP 
derived from pathogens and cell/tissue stress. The major PRR families TLRs, CLRs, 
NLRs and RLRs have adopted their specific recognition characteristics into a system 
for inflammatory signalling of cytokines, chemokines and type I interferons. These 
well-studied receptors are known as the canonical inflammatory regulators. 
Additionally, some of the un-categorised immune receptors are found to complement 
the canonical PRR activities, most of which are sensors for intracellular nucleic acids. 
Although these sensors differ in the nature of detection mechanisms, most of the RNA-
induced signalling events are mediated by MAVS in the mitochondria and the DNA 
sensing pathways act through STING in the ER. Nucleic acid detection leads to 
adaptor activation which subsequently recruit interferon regulatory factors to induce 
type I interferon response, which is indispensable for antiviral immunity. 
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1.4 TMEM203 – a novel proinflammatory mediator  
Our knowledge of pattern recognition receptors and components of the innate immune 
sensing pathways is continuously evolving. MAVS and STING were discovered only 
in the last 15 years, yet research has expanded rapidly in their role in antiviral, anti-
tumour and autoimmune responses. Their significance in supporting inflammation and 
its regulatory mechanisms have become the focus for therapeutic targeting for their 
potential. To link nucleic acid sensing pathways to the previously identified immune 
regulators or to identify novel regulators are priorities to identify potential drug 
candidates.  
 
Macrophages are central cellular regulators of inflammation, exhibiting potent anti-
microbial effects, linking the innate and adaptive immunity, and coordinating 
cellular/tissue inflammatory dynamics. To identify novel inflammatory mediators, we 
activated murine macrophages RAW 264.7 cell line with LPS, a bacterial endotoxin 
that induces both classical inflammatory pathways and type I interferon response [128, 
129]. In the functional screen of cDNA library of LPS-activated macrophages, 34 novel 
proinflammatory genes were identified [130, 131]. Amongst these, a protein named 
Tmem203 (transmembrane protein 203, TMEM203 in human) was shown to be 
upregulated Cxcl2 chemokine promoter activities upon LPS challenge. Preliminary 
studies on Tmem203 showed that the LPS-induced Cxcl2 promoter activity in RAW 
264.7 cells was enhanced by Tmem203 overexpression and it is impaired by 
Tmem203 knockdown (Chapter 2, Fig. 1D-E). However, Tmem203 overexpression-
induced Cxcl2 promoter activation was not reduced by the expression of dominant 
negative forms of the canonical LPS signalling components, such as MyD88 and TRIF 
(Chapter 2, Fig. F-G). Thus, we tested that whether TMEM203 could signal through 
an alternative immune regulator. Expression of Tmem203-mCherry showed a 
localisation pattern in punctate membrane structures (Chapter 2, Fig. 3A) and LPS 
stimulation causes Tmem203 translocation to LAMP1 positive endosomal membranes 
(Chapter 2, Fig. 3B). In 2015, Shambharkar et al., reported that TMEM203 
predominantly expressed on the ER membranes and it is essential in modulating 
calcium homeostasis by co-regulation and interaction with IP3R (inositol 1, 4, 5-
triphosphate receptor), SERCA (sarcoplasmic/endoplasmic reticulum calcium ATPase) 
and the calcium sensor STIM1 (stromal interaction molecule 1) [132]. To search for 
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potential candidate co-regulators for TMEM203, we considered the two intracellular 
signalling adaptors MAVS and STING. Considering its ER localisation, TMEM203 is 
likely to coordinate signalling events via nearby immune regulators, and a logical 
candidate would be the ER resident antiviral adaptor STING [132, 133]. STING is 
ubiquitously expressed in the ER and responds to DNA sensors and microbial 
secreted cyclic dinucleotides. It signals through the TBK1-IRF3 axis which specifies 
type I interferon activation and later an amplified interferon-stimulated response, 
including the expression of proinflammatory chemokines. Due to the close localisation 
in the ER, TMEM203 and STING are likely to interact directly and complex in a number 
of signalling activities. Thus, we tested the potential of TMEM203 signalling through 
STING. Knockdown of Sting and its signalling effectors Tbk1 and Irf3 can strongly 
suppress Cxcl2 promoter activation caused by Tmem203 overexpression (Chapter 2, 
Fig. 1H). Not only that co-expression of STING-GFP and TMEM203-mCherry showed 
strong colocalisation pattern in HeLa cells (Chapter 2, Fig. 2D), these two proteins 
form a stable complex in co-immunoprecipitation (Chapter 2, Fig. 2E). From these 
evidences, the novel inflammatory mediator TMEM203 is of significant interest for the 
characterisation of immune functions and it is likely to associate with STING signalling 
components.  
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1.5 Regulating STING in health and disease 
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Abstract 
The presence of cytosolic double-stranded DNA molecules can trigger multiple 
innate immune signalling pathways which converge on the activation of an ER-
resident innate immune adaptor named “STimulator of INterferon Genes (STING)”. 
STING has been found to mediate type I interferon response downstream of cyclic 
dinucleotides and a number of DNA and RNA inducing signalling pathway. In 
addition to its physiological function, a rapidly increasing body of literature highlights 
the role for STING in human disease where variants of the STING proteins, as well 
as dysregulated STING signalling, have been implicated in a number of inflammatory 
diseases. This review will summarise the recent structural and functional findings of 
STING, and discuss how STING research has promoted the development of novel 
therapeutic approaches and experimental tools to improve treatment of tumour and 
autoimmune diseases. 
 
Keywords: Stimulator of Interferon Genes (STING), double-stranded DNA sensor, 
cyclic dinucleotide, cGAS 
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Background 
Cellular stresses or infections lead to the release of DNA molecules into the 
cytoplasm which may threaten the stability of the host genome [1]. The intracellular 
appearance of naked DNA molecules triggers a double-stranded (ds)DNA sensing 
mechanism which consequently induces innate immune responses including the 
production and release of type I interferons (IFN-I). This response is central to the 
resolution of DNA-induced cellular stress [2–4] and prevents the emergence of 
autoimmunity [4, 5]. A recently described protein named STING (Stimulator of 
Interferon Genes, also known as TMEM173, ERIS, MITA and MPYS) is a critical 
regulator of these innate immune responses [6–9].  
 
STING is an endoplasmic reticulum (ER)-resident transmembrane protein and was 
first recognised as part of the ER translocon system [6, 10]. Suppression of 
components of the translocon-associated protein (TRAP) complex such as TRAP-β 
and Sec61 β have been found to impair DNA-induced type I interferon (IFN-I) signals 
downstream of STING [11]. The TRAP complex has been shown to be involved in 
two of the ER’s major responses: protein N-glycosylation [12] and endoplasmic 
reticulum-associated degradation (ERAD) [13]. Although the functional relevance of 
STING in the ER translocon system has not yet been fully elucidated, it has been 
proposed that STING can interact with TRAP component Ssr2/TRAPβ to enable its 
migration from the ER to perinuclear membranes, a process key to IFN-β promoter 
activation [6, 14].  
 
Recent reports have demonstrated that cytoplasmic DNA released by microbes and 
viruses can trigger dsDNA-sensing pathways which activate STING [6, 15–17]. 
STING then signals to the TANK binding kinase 1 (TBK1) / interferon regulatory 
factor-3 (IRF3) axis to upregulate type I interferon production [11, 18]. As an IKK (IκB 
kinase) –related kinase, TBK1 can also interact with IκB kinases to induce 
phosphorylation and thus degradation of IκB, thereby liberating NF-κB (nuclear factor 
kappa B) subunits allowing their nuclear translocation resulting in upregulation of 
type I interferon and other pro-inflammatory cytokines such as IL-6 (interleukin-6), 
CXCL10 (C-X-C motif chemokine 10), CCL5 (C-C motif chemokine ligand 5) and 
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CCL2 [19]. Table 1 summarises the pathogens that have been shown to activate 
STING [6, 20–37]. Of note, STING knockout mice generated by Ishikawa and Barber 
were highly susceptible to infection by the single stranded RNA viruses vesicular 
stomatitis virus (VSV) and Sendai virus [6], suggesting STING activation pathways 
may overlap with RNA sensing mechanisms or reverse transcription of viral RNA [6, 
24, 38]. 
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Table 1. STING is activated by a range of pathogens. 
The type I interferon signal adaptor protein STING is responsible for mediating double-stranded DNA 
sensing responses and the detection of bacterial cyclic dinucleotides c-di-AMP, c-di-GMP, and 3’-3’ 
cGAMP. Many DNA viruses, RNA viruses and bacteria have been implicated in the activation of 
STING. Abbreviations: dsDNA = double-stranded DNA; ssRNA = single-stranded RNA. 
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Name Type of Pathogen Mechanism of STING activation References 
Adenovirus Non-enveloped linear 
dsDNA virus 
dsDNA activates cGAS-STING pathway 
(cytoplasmic) 
[20] 
Kaposi’s sarcoma-
associated 
herpesvirus  
Enveloped dsDNA virus dsDNA activates cGAS-STING pathway 
(cytoplasmic) and IFI16-STING pathway (nuclear)  
[21] 
Herpes simplex virus Enveloped dsDNA virus dsDNA activates cGAS-STING pathway 
(cytoplasmic) and IFI16-STING pathway (nuclear)  
[22] 
[23] 
Epstein-Barr virus dsDNA virus dsDNA activates IFI16-STING pathway (nuclear) [24] 
Human 
cytomegalovirus 
dsDNA virus dsDNA activates cGAS-STING pathway 
(cytoplasmic), DAI-STING (cytoplasmic), and 
IFI16-STING pathway (nuclear) 
[25] 
[26] 
[27] 
Sendai virus Negative strand ssRNA 
virus 
Possibly via RIG-I –dependent RNA detection 
which may in turn induce STING 
[6] 
Vesicular stomatitis 
virus 
Negative strand ssRNA 
virus 
Unknown [6] 
Human 
immunodeficiency 
virus 
Negative strand ssRNA 
virus 
dsDNA reverse transcribed from viral RNA 
induces cGAS-STING pathway 
[28] 
Influenza A virus Negative strand ssRNA 
virus 
Possibly via membrane fusion or unknown 
mechanism independent of DNA recognition 
[29] 
Mycobacteria 
tuberculosis 
Bacteria producing c-di-
GMP 
c-di-GMP [30] 
[31] 
Streptococcus 
pneumoniae 
Bacteria dsDNA Bacterial dsDNA [32] 
Streptococcus 
pyrogenes 
Bacteria dsDNA Bacterial dsDNA [33] 
Staphylococcus 
aureus 
Bacteria producing c-di-
AMP 
c-di-AMP [34] 
Listeria 
monocytogenes 
Bacteria producing c-di-
AMP 
c-di-AMP [35] 
Vibrio cholera Bacteria producing 3’-3’ 
cGAMP 
3’-3’ cGAMP [36] 
[37] 
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Whilst the STING-mediated dsDNA-sensing mechanism is critical for successful 
cellular protection against infections and disease progression, dysregulated STING 
activity leads to the excessive production of inflammatory mediators with potentially 
detrimental effects on surrounding cells and tissues. Recent studies revealed some 
important functions for STING in autoinflammatory diseases [39–41], cancer [41–44] 
and lipid regulations [45, 46], highlighting the importance of this protein in health and 
disease. Here we review the recent insights into STING function in human 
pathologies and discuss the potential of STING-targeted therapies which are of 
considerable scientific and clinical interest. 
 
Main text 
STING Mediated Signalling 
Canonical STING Activators 
Whilst STING acts as an adaptor protein in the dsDNA sensing pathway, it is not 
activated directly by DNA molecules. Instead, STING responds to DNA sensing 
proteins and molecules known as cyclic dinucleotides (CDNs) [35, 47–49] (Figure 
1). CDNs are derived from infectious agents exogenously, or are produced by the 
mammalian dsDNA sensor cGAS (cyclic guanosine monophosphate – adenosine 
monophosphate synthase; cyclic GMP-AMP synthase). The canonical CDNs, or 
microbial secretory CDNs, are molecules made of 3’-5’ phosphodiester bonds joining 
two adenosines (A) – cyclic di-AMP [35, 50], two guanosines (G) – cyclic di-GMP 
[47] or one of each – cyclic GMP-AMP [37]. One of the STING-activating universally 
expressed DNA sensors, cGAS, is capable of catalysing a unique form of CDN 
endogenously upon DNA recognition [51]. This molecule is comprised of one 3’-5’ 
phosphodiester bond and a non-canonical 2’-5’ linkage between adenosine and 
guanosine, and is thus named 2’-3’ cGAMP to distinguish from the secretory cyclic 
dinucleotide cGAMP (3’-3’ cGAMP) which contains two 3’-5’ bonds [37]. Previous 
literature [52–54] has suggested that 2’-3’ cGAMP is ten- to a thousand-fold more 
potent than 3’-3’ cGAMP in activating STING. A number of studies reported that the 
change of phosphodiester linkage in 2’-3’ cGAMP results in a higher binding affinity 
to STING and thus leads to an augmented type I interferon response [55, 56]. It is 
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also possible that hydrophilic secretory cyclic dinucleotides are excluded by the 
selectively permeable plasma membrane [57], and thus cannot be recognised by 
STING.  
 
Alternative STING activators 
In addition to being activated by cyclic dinucleotides, STING also mediates antiviral 
responses downstream of DNA sensors including DNA-dependent activator of IFN-
regulatory factor (DAI) [17], IFNγ-inducible protein 16 (IFI16) [15], DEAD-Box 
Helicase 41 (DDX41) [16], and components of the RNA-sensing pathways [23, 38] 
(Figure 1). The Z-form DNA sensor DAI was the first identified activator for STING, 
whose expression is highly cell-type and tissue-specific and therefore could not fully 
account for the widespread IFN-I induction during viral infection [17, 58]. Further 
research identified that the DNA sensor DDX41 could interact with bacterial cyclic 
dinucleotides, in addition to DNA molecules [16], prior to activating STING signalling 
[59].  
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Figure 1. STING activation pathways. 
The endoplasmic reticulum (ER) adaptor STING is activated via recognition of bacteria-secreted 3’-5’ 
bond cyclic dinucleotides or DNA sensor cGAS-catalyzed 2’-5’ cGAMP. Cytoplasmic DNA, released 
from DNA viruses or reverse transcribed from the RNA viral genome, can induce direct interaction 
between STING and DNA sensors (in red) such as DDX41, IFI16, and DAI. Alternatively, RNA 
viruses also induce the RIG-I dependent MAVS activation which alters mitochondrial dynamics and 
indirectly induce STING activation. Mitochondrial stress can result in the release of mitochondrial 
DNA (mtDNA) which also induces DNA sensor activation (not shown) and STING-mediated 
signalling. RNA polymerase III (RNA Pol III) can convert dsDNA into dsRNA which activates RIG-
I/ MAVS axis which has been shown to induce STING activation. 
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Another interferon-inducible DNA sensor IFI61 is a pyrin-containing protein which 
also induces STING activation downstream of DNA detection. IFI16, as well as its 
mouse orthologue p204, is a universally expressed DNA sensor, which forms 
multimers prior to STING activation in response to HSV viral infections [15, 60]. 
Evidence shows that IFI16 is responsible for detecting foreign DNA both in the 
cytoplasm and in the nucleus and therefore it is capable of combating nuclear-
replicating viruses such as Kaposi’s Sarcoma associated herpesvirus [61, 62] and 
human cytomegalovirus (HCMV) [27, 63], implying an ability to discriminate between 
“self” and “non-self” DNA molecules. A recent report by Diner and colleagues 
showed dynamic regulation of IFI16 oligomers at different cellular compartments in 
response to altered viral infections [64]. Throughout HCMV infection, IFI16 oligomers 
are densely gathered nuclear “punctate” structures, whereas in Herpes simplex 
virus-1 (HSV-1) infection these “puncta” become gradually dispersed across the 
whole nucleoplasm and are eventually degraded. In contrast to previous studies, 
Diner et al. also found that IFI16 knockout cells do not impede TBK1 activation upon 
immune stimulation, whereas both STING and cGAS knockout cells will strongly 
suppress TBK1 activity, suggesting that nuclear DNA detection mediated by IFI16 is 
independent of the STING/TBK-1/IRF3 axis. Other studies indicate that antiviral 
cytokine production occurs in the absence of IFI16 via an unknown mechanism [64].  
 
Recent reports have revealed an interesting relationship between IFI16 and cGAS 
during DNA detection. It was shown that HSV infection can induce both DNA 
sensors in various cell types, and that cGAS is partially nuclear, thus is able to 
regulate the stability of nuclear IFI16 oligomers during detection of viral DNA [65]. 
This provides a molecular mechanism by which cGAS regulates nuclear DNA 
sensing. Further evidence also suggests a DNA dose-dependent interaction between 
IFI16 and cGAS in keratinocytes [66]. Although this interaction does not affect 
cGAS’s ability to generate cyclic dinucleotides, evidence indicates that IFI16 can 
facilitate the detection of these ligands by STING, and the loss of IFI16 can 
significantly impair downstream type I interferon and pro-inflammatory signalling [66]. 
Therefore, IFI16 and cGAS are not redundant during DNA infections, but instead 
cooperate and regulate each other’s activities. 
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RNA-induced STING activation 
Interestingly, several RNA viruses such as human immunodeficiency virus (HIV) [28, 
67], influenza A virus [29], Sendai virus and vesicular stomatitis virus [6] have been 
found to activate STING signalling, via mechanisms both dependent and 
independent of DNA detection. Complementary DNA (cDNA) produced from reverse 
transcription of negative-stranded RNA in retroviruses such as HIV, murine leukemia 
virus (MLV) and Simian immunodeficiency virus (SIV) can induce a cGAS-dependent 
DNA sensing pathway and STING activation [28, 68] (Figure 1). However, HIV, in 
particular, is capable of inhibiting transcription of immediate anti-retroviral factors [69] 
and exploits the host STING blocker NOD-like receptor NLRX1 to aid the 
establishment of virus latency [67, 69]. It was also reported that cationic liposomes 
and nucleic acid-free herpesvirus-derived virus-like particles can directly induce 
STING/TBK1 relocation regardless of DNA sensing pathways, suggesting that the 
membrane fusion mechanism may be an alternative route for enveloped DNA and 
RNA viruses to activate STING. Enveloped RNA virus Influenza A virus has been 
shown to release haemagglutinin fusion peptide which induces STING but not cGAS 
activation [29], thus indicating another  STING activation mechanism independent of 
cyclic dinucleotide recognition. It remains unclear whether the fusion particles alone 
are direct STING ligands or if activity requires facilitation by unidentified co-
regulator(s). 
 
The RNA-inducing adaptor MAVS (mitochondrial antiviral signalling protein; also 
known as VISA, Cardif, IPS-1) can also interact with and activate STING [6, 8] 
(Figure 1). The mitochondria-resident adaptor MAVS is the major molecular platform 
through which the RLR-dependent RNA sensing pathway elicits the type I interferon 
response. MAVS responds to the cytoplasmic RNA sensors RIG-I (the retinoic acid-
inducible gene I) and MDA5 (melanoma differentiation-associated protein 5) [70], 
and in turn induces proinflammatory transcription factors NF-κB (nuclear factor 
kappa-light-chain-enhancer of activated B cells), IRF1, IRF3, IRF5 and IRF7 [70–73]. 
Castenier and colleagues [74] found that RIG-I induced MAVS activation can 
modulate mitochondrial dynamic changes promoting signalling to STING at MAMs, 
“mitochondria-associated membranes”, where mitochondria and ER are closely 
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associated [75]. This adaptor interaction was found to be dependent on a 
mitochondrial fusion mechanism which induces mitochondrial elongation towards the 
ER, and hence MAM formation. Virus-induced mitochondria fragmentation disrupts 
membrane association and hence abolishes MAVS activation and secondary STING 
signalling [74]. Another report also suggests that RNA virus-induced release of 
stress-associated mitochondrial (mt)DNA activates the STING-dependent dsDNA 
sensing pathway [76]. This process, which is also likely to involve mitochondrial 
stress-induced apoptosis, may provide an effective means to remove damaged cells 
for infection control.  
 
Ablasser [77] and Chiu [78] noted that the STING inducer and a B-form dsDNA 
sensor RNA polymerase III (Pol III) activate the RIG-I –dependent RNA sensing 
pathways (Figure 1). RNA Pol III reversely transcribes dsDNA into dsRNA 
molecules that are activators of RIG-I. However, it is unclear how STING is involved 
in this process. 
 
 
Post activation trafficking of STING 
Activation of STING induces adaptor dimerization [7] and subsequent migration from 
ER membranes to punctate membranes of the Golgi by mechanisms similar to 
autophagy [11]. It remained difficult to identify the role of STING in autophagy 
regulation as little evidence was found to link STING with the recycling process 
during cell starvation. Yet many autophagy-related proteins such as autophagy-
related gene (Atg) 9a and Vps34 are key to STING inter-organelle trafficking [79], 
and that the loss of early autophagy marker LC3 II can significantly impair the 
STING-dependent innate response to viral and bacterial infections [79–81]. This 
autophagy-like behaviour could also be related to the ER-originated pre-
autophagosome formation, where STING is located [41].  
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Signalling Downstream of STING 
The STING-dependent cellular responses are mainly dependent on two transcription 
factors, IRF3 and NF-κB (Figure 2). STING activation first induces adaptor 
dimerisation [82] and TRIM56-dependent ubiquitination to enable TBK1 docking [83]. 
Together, STING and TBK1 migrate to the perinuclear membranes of the Golgi via 
autophagy-like processes [6, 18, 79]. The association between STING-TBK1 leads 
to auto-phosphorylation of TBK1 at S172, a residue known to induce TBK1 activation 
[84, 85]. This further allows TBK1 to phosphorylate STING at S358 and S366 (S357 
and S365, respectively, in mouse STING). Phosphorylated S366, together with L374, 
are important for the recruitment of IRF3 in close proximity to TBK1 at the C-
terminus of STING, thereby enabling TBK1 to phosphorylate and activate IRF3 by 
exposing its nuclear localisation signal [18]. Activated IRF3 then translocates into the 
nucleus and promotes expression of type I interferons. Via a rapid feedback 
mechanism, IFN-I is released and binds to cell surface interferon receptors 
(IFNαRs), which then induces the expression of interferon-stimulated genes (ISGs) 
via Tyk2/JAK1 [86–88] and STAT1-STAT2 dimers [89, 90]. 
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Figure 2. STING activated signalling pathways. 
STING activation leads to translocation from ER membranes to the perinuclear vesicles where it 
induces the signalling of two major pathways: the NF-κB -dependent proinflammatory response and 
the IRF3-dependent type I interferon response. The activation of mitochondrial antiviral adaptor 
MAVS also results in the activation of STING and recruitment of TBK1, which upregulates the 
transcription of antiviral chemokines via STAT6. 
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STING ligands have also been shown to activate the canonical NF-κB pathway 
(Figure 2), leading to the production of pro-inflammatory cytokines including IL-1α, 
TNF-α (tumour necrosis factor-α), IL-6, and numerous chemokines such as CXCL10 
and CCL-2 [9][19]. The mechanism of this was found to be dependent on STING-
TBK1 activation, which in turn regulates the activation loop of IKKα/β releasing p65 
to form active dimers with p50. Hence, the functional NF-κB complex can translocate 
into the nucleus and promote transcription of pro-inflammatory genes. Abe and 
Barber also suggested that TRAF6 may be involved upstream of TBK1, which likely 
facilitates NF-kB activation [19]. However, the IFI16-dependent STING pathway can 
only induce IRF3 but not NF-κB activation, which would serve to preserve the 
survival activities regardless of the antiviral response during infection [91]. 
 
Regulatory Motifs of STING Activity 
The sequence and topology of STING has been studied in parallel to its function. It is 
known that STING is a 379 amino acid long ER transmembrane protein encoded by 
the human TMEM173 gene (Accession NP_938023, XP_291127) and homologous 
genes in other mammalian species. The STING structure is highly conserved 
between mammalian species, with the N-terminal forming a putative multi 
membrane-spanning region, a middle CDN-recognition domain, and a cytoplasmic 
tail (Figure 3).  
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Figure 3. The domain structure of human STING protein.  
Human STING is a 379 amino-acid long ER-resident protein. The N-terminal contains 5 membrane-
embedded domains (dark blue) including 4 transmembrane domains and Helix α1 responsible for 
ligand sensing and protein dimerisation. The C-terminal is mainly cytoplasmic (pale blue). It contains 
the cyclic dinucleotide (CDN) binding domain and interaction sites for TBK1 and IRF3 at the tail. 
Numbers above STING sequence indicate the amino acids comprising the functional domain.  
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It is understood that the N-terminal 130 amino acids of STING form four 
transmembrane helices [92, 93] that are mainly responsible for membrane 
anchorage and inter-organelle trafficking [94] (Figure 3). An additional helix, named 
helix α1, was previously considered as the fifth transmembrane domain [6, 8, 95, 96] 
but has more recently been proposed to form a distinct domain with different 
functions [97]. Helix α1 is formed between residues 153-177 and has been reported 
to play an essential role in protein folding and dimerisation. Compromising the 
integrity of helix α1 causes STING precipitation in the cytoplasm and abolishes the 
homo-dimeric structure due to the loss of abundant hydrophobic interactions 
between dimers [97]. Ouyang’s group reported that helix α1 also supports strong 
hydrogen force between STING dimers and cyclic di-GMP, suggesting its importance 
in multiple STING functions [98]. 
 
In addition to helix α1, the rest of the cytoplasmic tail also contributes to STING 
dimerisation [7], cyclic dinucleotide recognition [99], and TBK1 and IRF3 recruitment 
[18, 100] (Figure 3). In the absence of ligands, STING dimers show an open 
structure susceptible to cyclic dinucleotides [98]. Upon recognition of cyclic di-GMP, 
residues 139-344 are rearranged to expose a docking site for TBK1 [98], enabling 
TBK1 to phosphorylate STING at serine 358 [8]. This phosphorylation in turn 
enhances TBK1-STING attachment. Tanaka’s group found that a 39-residue 
fragment at the carboxyl end of the STING protein was sufficient to activate IRF3 
signalling in response to DNA challenge [18], and the loss of this tail region, encoded 
by exon 7, creates a dominant negative STING isoform for TBK1-IRF3 signalling 
[101]. Further truncation of the STING C-terminal fragment revealed that S366 and 
L374 are the key residues for IRF3 recruitment and activation [18]. Therefore, TBK1 
and IRF3 are recruited to STING in a 20 amino acid –spanning region to facilitate 
their interaction by close proximity. 
 
Crystallisation of the STING protein has revealed that key residue substitutions or 
segment deletions significantly alter its structure, resulting in a dysfunctional protein 
[6, 7, 53, 97, 98, 102]. Mutations of single or multiple amino acids of STING have 
been found to influence its dimerisation capability [39, 103–105], ligand binding 
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capacity [39, 104–106], or the ability to be post-translational modified by regulatory 
proteins [102, 107]. Some of these mutations occur naturally in humans to cause 
lethal autoinflammatory diseases [39, 105, 108], and some were generated 
experimentally in order to understand the structure-function relationship of STING 
[53, 96, 97, 102]. 
 
 
STING Variants 
STING variations exist between mammalian species; the amino acid sequences of 
human and mouse STING are 68% identical and 81% similar [54]. Whilst this may 
not lead to dramatic differences in their three-dimensional structures, the structural 
differences at certain amino acid residues may be responsible for species-specific 
immune responses to some viral infections. For instance, Dengue virus (DENV) can 
inhibit STING signalling in human but not in mouse [107, 109]. DENV encodes for 
the protease NS2B3 that cleaves human STING at a highly-conserved putative 
cysteine motif (C88XXC91) to disable the adaptor. The equivalent cleavage target in 
mouse STING (mSTING) harbours a mutation that prevents NS2B3 cleavage, thus 
mouse STING can avoid DENV evasion. Mutant mouse embryonic fibroblasts 
transfected with hSTING re-constructed with a mouse NS2B3 cleavage site 
sequence blocks the type I interferon response against DENV. Specifically, a 
substitution of S135A in hSTING sequence results in inhibition of NS2B3 cleavage, 
suggesting that protecting STING at this residue may provide the basis for a novel 
anti-Dengue treatment [107].  
 
In humans, single nucleotide polymorphisms (SNP) of STING were found to result in 
different levels of IFN-I signalling modulation (Table 2). Substitution at R284M can 
greatly stabilize the STING dimer, indicating its strong potential to cause chronic 
STING-dependent autoimmunity [103]. Substitution at R293Q can strongly reduce 
the c-di-GMP –induced IFN-I signals and completely abolishes the signals induced 
by other 3’-5’ bond cyclic dinucleotides [104]. Other single residue polymorphisms 
such as R232H and G230A may affect the ligand binding pocket of STING, thereby 
reducing its response to bacterial ligands [104]. In particular, a loss-of-function triple 
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STING mutant, R71H-G230A-R293Q (named HAQ), abolishes almost 90% of the 
interferon response to all cyclic dinucleotides [110]. The HAQ mutant occurs in one-
fifth of the population from a thousand genome screen [104]. Homologous HAQ 
mutant knock-in mice have demonstrated that a variety of immune cells, including 
lymphocytes and Ly6Chi monocytes, express significantly less STING protein 
compared to the wildtype, and the mutant animals completely failed to respond to 
CDN challenge [106]. This suggested that the HAQ mutant may be a de facto null 
allele of STING, thereby reducing the availability of the STING protein to mediate a 
dsDNA sensing response. 
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Table 2. Mammalian STING variants and mutants. 
Single nucleotide polymorphisms of STING have been discovered in human and mouse which are 
implicated in dysregulation of type I interferon signalling and the proinflammatory innate immune 
response. STING mutations highlighted in green manifest as loss-of-function characteristics, 
mutations highlighted in red manifest as gain-of-function characteristics, and mutation in black lacks 
any gain-of-function or loss-of-function characteristic of STING. Gain-of-function mutations of 
V155M, N154S and V147L have been identified in human autoinflammatory disease called STING-
associated vasculopathy with onset in infancy (SAVI), and substitution of G160E is the major cause 
of another human autoimmune disease known as familiar chilblain lupus (FCL). The most 
predominant loss-of-function STING mutant named HAQ is considered to compromise host innate 
response against infection, yet no clinical evidence is available for further discussion. Others STING 
mutations are experimentally created to study type I interferon signalling pathways, but they are 
potentially pathological. 
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The function of several STING residues has been characterised using experimental 
point mutations (Table 2), some of which were also found to occur naturally in 
mammals. A C57BL/6 –derived, Goldenticket (Gt) mouse strain harbouring a single 
I199N mutation in STING leads to the complete abolishment of IFN-I activity to 
Listeria monocytogenes infection or stimulation of cyclic di-GMP and cyclic di-AMP 
[111]. The human equivalent mutation I200N was also considered to have the same 
effects, but no such spontaneous mutant has been discovered. Only a few gain-of-
function hSTING mutants have been identified clinically [39, 105] (Table 2). Patients 
with these STING mutations showed early on-set of severe systemic inflammation in 
blood vessels and various organs, displaying chronic inflammatory symptoms that 
are highly similar to pathologies of SLE (systemic lupus erythematous) and AGS 
(Aicardi-Goutières Syndrome) [39, 105]. All of these STING mutants have shown 
considerable structural resemblance to the active conformation, presumably leading 
to constitutive adaptor dimerization and signalling to type I interferon production. 
Both Liu and König’s groups suggested that inhibition of the interferon signalling 
adaptor JAK could significantly dampen IFN-I over-expression as measured in 
biopsy samples from these patients, indicating that JAK inhibitors could be a 
promising avenue to therapeutically control disease progression.  
 
As evidenced by the above studies, STING variants are likely to be associated with 
increased susceptibility to certain infections and autoimmune diseases, emphasising 
the value of genetic analysis of individual mutations to reveal novel targets for 
developing personalised therapy and immunisations. 
 
STING Regulations 
As a critical coordinator of the innate immunity, STING is tightly regulated by a 
variety of signalling molecules. Except that STING is post-translationally modified to 
enable dimerisation and activation, some regulators are essential for the prevention 
of constitutive type I interferon signalling which have been shown to cause 
autoimmunity both in animal models [6, 112] and in human [39, 108]. Negative 
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regulation of STING signalling is necessary for the resolution of inflammatory 
responses post infection (Figure 4). 
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Figure 4. Negative regulation of STING-mediated response. 
STING-mediated signalling can be negatively regulated via multiple mechanisms, including E3 
ubiquitin ligase TRIM30α- and TRIM21- mediated degradation of STING and its upstream DNA 
sensor DDX41, respectively. Certain phosphodiesterases (PDEs) also specifically hydrolyse bacterial 
cyclic dinucleotides to prevent them being sensed by STING. Akt kinase is also capable of inhibiting 
cGAS detection of cytoplasmic DNA. Activated cGAS produces 2’-3’ cGAMP to release AMPK-
mediated inhibition of ULK1, which in turn blocks IRF3 recruitment downstream of STING 
activation. 2’-3’ cGAMP produced by cGAS can also activate Beclin-1 which can sequester cGAS as 
well as induce degradation of dsDNA. In a negative feedback loop, the product of the IRF3-dependent 
antiviral response, microRNA-576-3P (miR-576-3P), can prevent further STING activation. Some 
viruses can encode proteases or protein inhibitors to interfere in STING signalling, while others may 
enhance the activity of inflammasome complexes NLRC3 and NLRX1 to block STING/ TBK1 
interaction. 
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Post-translational regulators 
Post-translational modifications contribute to the spatio-temporal regulation of STING 
signalling. STING is commonly modified by ubiquitination and phosphorylation. Upon 
ligand binding, the E3 ubiquitin ligase TRIM56 is recruited to initiate K-63 linked 
ubiquitination on STING, a prerequisite for STING dimerisation and activation [83]. 
Another E3 ligase AMFR (Autocrine motility factor receptor), together with its 
interacting partner INSIG1 (insulin-induced gene 1), catalyses K-27 linked poly-
ubiquitination, which is critical for TBK1 recruitment [113]. In contrast, TRIM30α-
dependent K275 ubiquitination [112] and RNF5 (RING finger protein 5) -dependent 
K150 ubiquitination [114] degrade STING dimers and negatively regulate antiviral 
signalling (Figure 4). This process is likely to involve the antiviral adaptor protein 
MAVS on mitochondria at the MAMs where the closely associated ER and 
mitochondrial membranes bring STING and MAVS in close proximity [115, 116]. 
Since ubiquitination is critical to STING regulation, some viruses can secrete 
proteases to specifically disrupt this process to suppress innate immune recognition, 
as summarised below (Table 3). 
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Table 3: STING-mediated evasion of antiviral immunity. 
A number of DNA and RNA viruses have been found to encode and secrete STING-targeted 
proteases or inhibitors to prevent innate immune detection to help establish the of latent phase of 
infection. Viruses of the same family tend to adopt similar strategies/mechanisms to block STING 
activation. Some viruses also express multiple inhibitors to target both DNA sensors and STING, or 
release viral oncogenes in parallel to further compromise immunity, which consequently increases 
their chance of survival in the host. 
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Pathogen Mechanism of Action References 
Yellow fever virus 
Dengue virus 
NS4B interrupts STING activation [11] 
Hepatitis C virus NS3/4A, NS4B proteases interrupt STING activation [137] 
[138] 
Herpes simplex virus-1 Release ICP0 E3 ubiquitin ligase to degrade IFI16  
Viral protein ICP27 binds to STING-TBK1 complex to 
prevent IRF3 signalling 
[139][140] 
[147] 
Coronaviruses SARS 
and NL63 
Disrupt K63-linked ubiquitin-mediated STING dimerisation [140] 
Human papillomavirus E2 protein inhibits STING transcription 
E7 oncogene blocks cGAS/STING signalling 
[141] 
[142] 
Adenovirus E1A oncogene blocks cGAS/STING signalling [142] 
Hepatitis B virus Disrupts K63-linked ubiquitin-mediated STING 
dimerisation 
[143] 
Kaposi’s sarcoma-
associated herpesvirus 
ORF52 proteins bind to and inhibit cGAS 
Targets IFI16 degradation during lytic reactivation 
[62] 
Epstein-Barr virus,  
Murine 
gammaherpesvirus 68,  
Rhesus monkey 
rhadinovirus 
ORF52 proteins bind to and inhibit cGAS [144] 
[145] 
Human 
immunodeficiency 
virus 
Enhance STING suppressor NLRX1 
Enhance TREX1 to degrade excessive cDNA 
Viral Capsids prevent innate sensing of cDNA 
[67] 
[65][68] 
[146][148] 
Human 
cytomegalovirus 
Tegument protein pUL83 disrupts IFI16 oligomerization 
and activation 
[63] 
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Some STING activities are also critically dependent on its phosphorylation. One such 
example is the phosphorylation of S366 on the C-terminal domain to provide docking 
sites for IRF3 prior to its phosphorylation by TBK1 [6, 100, 117]. ULK1-dependent 
phosphorylation on S366 post Golgi trafficking blocks IRF3 binding to STING and 
thus prevents chronic STING activation [102] (Figure 4). ULK1 acts upon release 
from its repressor AMPK (adenosine monophosphate activated protein kinase) which 
is induced by production of 2’-3’ cGAMP from cGAS. Interestingly, both loss-of-
function (S366A) and gain-of-function (S366D) mutations can abrogate IRF3 
signalling [18], suggesting that either the phosphorylation of S366 is temporally and 
spatially regulating IRF3 docking, or that alternative post-translational modifications 
are responsible for this functional regulation. In particular, S366-dependent inhibition 
of IRF3 does not impair the NF-κB pathway, indicating that these two pathways act 
independently of each other, which has likely evolved to prevent dysregulated 
antiviral responses from affecting survival activities [102]. 
 
 
STING can be negatively regulated by the NLR family inflammasome components 
NLRC3 [118] and NLRX1 [67] (Figure 4). Both of these have been shown to 
sequester STING to prevent TBK1 recruitment; in particular the latter is strongly 
enhanced in HIV infection to suppress STING-dependent recognition of reverse-
transcribed dsDNA [67]. Depletion of NLRX1 not only impedes nuclear transportation 
of viral DNA, but also restores the STING-mediated interferon response to stall 
progression of infection. This suggests that pharmacological suppression of intrinsic 
STING inhibitors could potentially support the re-establishment of STING-mediated 
innate immunity against RNA viruses, and thus may offer promising adjuvant therapy 
to combat retrovirus infection. However, Guo and colleagues also noted that such 
suppression must be finely controlled to avoid excessive inflammatory responses 
that may lead to autoimmunity [67].  
 
Post-transcriptional regulation 
A primate specific microRNA (miR)-576-3p has been identified as a novel STING 
regulator that promotes virus replication [119] (Figure 4). Over expression of this 
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microRNA promotes the spread of vesicular stomatitis virus, whereas its inhibition 
protects against virus growth. Further studies show that miR-576-3p is an IRF3-
induced gene that can target multiple genes of interferon-stimulators, including 
STING, MAVS, TRAF3 and STAT6, thereby reducing their levels [119]. Since IRF3 is 
a downstream signalling molecule in the STING-TBK1 axis, upregulation of miR-576-
3p serves as a negative feedback loop to prevent sustained inflammatory response 
during and post infections.  
 
Alternative mechanism of STING downregulation 
A recent discovery suggests that certain phosphodiesterases (PDEs) may 
specifically degrade bacterial cyclic dinucleotides to halt excessive STING activation 
[120–123] (Figure 4). The pathogen Mycobacterium tuberculosis secretes 
phosphodiesterases MtbPDE (Rv3586), cnpB and CdnP to remove cytosolic CDN, 
thus avoiding STING mediated detection [124–126]. Although this may appear to 
undermine bacterial virulence and growth signals that are critical to infection [124], it 
can also significantly reduce early type I interferon induction. In particular, the 
enzyme CdnP can degrade both bacterial-derived and host-derived cyclic 
dinucleotides, critically promoting survival of M. tuberculosis at early stages of 
infection [125].  
 
In addition to the above regulatory mechanisms, Akt kinase (or protein kinase B, 
PKB) has been shown to phosphorylate cGAS at residues S291 or S305 to stall 
signalling via STING [127], while the E3 ubiquitin ligase TRIM21 can specifically 
target the DNA sensor DDX41 at residues K9 and K115 for proteasome degradation 
and hence prevent recognition of DNA and STING-dependent type I interferon 
expression [128] (Figure 4). The autophagy protein Beclin-1 may also terminate 
STING-dependent immunity by sequestering cGAS and promoting autophagy-
dependent digestion of dsDNA [129] (Figure 4). This is thought to prevent prolonged 
DNA recognition, which could lead to autoimmunity. 
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STING in parasitic infection 
Immune responses to malaria infection are highly strain specific; the lack of 
understanding linked to these strain specific responses makes the disease clinically 
difficult to manage [130–132]. Recent studies on host-parasite interaction have 
revealed distinct roles for STING-dependent type I interferon responses during 
crosstalk with other pro-inflammatory pathways. CD40 receptors expressed on 
antigen-presenting cells are understood to initiate the cellular and humoral response 
of the adaptive immunity, specifically enhancing the generation of immunoglobulins 
against pathogens [133, 134]. Mice infected with Plasmodium yoelii nigeriensis, 
infected red blood cells, TLR ligands or parasitic DNA/RNA upregulate both CD40 
and type I interferon expression, whereas the loss of CD40 can reduce the level of 
STING further impairing the early type I interferon response in macrophages and 
dendritic cells [135]. Although CD40-induced STING upregulation leads to reduced 
CD40 levels and thus downstream NF-κB signalling, type I interferon immunity has 
been suggested to be highly inducible in certain strains of parasitic infection [135]. 
 
The establishment of malaria infection in the host is critically dependent on early 
innate immune mechanisms. Yu et al. suggested that depletion of plasmacytoid 
dendritic cells, rather than canonical dendritic cells and macrophages, can 
significantly impair type I interferon signalling at 24 h post Plasmodium yoelii 
infection [136]. The ubiquitous STING-cGAS pathway has been shown to enhance 
type I interferon production, and also potently induces SOCS1 to inhibit the MyD88 / 
IRF7-dependent type I interferon production which specifically acts on pDCs to 
protect against early malaria infection. The loss of STING and cGAS in mice 
augments the immediate type I interferon response from pDCs following malaria 
infection, and therefore protects the animal against early mortality [136]. Therefore, 
STING’s activity and its crosstalk with other proinflammatory pathways may be 
variable in complex diseases such as malaria, and thus the manipulation of STING 
signalling axis for therapeutic benefits may be difficult to achieve. 
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Viral Evasion of STING 
It is evident that many viruses can evade STING signalling to establish a biological 
niche in mammalian cells, and that those within the same family tend to adopt similar 
evasive strategies [11, 62, 63, 65, 67, 68, 137–148] (Table 3). For instance, several 
members of the Gammaherpesviridae family were found to express ORF52 protein 
homologs to disrupt cGAS activities, preventing subsequent production of 2’-3’ 
cGAMP [48]. Species of the Flaviviridae and Coronaviviridae families tend to secrete 
proteases that directly cleave or block STING [140]; typical examples include the 
NS2B/3 and NS4B proteases released by flaviviridae Dengue virus and hepatitis C 
virus, respectively, which can both degrade hSTING. In particular, NS4B protease 
shows strong homology to the ER-embedded N-terminal domains of STING, leading 
to colocalisation and direct protein-protein interactions with STING [11]. It has also 
been suggested that tumour associated viruses such as human papillomavirus and 
adenovirus could potentially release oncogenic proteins to block cGAS/STING 
interactions with tumour suppressors, hence compromising innate immunity and 
supporting cancer progression [142]. 
 
The impairment or absence of interferon responses often seen in HIV infection has 
been proposed as one of the mechanisms by which this virus is capable of 
suppressing host immunity [148–151]. Recent research suggests that HIV-1 
enhances the action of NLRX1 to dampen STING activity [67] and recruits host 3’ 
exonuclease TREX1 to degrade excessively produced, reverse-transcribed, viral 
DNA thereby avoiding detection by the cGAS/STING pathway [68, 152]. The capsid 
of HIV also regulates its association with host protein cyclin A, which controls the 
masking of viral cDNA from cGAS recognition in the cytoplasm and its exposure in 
the nucleus to facilitate genome integration [146]. Mutations in the HIV-1 capsid 
sequence enhance its binding to cyclin A prematurely in the cytoplasm enabling DC 
sensing of double-stranded DNA and a potent innate immune response against viral 
infection [146].  
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STING Related Autoimmunity 
Type I interferons are key cytokines induced by antimicrobial and antiviral immunity. 
This family of cytokines consists of the predominantly produced interferon-α and 
interferon-β, and the less abundantly expressed subtypes such as IFN-ε, -κ, -τ, and –
ζ [153]. Type I interferons are ubiquitously expressed by a variety of cells including 
macrophages, lymphocytes, dendritic cells, fibroblasts and haematopoietic 
plasmacytoid dendric cells, with a widespread role in cellular biology [153, 154]. 
 
“Basal” expression of type I interferons is regulated via an autocrine mechanism 
[155], whereas the activation of interferon-inducing regulators such as STING can 
significantly boost their expression by activating the transcription factor IRF3. Type I 
interferons are released extracellularly for detection by self or nearby interferon 
receptors, IFNαRs, which are coupled to JAK1 (Janus kinase 1) and TyK2 (tyrosine 
kinase 2) [86, 87]. This activation further promotes the formation of STAT1-STAT2 
heterodimers [23, 89, 90] and the subsequent recruitment of IRF9 to assemble the 
transcription complex ISGF3 to upregulates the expression of a series of interferon-
stimulated genes (ISGs) [154]. A broad range of ISGs have been found to control 
chemotaxis, cell migration, apoptosis, cell proliferation, and to regulate immune 
detection and defence against infection; many of which have been thoroughly 
reviewed previously [156–160] (Table 4). Thus, dysregulation of type I interferon 
signalling can cause an excessive production of ISGs, in turn over-activating the 
immune system. 
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Table 4. Summary of interferon-stimulated genes (ISGs). 
Expression of ISGs are induced by type I interferon via the JAK-STAT signalling pathway. ISGs are 
involved in a wide spectrum of cellular activities including apoptosis, immune modulation, cell 
migration and adhesion, and antiviral responses. Some ISGs have multiple roles in immune regulation 
but are not repeatedly indicated in the table. 
 
  
 
Apoptosis 
 
Immune Modultion 
Cell Attraction 
& 
Adhesion 
Antiviral 
& 
Pathogen Detection 
CASP4 
CASP8 
BAK1 
Fas/ CD95 
PLSCR1 
XAF-1 
DAP kinase 
RID 
MxA 
MxB 
ICAM1 
SELL 
CD47 
ALCAM 
IRF1-5 & 7 
LGALS3B 
IFN-γ 
IL-12 
TNF-α 
SOCS 
USP18 
VEGF 
FGF 
VRP 
PDGFRL 
ECGF1 
EREG 
CTGF 
MHC I&II 
OAS1 
Protein Kinase R 
Viperin 
Tetherin 
IFI6 
IFITM2 
IFITM3 
IRF1 
IRF7 
MHC I&II 
Ribonuclease L 
GTPase Mx1 
ISG15 
ISG20 
ADAR1 
APOBEC 
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The persistent or excessive presence of cytoplasmic DNA is one of the major causes 
for chronic inflammation and autoimmune diseases. Chronic production of type I 
interferons, termed “type I interferonopathy”, is a key indication of immune 
dysregulation predominantly associated with DNA-induced autoimmunity. The 
overactive IFN-I response alerts cytotoxic immune cells systemically via ISG 
production. This in turn promotes sustained release of proinflammatory cytokines 
including IL-1α/β, IL-12, and TNF-α, causing excessive inflammation and tissue 
damage [161–163]. Autoimmunity also induces aberrant cell death, which releases 
cellular components to T and B lymphocytes and leads to the production of self-
reacting antibodies that congest in capillaries [164]. Unresolved B cell activation 
predisposes individuals to the development of systemic lupus erythematosus (SLE) 
that is clinically challenging to treat [152, 165, 166]. 
 
 
Systemic lupus erythematosus is a systemic chronic autoimmune disease. [152, 165, 
166] (Figure 5). SLE is often diagnosed by the accumulation of serological 
antinuclear antibodies (ANA) against nucleic acids released from dead cells, which 
cause multiple tissue and organ damage [167]. Chronic activation of DNA and RNA 
sensing pathways triggered by infection and cell death can contribute to the type I 
interferonopathy that predisposes individuals to SLE [166]. Mutations in nucleic acid 
sensors (such as endosomal Toll-like receptors [168], RIG-I [169], and DAI [170]), 
interferon regulatory factors [171] and DNases [172, 173] can also increase SLE 
susceptibility. Recently, Ding and colleagues proposed that the cGAS-STING axis 
could be another pathway potentially exacerbating SLE, via the upregulation of type I 
interferon production downstream of cytoplasmic DNA sensing cascades [174]. 
However, STING deficiency in macrophages in fact renders hyper-responsiveness to 
endosomal TLR ligands, and STING knockout mice have shown accelerated 
lymphocyte accumulation and expansion of an IFN-α -responding cell population 
[175]. This therefore suggests inhibitory roles for STING in SLE development. 
Sharma et al. also showed that STING suppression can restrict the expression of 
regulatory T cell activation factor IDO-1 and TLR negative regulators such as A20, 
SOCS1 and SOCS3, contributing to uncontrolled systemic inflammation [175]. Since 
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this effect is not seen in cells lacking IRF3, the transcription factor mediating most of 
DNA sensing responses downstream of the STING-TBK1 axis, it is possible that 
STING is immunosuppressive in inflammatory pathways independent of cytoplasmic 
DNA recognition. Therefore, autoimmune therapies targeting the STING pathway 
should be considered with caution and an awareness of the resultant STING down-
regulation, which may have opposing effects in certain diseases. 
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Figure 5. Cells and cytokines involved in STING-associated autoimmune diseases.  
Unresolved accumulation of cytoplasmic DNA can potentially trigger chronic inflammatory responses 
which result in autoimmune diseases, including (A) systemic lupus erythematosus (SLE) and (B) 
Aicardi-Goutières Syndrome (AGS). Both diseases are strongly associated with persistently enhanced 
type I interferon upregulation named type I interferonopathy and subsequent B and T lymphocyte 
activation that potentiates systemic tissue and organ damage. Though STING dysregulation has been 
suggested to play an essential role in the development of these diseases, current treatment of SLE and 
AGS still relies heavily on anti-inflammatory therapies and DNA resolving methods to ameliorate 
symptoms. Gain of function mutations of STING can cause two autoimmune diseases named (C) 
STING-associated vasculopathy with on-set in infancy (SAVI) and (D) familial chilblain lupus (FCL). 
Both diseases show similar manifestations to SLE and AGS and are much less responsive to STING 
ligands than other immune stimuli. Treatments for SAVI and FCL are limited but JAK inhibitors have 
been shown to ameliorate symptoms in patients with these two diseases. 
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AGS (Aicardi-Goutières Syndrome) is another genetically-based autoimmune 
disease, characterised by DNA-triggered type I interferonopathy [176] (Figure 5). 
Patients with AGS often carry mutations in DNA restriction factors including the 3’ 
exonuclease TREX1 [177, 178], dNTP restriction factor SAMHD (SAM domain and 
HD domain) [179, 180], RNase H2 (ribonuclease H2) [181, 182], dsRNA sensor 
IFIH1 (IFN-induced helicase C domain containing protein 1) [183, 184], and the 
dsRNA-specific adenosine deaminase ADAR1 [185]. These regulators maintain a 
balance between the production and degradation of nucleic acids, providing intrinsic 
protection against immune activation due to “self-recognition”. Mutations of DNA or 
RNA restricting factors cause nucleic acids to accumulate in the cytoplasm leading to 
SLE and AGS. Recent studies show that the type I interferonopathy associated with 
SLE and AGS is potentially cGAS-STING dependent, and that the aberrant IFN-I 
response can be suppressed by the loss of DNA sensor or STING in cells or animals 
expressing mutated Trex1 or Samhd [180, 186].  
 
Gain-of-function mutations in STING have been identified in infants who suffer from 
severe and chronic vasculopathy and pulmonary inflammation, a condition known as 
STING-associated vasculopathy with onset in infancy (SAVI) [39] (Figure 5). 
Mutations of STING V147L, N154S, V155M, and V155R were found to direct it to an 
active conformation enhancing dimerisation and inducing TBK1-IRF3 signalling 
(Table 2). This results in an excessive IFN-I response in fibroblasts, keratinocytes 
and immune cells to attract and amass proinflammatory cells and regulators in 
capillaries and tissues, ultimately causing lesions in these regions. Sustained IFN-I 
signals activate interferon receptors and promote expression of interferon-stimulated 
genes via JAK1-Tyk2 signalling and STAT1-STAT2 dimers. In vitro experiments and 
pioneering clinical studies suggest that JAK adaptor inhibition effectively dampens 
STING-mediated IFN-I over-activity. For instance, the elevated IFN-I levels in biopsy 
samples from SAVI patients can be restored close to that of the normal controls with 
treatment using the JAK inhibitor, tofacitinib [39]. Further investigation is required to 
examine the potential adverse effects of interferon suppression, which is likely to 
increase host susceptibility to infection.  
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Gain-of-function mutations of STING (Table 2) have also been linked to the 
autoimmune disease familial chilblain lupus (FCL) [105, 108], a rare hereditary form 
of SLE commonly associated with cytoplasmic DNA accumulation in monogenic 
mutations of exonucleases TREX1 [187, 188] or SAMHD [189] (Figure 5). A recent 
discovery reports FLC in five members of a four-generation family sharing the same 
TMEM173 (STING) variant that encodes a single polymorphism of G166E. Structural 
analysis of mutated STING dimers reveals strong hydrogen attractions between 
E166 on one monomer and two threonine residues on the associating monomer, 
hence leading to enhanced adaptor dimerization and constitutive IFN-I -activated 
signalling [105]. Although limited treatment data is currently available for FCL, the 
authors showed that continuous administration of the JAK inhibitor tofacitinib can 
markedly ameliorate type I interferonopathy and associated symptoms in two 
patients. A similar therapeutic strategy was previously proposed by Liu and 
colleagues for treatment of STING-associated vasculopathy with onset in infancy 
(SAVI) [39]. Therefore, this therapeutic approach, based on mechanistic data, could 
be adapted to treat type I interferonopathy found in various diseases. 
 
STING Regulates Lipid Metabolism 
A new insight into STING research was recently provided by York and colleagues 
who suggested that this protein is a crucial element of cholesterol metabolism [45]. 
Previous studies indicate that high cholesterol levels in the plasma membrane 
correlate with viral loads and host susceptibility to infections [190, 191]. Virus and 
microbial infections have been shown to modulate lipid metabolism in the plasma 
membrane to facilitate infectivity. For instance, influenza virus encodes fusion protein 
haemagglutinin that is specialised in manipulating membrane lipid to permit 
penetration into the cytoplasm, a central step to viral infectivity and survival [192]. In 
addition, membrane lipids can also form signalling microdomain named lipid rafts 
which are frequently hijacked by HIV for attachment, signalling and budding to 
further promote infection [193, 194]. The antiviral type I interferon response reduces 
cholesterol availability in membranes to prevent viral infection; however the 
underlying mechanism remains largely unknown [195–197]. York’s group recently 
identified that STING/TBK1 signalling is critical to the production of type I interferons 
to reprogram lipid biosynthesis in pathogenic infection [45]. They demonstrated that 
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the shift from lipid biosynthesis to lipid uptake not only affects the plasma membrane 
but also ER membranes, a cue to activate STING, bypassing the dsDNA sensing 
pathway. However, since STING is not the only adaptor for innate immunity against 
pathogenic DNA in the cytoplasm, it is conceivable that additional DNA sensors may 
further enhance STING actions to modulate cholesterol metabolism and promote 
antiviral processes. In light of the membrane fusion theory that potentially mediates 
STING activation [198], virus-host lipid regulation at the plasma membrane offers a 
promising  and novel future research direction. 
 
Therapeutic Targeting of the STING Pathway 
Studies on STING regulatory pathways provide novel insights into antiviral and anti-
inflammatory therapies. Activating STING-dependent pathways has been developed 
therapeutically for antiviral and, more recently, anti-tumour benefit. The predominant 
approach taken has been to introduce STING ligand cyclic dinucleotides to promote 
the IFN-I response, to combat infection or to prevent tumour progression. In contrast, 
type I interferonopathy associated with STING over-activity represents another set of 
pathologies underlying autoimmunity. Counteracting these disease processes 
requires potent suppression of STING signalling; attenuation of the interferon 
receptor adaptor JAK is used as a current target, whilst inhibiting immune cell 
activation may also help ameliorate symptoms.   
 
Anti-tumour Immunotherapies 
Certain types of cancer cells express molecular structures specifically recognised by 
CD8α+ dendritic cells (DCs), which subsequently interact with cytotoxic T cells to 
induce cancer cell death. This event, known as T cell priming, is a prerequisite for 
anti-tumour adaptive immunity relying on activation of CD8α+ dendritic cells to 
promote IFN-I signaling in immature T cells [199]. However, cancer cells also boost 
anti-inflammatory immune cells and regulatory T cells (Treg) to restrict CD8α+ DC 
activity thereby attenuating the activation of tumour-suppressive T cells [200, 201]. 
Therefore, a potent and long-acting adjuvant that can promote CD8α+ DC activities 
is highly desirable to enhance T cell priming and subsequent anti-tumour immunity.  
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It has been reported that the IFN-I response critical to T cell priming during 
tumourigenesis is dependent on the cGAS / STING pathway [42, 43]. Loss of STING 
in dendritic cells abolishes antigen cross-presentation from CD8α+ DC to T cells, 
whereas neither MyD88 nor TRIF knockouts can significantly affect DC IFN-I 
signalling, suggesting that STING may be the only adaptor central to this process 
[43]. In both immunogenic and irradiation-induced tumour models, tumour-derived 
DNA was engulfed and recognised by the universal DNA sensor cGAS prior to 
STING activation [42, 43]. However, direct stimulation with STING ligands also 
enhanced DC production of type I interferons, suggesting that STING-inducing 
therapies may offer potential as anti-tumour adjuvants.  
 
Preclinical studies published recently suggest that DMXAA-derived cyclic 
dinucleotides have been successfully applied in established mouse models of 
malignant tumours achieving sustained tumour regression [202]. In malignant tumour 
B cells, STING also induces an ER stress response through the IRE-1 / XBP-1 (X-
Box binding protein 1) pathway [203]. In the presence of 3’-3’ cGAMP STING dimers 
are phosphorylated and aggregate, rather than undergoing degradation. This 
consequently enables prolonged STING signalling to induce apoptosis of tumour 
cells. Similarly, Tang et al. showed administration of 3’-3’ cGAMP induces rejection 
of chronic lymphatic leukemia in mouse models [203]. Another promising vaccine 
candidate is the recently developed STINGVAX which combines granulocyte-
macrophage colony-stimulating factor (GM-CSF) and formulated 2’-5’ – 3’-5’ linked 
cyclic dinucleotide [204]. In various established in vivo tumour models, STINGVAX 
has shown notable positive effects on dendritic cell activation and in promoting 
tumour-infiltrating T cells. Interestingly, activated cytotoxic T cells also upregulate the 
expression of PD-L1 (programmed death ligand 1), which enhances the therapeutic 
action of pro-apoptotic ligand PD-1 to promote tumour cell death. Although these 
STING-based vaccines have recently been developed and have been tested in 
mouse models, the synergistic effect of the combined STING agonist and immune 
promoting therapy represents a novel strategy to combat tumours by reinforcing both 
adaptive immunity and anti-tumour targets. 
84 
 
 
JAK Inhibitors Ameliorate STING Mutated Autoimmunity 
Inhibition of STING signalling can be achieved by targeting interferon receptors. As 
previously mentioned, gain-of-function mutations in TMEM173 (the gene encoding 
STING) underlie type I interferonopathies that manifest in the autoimmune diseases, 
SAVI [39] and FCL [105]. Constitutive STING signalling was detected in both of 
these diseases resulting in dysregulated IFN-I signalling via interferon receptors and 
the adaptors JAK and Tyk. This leads to the accumulation of activated STAT1/2 
dimers in the nucleus, promoting transcription of interferon-stimulated genes. Both 
Liu and König’s groups demonstrated that treatment with the JAK1/3 inhibitor 
tofacitinib in patient biopsy samples suppresses STAT activation and restores the 
STING response to immune stimuli similar to healthy control cells [39, 105] (Figure 
5).   
 
Following the work of Liu and colleagues, Fremond’s group conducted an 18-month 
clinical investigation on three patients expressing STING-mutations to assess the 
efficacy of the JAK1/2 inhibitor ruxolitinib [205] (Figure 5), which was previously 
found to partially inhibit STAT activation in in vitro studies of STING mutants [39]. 
Marked amelioration of systemic inflammation and reduction of interferon-stimulated 
gene expression was consistently observed in all three patients and in the 
subsequently recruited additional four patients with STING gain-of-function 
mutations. However, suspension of JAK inhibition in one patient resulted in a 
dramatic inflammatory relapse, though rescued by re-introducing ruxolitinib, 
demonstrating that this approach may be unsustainable and requires continuous 
monitoring [205–207]. Nonetheless, it is arguable that the partial inhibition of JAK-
STAT pathway has the advantage of preserving STING-dependent immune 
protection against infection in these patients, since no excessive infection incidents 
were observed during these clinical trials [205]. Thus, it is timely to determine 
whether such JAK inhibitors can be modified and adapted for future treatment of type 
I interferonopathy. 
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Anti-inflammatory Biologics 
Anti-inflammatory biologics represent a further opportunity to suppress interferon 
responses in order to control type I interferonopathy in autoimmune diseases, 
including but not limited to SLE, a major manifestation linked to STING over-activity. 
For instance, the anti-IFN-α drug sifalimumab is effective in controlling cutaneous 
and joint pain in SLE patients [208] (Figure 5).  
 
Another approach to control SLE in STING gain-of-function mutations is to deplete or 
inhibit B-cell responses to prevent the over-production of auto-antibodies. The 
effective anti-SLE biologics, belimumab, targets the BLyS protein of B lymphocytes, 
preventing B cell activation and expansion critical to the production of autoantibodies 
and downstream activation of T lymphocytes [209, 210] (Figure 5). A series of stage 
II and stage III clinical trials have shown effective B-cell inhibition and significant 
improvement of clinical symptoms in combination with traditional care therapy of SLE 
in the treatment group compared to placebo control, whilst drug tolerance and 
immunosuppression-induced infection susceptibility were not markedly increased 
[210–212]. This suggests an effective drug efficacy and safety of belimumab over 
another B-cell depleting drug rituximab, which failed to ameliorate SLE symptoms in 
phase II and III trails [213]. Unlike JAK inhibitors and anti-IFN biologics, B-cell 
targeted therapies are much less effective in controling type I interferonopathy that 
consequently cause complex inflammatory responses in STING mutant patients. 
However, they are still commonly used to treat the SLE-related consequences of 
STING over-activation to stall symptom deterioration, while they have also been 
considered suitable adjuvant candidates for STING-targeted therapeutics.   
 
Delivery of STING ligands 
Accumulating evidence link STING-mediated IFN-I signaling to anti-tumour activity, 
and thus STING ligands have been proposed to offer promising immune-enhancing 
therapies to defend against DNA infections and tumourigenesis [41, 214]. However, 
targeting intracellular proteins such as STING remains challenging as the plasma 
membrane is a highly hydrophobic and size-selective barrier that resists passive 
entry of chemicals [57]. In contrast to the de novo STING ligand 2’-3’ cGAMP [48], 
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other cyclic dinucleotides are produced exogenously by pathogens and introduced 
into the cytoplasm by active transport or particle fusion [47, 50, 215]. Since the 
hydrophilic phosphate groups in dinucleotide compounds are strongly repelled by 
membrane lipid bilayers, designing an effective delivery system for cyclic 
dinucleotides would provide a significant step forward in the development of STING-
specific therapeutics. 
 
Under in vitro studies, transfection of microbial cyclic dinucleotides is aided by 
digitonin [35, 39, 50, 104] or liposomal-based systems such as Lipofectamine® [47, 
102] (Figure 6). The former method, first described by Woodward’s group [35], aims 
to achieve reversible permeabilisation of cellular membranes to increase uptake of 
chemicals [216–218], but is limited to in vitro studies due to high toxicity in vivo. In 
contrast, the liposomal-based delivery system is based upon the principle of 
encapsulating drugs in artificial double-layered liposomes for cytoplasmic delivery via 
liposomal fusion. The system is highly adapted for a variety chemicals and has been 
used in both laboratory studies and clinical practice [219].  
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Figure 6. In vitro and in vivo delivery of STING agonists. 
The plasma membrane is a selectively permeable barrier that prevents cytoplasmic entry of large or 
hydrophilic molecules, including naked cyclic dinucleotides (CDNs) (1). In vitro (blue background) 
delivery of dinucleotide compounds could be achieved by the liposomal delivery system (2), or via 
reversible permeabilisation of plasma membrane to allow diffusion of naked CDNs into the cytoplasm 
(3). Recently designed YSK05-containing liposomes (4) could carry c-di-GMP across plasma 
membranes to induce DDX41-mediated STING activation as well as enhance the expression of MHC 
class I molecules and T cell co-stimulatory receptors (not demonstrated), and thus it is considered to 
be a potential adjuvant for cancer immunotherapy. In addition, the polyethyleneimine/ hyaluronic acid 
(LH) hydrogel-based vesicles use phagocytosis to deliver both STING ligands and antibody-
stimulating agents such as ovalbumin (dark triangles) to cells (5), and enhance both STING-
dependent innate immunity and MHC class II-activated adaptive immunity to suppress cancer growth. 
Both YSK05 particles and LH hydrogel-based particles have been tested in vivo (green background) 
to stall tumour progression in mice (6). 
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In light of the liposome-based designs, Miyabe’s group has reported that the YSK05-
based lipid particles were able to entrap and deliver cyclic di-GMP into the RAW 
264.7 macrophage cell line [220] (Figure 6). These particles induced cellular 
expression of type I interferon genes which were effectively blocked by the TBK1 
inhibitor BX795, suggesting that the interferon response was specifically induced via 
the STING/TBK1 pathway. Furthermore, the YSK05-based particles also express 
high levels of the antigen-presenting molecule MHC class I and T cell co-stimulating 
molecules CD80 and CD86 that are a prerequisite of T lymphocyte activation; all of 
these characteristics suggest they offer potential as adjuvants in anti-tumour 
therapies. Preliminary tests carried out by Miyabe and colleagues showed that mice 
immunized with cyclic di-GMP containing YSK05-liposomes reject tumour 
implantation compared to matched controls [220]. Subsequently, Nakamura’s group 
demonstrated that in vivo injection of these particles greatly enhances the 
expression of IFN-I and MHC class I molecules in tumourigenic mice, resulting in 
augmented NK cell activation and potent innate immune protection against lung 
melanoma metastasis [221]. Therefore, the YSK05 liposomes offer a potential 
vehicle to assist delivery of STING ligands and to develop STING-based adjuvants 
for cancer immunotherapy. 
 
As an alternative approach, a nanoparticle-based delivery system developed by Lee 
and colleagues also enables in vitro delivery of cyclic dinucleotides to target STING 
pathways for anti-tumour effects [222] (Figure 6). This method employs 
polyethyleneimine / hyaluronic acid (LH) -based hydrogels to enclose dinucleotide 
drugs into micron size spheres, which are selectively taken up by phagocytic cells 
such as RAW 264.7 macrophages, L929 fibroblasts and bone marrow-derived 
macrophages (BMDMs), but not by non-phagocytic fibroblasts. Thus, the micron-
sized particles appear to target phagocytosis specifically to gain entry into the 
cytoplasm. Furthermore, Lee et al. showed that LH-cGAMP hydrogel can induce 
IFN-I spikes in RAW264.7 macrophages, which were more than twice the magnitude 
of that induced by lipofectamine-delivered cGAMP at the same dose [222]. 
Administration of ovalbumin-containing LH-cGAMP particles in mice activates both 
the type I interferon response and humoral production of IgG to protect against 
ovalbumin challenge. Taken together, Miyabe and Lee’s work indicates that the 
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modified liposome-based delivery systems can markedly enhance in vitro and in vivo 
delivery of cyclic dinucleotide to cytoplasmic STING, and this success will promote 
the development of novel cancer vaccination and immunotherapies dependent on 
STING signalling.  
 
Conclusions 
Cytoplasmic DNA has been implicated in many human pathologies, many associated 
with chronic inflammation. Research has revealed that the ER transmembrane 
protein STING is a crucial player in dsDNA pathogen -sensing pathways whose 
dysregulation contributes to the development of several diseases. By responding to 
DNA sensors and cyclic dinucleotides, STING induces IRF3- and NF-κB –dependent 
pathways to elicit proinflammatory responses against infection and cancer 
progression. STING also directly cross talks with several other regulators to 
modulate critical biological processes including autophagy and cholesterol 
biosynthesis. It is evident that activating STING results in the type I interferon 
response to protect against infection and tumour formation, while dysregulated gain-
of-function STING mutations lead to detrimental consequences of autoimmunity. 
Understanding the molecular signalling mechanisms of STING activation has 
provided new insights to advance therapeutic strategies in treating infection, cancer 
and autoimmune diseases. It has also prompted the development of intracellular 
delivery systems to administer STING agonists. Despite the fact that STING has only 
been studied for a decade, this adaptor protein will continue to attract attention in 
immunology research and clinical practice into the future. 
 
List of Abbreviations: 
 
STING: STimulator of INterferon Genes 
ER: Endoplasmic reticulum 
DNA: deoxyribonucleic acid 
RNA: ribonucleic acid 
dsDNA: double-stranded DNA 
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ssRNA: single-stranded RNA 
cDNA: complementary DNA 
mtDNA: mitochondrial DNA 
TRAP: Translocon-associated protein 
ERAD: Endoplasmic Reticulum-associated degradation 
Type I interferon/ interferon: IFN-I/ IFN 
TBK1: TANK binding kinase 1 
IRF: Interferon regulatory factor 
VSV: Vesicular stomatitis virus 
CDN: cyclic dinucleotide 
cGAS: cyclic guanosine monophosphate – adenosine monophosphate synthase; 
cyclic GMP-AMP synthase 
cGAMP: cyclic guanosine monophosphate – adenosine monophosphate; cyclic 
GMP-AMP 
DAI: DNA-dependent activator of IFN-regulatory factor 
IFI61: IFNγ-inducible protein 16 
DDX41: DEAD-Box Helicase 41 
HCMV: Human cytomegalovirus 
HSV: Herpes simplex virus 
HIV: Human immunodeficiency virus 
MLV: Murine leukemia virus 
SIV: Simian immunodeficiency virus 
NLR: NOD-like receptor; nucleotide-binding oligomerization domain-like receptor 
MAVS: Mitochondrial antiviral signalling protein 
RLR: RIG-I like receptor; retinoic acid-inducible gene I –like receptor 
MDA5: Melanoma differentiation-associated protein 5 
NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells 
MAMs: Mitochondria-associated membranes 
Pol III: RNA polymerase III 
Atg: Autophagy-related gene 
ISG: Interferon-stimulated gene 
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Tyk: Tyrosine kinase 
JAK: Janus kinase 
STAT: Signal transducer and activator of transcription 1 
IL-1α: Interleukin-1α 
TNF-α: Tumour necrotic factor-α 
IKKα/β: IκB kinase α/β subunits 
DENV: Dengue virus 
hSTING / mSTING: human STING / mouse STING 
SNP: single nucleotide polymorphism 
HAQ mutant: R71H-G230A-R293Q mutant 
SLE: Systemic Lupus Erythematous  
AGS: Aicardi-Goutières Syndrome 
TRIM56: Tripartite motif containing 56 
AMFR: Autocrine motility factor receptor  
INSIG1: Insulin-induced gene 1 
RNF5: RING finger protein 5 
AMPK: Adenosine monophosphate activated protein kinase 
microRNA: miR 
PDE: phosphodiesterase 
TREX1: 3’ repair exonuclease 1 
ISGF3: Interferon-stimulated gene factor 3 
ANA: Antinuclear antibody 
SAMHD: SAM domain and HD domain 
RNase: Ribonuclease 
IFIH1: IFN-induced helicase C domain containing protein 1 
ADAR1: Adenosine deaminase acting on RNA 1 
FCL: Familial Chilblain Lupus 
SAVI: STING-associated vasculopathy with onset in infancy 
DC: Dendritic cell 
Treg: Regulatory T cells 
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XBP-1: X-Box binding protein 1 
GM-CSF: Granulocyte-macrophage colony-stimulating factor 
PD-L1: Programmed death ligand 1 
MHC class I: Major histocompatibility complex class I 
LH: Polyethyleneimine / Hyaluronic acid 
BMDM: Bone marrow-derived macrophage 
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1.6 Interferon signalling 
STING is an indispensable regulator of type I interferon signalling as initially described 
by Ishikawa and Barber. In the next section, I summarise the interferon signalling and 
the importance of type I interferon in immune regulation and pathogenesis.  
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1.6.1 Interferons 
The term “interferon” was first proposed by Isaaca and Lindenmann to describe a type 
of secretory protein produced in chick embryonic culture (chorio-allantoic membrane) 
that could interfere influenza virus infection in other cells [134]. After 60 years of 
research on these proteins, our knowledge of interferons has expanded with regard to 
their classifications, actions, and the physiological changes that are associated with 
either their activation or dysregulation. Interferon release is central to the activation of 
cellular and molecular responses against infections, tumourigenesis, and neurological 
disorders [135]. They are ubiquitously produced by many tissues and cells including 
monocytes, macrophage, dendritic cells, lymphocytes, leukocytes, fibroblasts, and 
natural killer cells to regulate immune and proliferative functions and to enhance 
further immune activations [128, 135–138].  
 
Interferons (IFN) belong to the super family of class II α-helical cytokines which are 
further categorised into three subtypes, I, II and III (IFN-I, IFN-II and IFN-III) [139]. 
Interferon signalling is initiated by cytokines binding to heterodimeric interferon 
receptors on the plasma membrane to trigger the intracellular Janus kinase - signal 
transduces and activators of transcription (JAK – STAT) pathways, leading to the 
phosphorylation and assembly of STAT dimers [140]. This complex recruits IRF9 to 
form a trimeric transcriptional complex ISGF3 (STAT1-STAT2-IRF9) which migrates 
to the nucleus and promote the expression of interferon-stimulated genes. Although 
interferons engage distinct sets of receptors and activate specific DNA promoter 
regions, their signalling process is highly conserved, facilitating a rapid antiviral and 
immune regulatory response. 
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1.6.2 Type II and Type III interferon signalling 
The type II and the type III interferon families consist of fewer members in comparison 
to the type I interferons. The IFN-γ is encoded by multiple genes and is largely 
released by T lymphocytes and natural killer cells. It binds to a distinct receptor 
complex the interferon-γ receptor (IFNGR or IFN-γR) which promotes MHC II -
dependent pathogen eradicating mechanisms [141–143]. A crucial function of IFN-γ 
is to program macrophage proinflammatory polarisation (Th1 or M1 activation) [42, 
144] which has been discussed in Chapter 1.2.2.2. Whilst IFN-γ has similar, albeit less 
significant function in direct host microbial/stress defence, it strongly promotes 
adaptive immune activation and potentiates antigen-specific immune response and 
cytotoxic cytokine secretion [144–148]. IFNGR activation induces JAK1/2 - TyK2 
(Tyrosine kinase 2) which assembles STAT1 homodimers [149]. STAT1 promotes 
nuclear accumulation of gamma-interferon activating factor (GAF) and binding to 
interferon-γ -specific promoter site (GAS), which controls the expression of interferon-
stimulated genes (ISG) [150, 151].  
 
IFN-III is a family of IL-10 related proteins consist of IFN-λ1, -2, -3 (also known as IL-
29, IL-28A and IL-28B, respectively), and a recently identified and poorly characterised 
IFN-λ4 [152–154]. These cytokines signal through the heterodimeric interferon-λ 
receptors (IFNLR) complex made up of interferon-lambda receptor 1 (IFN-λR1 or 
CRF2-12) and IL-10 receptor 2 (or CRF2-4). In addition to the STAT1 dimer-GAS axis, 
IFN-λ signalling also assembles STAT1-STAT2 heterodimer which further recruits 
IRF9 to form ISGF3. This complex recognises the DNA promoter interferon-stimulated 
response element (ISRE) to induce expression of interferon-stimulated genes (ISG) 
[155–157]. IFN-λ has also been shown to activate STAT3, STAT4 and STAT5 in a cell 
specific manner [158]. Since type I and type III interferons activate the same kinase 
cascades and both GAS and ISRE promoted gene expression, their biological 
activities are largely similar. Viruses including vesicular stomatitis virus, Dengue virus, 
Sindbis virus, encephalomyocarditis virus and rotavirus can activate both IFN-I and 
IFNIII [145,151]. IFN-λ is preferentially induced over type I interferons by certain 
viruses such as influenza A virus and respiratory syncytial virus as an mechanism of 
immune redundancy, potentially to protect local cell/tissue environment [160–162].  
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1.6.3 Type I interferon signalling 
The IFN-I family includes the abundantly expressed IFN-α and IFN-β and numerous 
less-widely expressed cytokines such as IFN-ε, -κ, -τ, and –ζ [139]. In humans, IFN-α 
is transcribed by 12 different genes whereas IFN-β is encoded by a single transcript 
[163]. The type I interferons are stimulated in macrophages, myeloid and plasmacytoid 
dendritic cells amongst a wide spectrum of infected cells. The type I interferon 
response is triggered in response to RNA and DNA sensing by TLRs, RLRs and 
cytosolic DNA sensors. These PRR receptors mediate signal transduction through 
adaptor proteins TRIF, MAVS and STING, where their activities converge at the 
induction of TANK-binding kinase 1 (TBK1) and IκB kinase (IKK), which further recruit 
and activate IRF3 and NF-κB [164–167]. These transcription factors then accumulate 
into the nucleus and initiate the expression of type I interferons [Reviewed in [81]]. 
IRF3, NF-κB and other IRFs (IRF1, IRF4, IRF5, IRF7 and IRF8) bind to different sets 
of the positive regulatory domains (PRD) of interferon promoters [168–171]. TNF also 
weakly activates type I interferons due to its induction of IRF1 rather than IRF3 and 
IRF7 [172, 173]. All transcription factors other than IRF3 and IRF7 have lower and 
different affinities for interferon promoters and hence these two IRFs are the most 
critical regulators of interferon expression [81]. The type I interferon response not only 
provides early defence against infection and immune dysfunction, it also induces a 
secondary and higher amplitude of interferon-stimulated response. A schematic 
summary of type I interferon / ISG signalling cascade is shown in Figure 3. 
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Figure 3. Schematic summary of Type I interferon signalling/ ISG feedback pathway. 
Pathogen-derived molecules and nucleic acids are recognised by transmembrane and 
cytoplasmic pattern-recognition receptors (PPRs) and induce signalling activation of NF-κB 
and IRF3 –dependent transcription of type I interferons (predominantly IFN-α and IFN-β). 
These cytokines are released to the extracellular interferon receptors IFNARs and respond in 
both autocrine and paracrine manners. These receptors couple to the adaptor protein Tyk2 
and JAK1 which activates three transcriptional complexes: ISGF3 (consists of STAT1-STAT2-
IRF9), STAT1 homodimer, and STAT3 homodimer. These factors bind to and activate GAS 
or ISRE promoter-containing interferon-stimulated genes (ISGs), including the ones indicated 
in the figure. STAT3-dependent ISG production negatively feeds back to STAT1 activation 
and hence suppresses further ISG response. ISGs are responsible for various cellular 
response against microbial infections and immune regulatory activities. Figure summarised 
from [174–177]. Abbreviations: ER= endoplasmic reticulum, JAK1= Janus kinase 1, IFNAR= 
Interferon-alpha/beta receptor, TyK2= Tyrosine kinase 2, STAT= signal transducer and 
activator of transcription 1,  GAS= gamma-interferon-activation site, ISRE= interferon-
stimulated response element, IP-30= gamma-interferon-inducible protein 30, GBP1= 
guanylate-binding protein 1, OAS= 2’-5’-oligoadenylate synthase, MxA= Myxovirus resistance 
protein 1, IFIT1= interferon-induced protein with tetratricopeptide repeats 1, ISG15= 
interferon-stimulated gene 15.  
116 
 
IFN-I signals through the heterodimeric IFNAR1/IFNAR2 receptor complex named 
IFNAR (interferon-α/ β receptor) [156]. The receptor complex shows little architectural 
change when binding to cytokines; however, the receptor affinity to IFN-β was ten to 
twenty-fold higher than that to IFN-α, and the former is reflectively more capable of 
activating downstream signalling effects [178]. Following IFNAR activation, kinases 
JAK1/2-TyK2 are activated and in turn induce ISGF3 formation (STAT1-STAT2-IRF9) 
[140, 179] which promotes ISRE-regulated gene transcription [155–157]. Unlike IFN-
γ which recruits STAT1 homodimers, IFN-I activates both GAS and ISRE promoters 
via STAT1 homodimers or ISGF3 [Reviewed in [174]], exhibiting an overlapping but 
much broader antiviral response compared to IFN-γ. IFN-I/IFNAR also recruit STAT3 
homodimer to antagonise STAT1 dimer assembly but it supports ISGF3-dependent 
antiviral ISG expression [180, 181]. The competition between STAT1 and STAT3 
controls an appropriate cellular response. 
 
Gene CHIP (chromatin immunoprecipitation) analysis of type I (α and β) and type II (γ) 
interferon-activated human fibrosarcoma cells revealed that STAT1 and gamma-
interferon inducible GTPase guanylate-binding protein (GBP) are universally induced 
by all three interferons, whereas IRF1 and gamma-interferon-inducible protein (IP-30) 
are preferentially stimulated by IFN-γ [182]. Furthermore, IFI16, STAT1 and GBP-2 
are preferentially induced by IFN-β over IFN-α. This selective ISG induction is likely 
regulated by STAT1 C-terminal transcriptional activation domains (TAD, or 
transactivation domain) where multiple serines are available for targeting by JAK, TyK, 
and other kinases (p38, CaMKII, PKCδ and others) [183–187].  
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1.6.4 Interferon-stimulated genes (ISG) 
More than a hundred ISGs have been found to control cellular processes including but 
not limited to chemotaxis, apoptosis, cell proliferation, infection detection and defence, 
and some ISGs obtain redundant functions to others [188]. Some ISGs have been 
characterised with specific functions, such as the RNA sensors OAS1 and PKR, 
whereas others are multifunctional, such as the pro-apoptotic factors of the caspase 
family. One of the most important ISG is IRF7. This interferon-activating transcription 
factor has high affinity for interferon promoters yet it is only expressed at high levels 
during ISG production to exhibit and sustain further antiviral response [81, 189, 190]. 
Chapter 1.5 (Table 4) summarises some of the ISGs involved in apoptosis, immune 
modulation, cell adhesion and motility, and antiviral responses, although many more 
ISGs are being identified to have physiological importance in enhancing innate 
immunity [176, 191, 192].  
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1.6.5 Mechanisms of activating type I Interferons  
Despite the similarity between type I and type III interferons, the antiviral response is 
a lot potent in the former [193]. IFN-α and IFN-β are the most highly expressed 
cytokines of the interferon superfamily. Rapid release of type I interferons underpins 
the success of anti-pathogenic defence. Apart from the TRIF-dependent signalling, 
other intracellular TLRs also contribute to interferon release through MyD88 and the 
transcription factors IRF1, IRF3 and IRF7 [164, 194]. The depletion of RNA-
recognising TLR3, TLR7, and TLR8 in combination has not fully abolish the IFN-I 
release, nor did the depletion of the CpG motif-containing DNA sensor TLR9 impair 
the recognition of DNA challenge. This evidence highlights the necessity and 
importance of TLR receptor redundancy in nucleic acid sensing mechanism.  
 
As previously mentioned (Chapter 1.3), the mitochondrial adaptor protein MAVS and 
the ER adaptor STING are the two TLR-independent platforms downstream of nucleic 
acid sensing mechanisms [Reviewed by [118, 195]]. These two adaptors are central 
in complementing the canonical PRR recognition paradigms, where MAVS facilitates 
RNA activated RLR receptors and RNA sensor such as OAS and RNAse L, and 
STING regulates DNA-activated sensor dynamics. Signalling though these two 
proteins results in distinct IFN-I induction mechanisms. Upon interacting with RNA 
sensors via the N-terminal CARD domain, MAVS polymer transforms into prion-like 
filaments and complexes with multiple TRAFs (tumour necrotic factor (TNF) receptor-
associated factors) to activate the TBK1 – IRF3 axis [165, 196–198]. TBK1 and IKK 
trigger IRF3 and NF-κB - dependent signalling events respectively, and together they 
upregulate type I interferon gene expression. MAVS has been found on both 
peroxisomal and mitochondrial membranes, especially at mitochondria-associated 
membranes (MAM) [103, 199].   
 
The discovery of DNA sensing adaptor protein STING by Ishikawa and Barber led to 
a new paradigm of understanding virus infection and autoimmunity [133]. As 
mentioned in Chapter 1.3.2 and reviewed in the Chapter 1.5 [119], STING responds 
to a number of DNA sensors and signalling messengers named cyclic dinucleotides 
(CDN) [119]. CDNs consist a chemical made of two purine nucleotides GMP 
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(guanosine monophosphate) and AMP (adenosine monophosphate). These 
molecules are either directly released into the cytoplasm by bacteria such as Listeria 
monocytogenes, Vibrio cholerae, Streptococcus pyrogenes and Staphylococcus 
aureus [200–202] or endogenously produced from ATP and GTP by the DNA sensor 
cyclic-GMP-AMP synthase (cGAS) [114, 203, 204]. Bacteria-secreted STING ligands 
c-di-AMP, c-di-GMP and c-GMP-AMP (cGAMP or 3’-3’ cGAMP) are joint by two 3’-5’ 
phosphodiester bonds between the nucleotides whereas the endogenous cGAMP 
contains a combination of canonical 3’-5’ bonds and a unique 2’-5’ link between GMP 
and AMP, giving its name 2’-3’ cGAMP (cyclic[G(2’-5’)pA(3’-5’)p]). Ligand recognition 
activates STING dimers which signal though the TBK1-IRF3/NF-κB –dependent 
interferon signalling cascade [165–167]; a pathway that is common to both MAVS and 
intracellular TLRs. 
 
Both MAVS and STING protect the host by recognising viral and bacterial genomes 
or their products. RIG-I/MAVS and cGAS/STING pathways not only converge at the 
induction of IRF3-mediated interferon response, they also directly collaborate in 
antimicrobial defence. RIG-I -engaged MAVS at the MAM of mitochondrial and ER 
membranes can transduce activation signal via STING, displaying an amplification 
antiviral response to ssRNA viruses, such as Japanese encephalitis virus, Sendai 
virus, Hepatitis C virus and vesicular stomatitis virus [133, 205, 206]. The DNA virus 
herpes simplex virus-1 (HSV-1) can directly activate both STING and MAVS by either 
the DNA-sensing mechanism and Pol III –catalysed DNA breakdown to generated 
ssRNA for RIG-I/MAVS recognition [207, 208]. In contrast, single-stranded retrovirus 
HIV can be detected by RIG-I while its cDNA, produced by reverse transcription, can 
be processed and recognised by DNA sensors TREX1 and cGAS which activate 
STING [116, 209–211]. MAVS, STING and nucleic acid sensing redundancy not only 
broadens detection spectrum but also prevents viral antagonism of interferon 
response, providing alternative sources for antiviral defence. 
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1.6.6 Mechanisms of type I interferon inhibition 
Type I interferons are regulated at various levels, from the detection of pathogens to 
the production of interferon-inhibitory ISG. The need for downregulating type I 
interferon signalling is mainly to restricting the amount and duration of proinflammatory 
response [174]. Intercepting IFN-I signalling can be achieved by E3 ubiquitin ligase 
SCF(HOS) (Skp1-Cullin1-HOS-Roc1)-dependent degradation of IFNAR or via 
clathrin-dependent receptor endocytosis [212, 213]. Furthermore, IFNAR activity is 
also regulated by Jak and TyK through USP18 (Ubiquitin specific protease 18) and 
SOCS (suppressor of cytokine signalling) proteins via IFN-I promoted negative 
feedback loops. USP18 competitively associates with IFNAR and hence dissociating 
Jak1 from the receptor as well as blocking the recognition site for IFN-α2 [214, 215]. 
Similarly, SOCS1 indirectly reduces the level of active IFNAR by phosphorylating and 
associating with TyK2, hence blocking its activation capacity [216]. Persistent infection 
also induces interferon-inhibitory ISG release, such as ISG56, which is induced by 
VSV (vesicular stomatitis virus) that disrupts STING - TBK1 communication and 
consequent in a reduced IRF3-mediated ISG production [217]. The regulation of IFN-
I signal protects against chronic inflammation and yet can be hijacked by viruses to 
evade antiviral response. 
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1.6.7 Virus inhibition of STING-dependent type I interferons 
Type I interferon responses are readily induced by viral and bacterial infections and 
therefore numerous PRRs are limited by microbial evasion techniques as reviewed in 
the literature [218–220]. The two intracellular antiviral adaptors STING and MAVS are 
heavily suppressed in favour of establishing infection. As these central adaptors 
mediate the majority of intracellular pathogen detection, antagonising them in addition 
to the upstream sensors would be an effective approach to intercept interferon 
activation. As reviewed in Chapter 1.5 [119], several viruses are known to specifically 
degrade DNA sensors and STING by secreting protease complexes, and members of 
the family Flaviviridae are the most renowned culprits [221].  
 
Flavivirus has the most abundant members compared to the other three genera of the 
family (Hepacivirus, Pegivirus, and Pestivirus). This genus is comprised of arthropod-
borne viruses (arboviruses) that encode the positive-sense single stranded (ss)RNA 
genome with a 5’ G7 cap [221]. This group contains Dengue virus (DENV), Yellow 
Fever virus (YFV), West Nile virus (WNV), Japanese encephalitis virus (JEV), and Zika 
virus (ZIKV). These pathogens are known to cause severe diseases including 
haemorrhagic, fever, and various neurological disorders such as encephalitis (brain 
inflammation) and microcephaly (a birth defect associated with a reduced head 
circumference) [222, 223]. Through insect vectors, these viruses penetrate 
mammalian cells and introduce their RNA molecules, containing a single, 9.5 to 12.5 
kb long open reading frame, into the host cytoplasm where they hijack the de novo 
molecular machineries to translate a single polyprotein. The protein is processed by 
viral and cellular enzymes and released as three structural (S) and seven non-
structural (NS) proteins [224]. The structural proteins capsids (C), pre-membrane 
proteins (prM) and envelop glycoproteins (E) support the virion structure [225], and 
the non-structural proteins form the RNA polymerases, helicases, proteases, and 
nucleoside phosphatases and together functions as the replicative complex [224]. 
Compared to the other five non-structural proteins (NS1, NS2a, NS2b, NS4a and 
NS4b), the functions of NS3 helicase and NS5 RNA polymerase are pivotal for viral 
replication [226, 227]. Due to these features, anti-replication drugs often target NS3 
activation and binding to co-factor NS2B or NS5-dependent RNA-capping 
methyltransferase activity and RNA polymerisation [228, 229]. Furthermore, the 
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structural C and E proteins are also common targets to block attachment, folding and 
spreading of flaviviruses. Examples are C protein inhibitor ST-148 and E protein 
inhibitors NITD-448 and Compound 6 [230, 231]. 
 
Chapter 1.5 (Viral Evasion of STING, Page 73) [119] has reviewed the key strategies 
used by flaviviruses to inhibit and evade STING activation. However, Dengue virus 
amongst other flaviviruses can inhibit only human but not mouse STING [232, 233]. 
The principle of inhibition lies at residue 78R/79G within the third transmembrane 
domain which is a cleavage target for dengue-secreted NS2B/3 protease complex 
specifically present in human and closely related species [234]. STING in Rodents and 
several primates contains different sequences in the Dengue cleavage site and are 
thus remain immune responsive to dengue infection.  
 
Studies of STING-targeted type I interferon inhibition are also considered critical for 
characterising novel flaviviruses, one of which is Zika virus. ZIKV is emerging as an 
important pathogen around the globe [235–237]. ZIKV and DENV are closely related 
species and can induce similar and cross-reactive serological responses in human, 
suggesting similarity between their envelope protein structures [238, 239]. This 
characteristic is likely to impact on their pathogenesis in human and animals and thus 
it is of intense interest whether these two viruses adopt the same STING blocking 
strategies. ZIKV is most devastating in mother-to-child transmission and causing 
microcephaly and other neurological defects in the new born [240, 241]. In human, this 
transmission is highly dependent on the placental macrophages which substantially 
facilitate ZIKV replication and spread [54]. Although type I interferon signalling was 
detected in these cells, limited viral restriction and cell death was observed. It has 
been established that early ZIKV invasion in murine placenta can induce type I 
interferons which lead to tissue remodelling and fetal resorption [242]. Furthermore, 
ZIKV also expresses NS5 protease to intercept interferon-activated STAT1 and 
STAT2 in human cells [243, 244], a strategy also observed by DENV-secreted NS5 
[245, 246]. I therefore wanted to test whether the ZIKV-secreted NS2B/3 protease 
homolog is capable of degrading STING, and whether macrophages are essential 
regulators of ZIKV infection. Addressing these questions will help us reveal novel 
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functions of STING and to compare and contrast the physiological regulation of key 
immune mediators that can distinguish flaviviruses. Understanding virus-mediated 
interferon inhibitory mechanism is critical to innovate antiviral therapeutic development. 
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1.6.8 Type I interferon -associated pathologies 
Dysregulation of type I interferons and the stimulated ISG response is implicated in a 
variety of pathologies, ranging from immunodeficiency to autoimmunity.  
 
Signalling in both autocrine and paracrine manners, type I interferons form one of the 
broadest acting signalling networks across the host system, involving almost every 
cell type and tissue, and exhibiting their pivotal role in early pathogen defence. The 
role for IFN-I in bacterial and viral infections has been extensively reviewed [175, 247, 
248]. Deficient IFNAR expression in mice reduces early viral interference as observed 
by an elevated and extended vaccinia virus accumulation in the liver and spleen 
compared to wildtype (WT) mice [249]. Also, both the individual and combined 
knockout of IRF3 and IRF7 can significantly enhance infection susceptibility to HSV-1 
[250]. Additionally, RIG-I deficient variants render higher severity of influenza virus 
infection in patients [251] and loss-of-function STING allele HAQ (R71H-G230A-
R293Q) leads to a defective type I interferon response and an enhanced 
Streptococcus pneumoniae and Legionella pneumophila infection [252, 253]. 
Furthermore, cytotoxicity and antigen presentation on CD8+ T cells, macrophages and 
CD8α+ dendritic cells also rely on the appropriate IFN-I signature, and it potentiates B 
cell-associated humoral immunity [254–256]. Breast cancer, melanoma and 
gastrointestinal cancer patients also displayed downregulated IFN-I (IFN-α) immunity 
in peripheral blood lymphocytes, suggesting an possible role for type I interferon signal 
in cancer progression and immunotherapies [257]. 
 
Excessive IFN-I production, termed type I interferonopathy, also drives pathological 
processes. Non-resolving inflammatory activation is a major cause of disease. In 
chronic infection, viruses can persist in the host system and continuously stimulate 
type I interferon that damage the infected tissues and organs. Human 
immunodeficiency virus (HIV), Hepatitis C virus (HCV) and the mouse chronic infection 
model lymphocytic choriomeningitis virus (LCMV) have been shown to induce and 
exacerbate chronic IFN-I release, leading to a dysregulated and prolonged immune 
response that stimulates cell apoptosis [258, 259]. Although IFN-I is often suppressed 
by viruses to establish a stable niche in the host, during the pathogenic stage of 
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infection, type I interferons are highly active and they can induce aberrant proliferation 
and activations of CD4+ T cells and antibody-producing B cells. Although IFN-I initially 
promotes viral clearance and cellular activations, a prolonged presence of IFN-I signal 
drives immune exhaustion, and a proportion of patients with established chronic 
infection show IFN-α unresponsiveness potentially due to immunosuppression via an 
IFN-I blocking negative feedback loop [Reviewed in [260, 261]]. IFN-I signalling can 
then become a double-edged sword in specific viral infections. For instance, LCMV 
takes advantage of the negative feedback mechanism that suppresses B cell-
mediated humoral response and CD4+ T-cell replenishment, enabling their survival in 
a dampened immune environment [262]. Similarly, CD4+ T-cell depletion was seen in 
HIV-1 –induced IFN-I hyperactivation, which can be rescued by administrating an 
IFNAR blocker [263]. 
 
Over-activated type I interferon response is one of the critical factors contributing to 
and amplifying autoimmunity. Autoimmune diseases arise when type I interferon 
responses overcome the limit of immune tolerance directed by B cells and T cells [264, 
265]. This can be caused by chronic infections, injuries and natural mutants that 
constitutive activate IFN-I inducing pathway. This may result in an excessive leukocyte 
infiltration and cytotoxicity which cause aberrant cell apoptosis and necrosis, 
processes that break down cells and expose the intracellular contents. The DNA 
molecule is one of the most potent stimulant of immune response and the extracellular 
release will induce B cells to produce autoantibodies [266]. Additionally, autoantigens 
activate a number of additional PRRs which further augment IFN-I signalling [267, 268]. 
A growing literature reports that type I interferonopathy is observed in patients with 
type I diabetes, multiple sclerosis, myositis, rheumatoid arthritis, and the prototypical 
systemic disease SLE [269, 270]. The “IFN signature”, an overexpression of type I 
interferon transcripts (normally IFN-α and IFN-β) in the circulating peripheral blood and 
multiple organs, reflects disease severity and the level of anti-dsDNA autoantibodies 
amongst other disease parameters [271, 272].  In particular, IFN-α therapies 
administered to HCV infected patients sometimes leads them to develop spontaneous 
and de novo lupus-like symptoms, indicating the complexity of IFN-I regulation at 
different stages of infection-immunity balance [273, 274].  
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1.7 Background summary 
Macrophages are a potent defender of pathogenic infection and a critical regulator of 
tissue homeostasis. Macrophages exhibit their immune functions via signalling 
networks coordinated by numerous pattern recognition receptors. In addition to the 
canonical inflammatory receptors TLRs, CLRs, NLRs and RLRs, a non-canonical 
inflammatory signalling network makes a substantial contribution to innate immunity. 
To reveal novel inflammatory mediators, a functional cDNA screen was undertaken in 
murine macrophage RAW 264.7 cell line. One of the “hits” from this screen was a 
protein with unknown biological properties. This gene, Tmem203, encodes a 
transmembrane protein TMEM203, known to maintain ER calcium store homeostasis 
yet with unknown functions in immunity. Based on some unpublished pilot data (2014) 
from our group, we speculate that TMEM203 is a potential co-regulator for the antiviral 
adaptor protein Stimulator of Interferon Genes (STING). STING is ubiquitously 
expressed in the ER and responds to DNA sensors and microbial secreted cyclic 
dinucleotides. It signals through the TBK1-IRF3 axis which specifies type I interferon 
activation and later an amplified interferon-stimulated response. Due to the close 
localisation in the ER, TMEM203 and STING are likely to interact directly and complex 
in a number of signalling activities. To facilitate our research, we reviewed the recent 
findings for STING and type I interferon signalling to explore the potential areas that 
can relate to TMEM203 characterisation [119]. Type I interferon signals through the 
JAK-STAT axis and mediates ISG feedbacks. Both Type I interferons and ISGs are 
indispensable for antiviral and antibacterial response in human. Viruses often adopt 
evasive strategies to inhibit type I interferon activation and STING is a critical target 
for such inhibition. The Flaviviridae family is particularly renowned for blocking STING-
interferon signalling, and the two close-related members Dengue virus and Zika virus 
have shown similarity in the mechanism of STING antagonism. Due to the profound 
influence of STING research that identified its value in anti-tumour, anti-microbial, and 
auto-inflammation regimes, novel studies on STING regulation will be innovative to 
scientific and clinical advancement.  
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1.8 Hypotheses 
 
1.8.1 Chapter 2 (Paper 2): TMEM203 is a novel binding partner and regulator of 
STING mediated inflammatory signalling in macrophages. 
Hypothesis: TMEM203 interacts directly with STING to regulates its type I interferon 
response in macrophages.  
 
Figure 4. Hypothesis for paper 2. 
A schematic describing the hypothesis of this research. The novel proinflammatory protein 
TMEM203 regulates the STING-mediated immune detection of bacterial cyclic dinucleotides 
(CDN) and the DNA sensor cGAS-catalysed 2’-3’ cGAMP. STING and TMEM203 interact and 
together they promote TBK1-IRF3 axis which upregulates type I interferon expression. STING 
exists as a dimer yet a monomeric structure is shown here for simplicity.  
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1.8.2 Chapter 4 (Paper 3): STING mediates responses to Zika virus and Dengue 
virus infection in human primary monocyte-derived macrophages. 
Hypothesis: STING regulates type I interferon stimulated gene expression upon 
infection of Zika virus (ZIKV) and Dengue virus (DENV) in human monocyte-derived 
macrophages.  
 
Figure 5. Hypothesis for paper 3.  
ZIKV and DENV attach to, enter and replicate in human macrophages. Accumulation of ZIKV 
activates STING via unknown mechanism whereas DENV induces mitochondrial dsDNA 
leakage which is recognised by DNA sensor cGAS. This enables the production of 2’-3’ 
cGAMP and activation of the STING-dependent TBK1-IRF3 axis, which in turn upregulates 
type I interferon expression. The type I interferons can then activate IFNAR receptors and 
induce the JAK/TyK-STAT pathway and express interferon-stimulated genes. 
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1.9 Aims and objectives: 
Chapter 2 (Paper 2) contains the PhD research work addressing the hypothesis stated 
in Chapter 1.8.1. My experiments, determined in Authors’ Contributions, aim to 
investigate the following points: 
1. To understand if TMEM203 is critical to STING-activated type I interferon 
expression in macrophages. 
2. To identify if a direct interaction exists between TMEM203 and STING. 
3. To identify the immunological challenge that alters TMEM203-STING 
interaction. 
4. To identify the molecular determinant of TMEM203-STING interaction. 
 
Chapter 4 (Paper 3) resulted from the EMBO-funded collaborative work between our 
lab and Dr Marlene Dreux’s lab. This report addresses the hypothesis stated in 
Chapter 1.8.2 and aims to elucidate the following points: 
1. To investigate how Zika virus (ZIKV) and Dengue virus (DENV) infection in M-
CSF differentiated primary monocyte-derived macrophages. 
2. To compare and contrast the dose and time-dependent ISG response caused 
by ZIKV/DENV infections. 
3. To investigate whether STING is regulated by or regulating the infection of 
ZIKV/DENV in primary macrophages. 
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Summary: 
Regulation of interferon signalling is critical in host recognition and response to pathogens, 
whilst its dysregulation underlies the pathogenesis of several chronic diseases.  STimulator of 
INterferon Genes (STING) has been identified as a critical mediator of Interferon inducing 
innate immune pathways, but little is known about direct co-regulators of this protein. We 
report here that TMEM203, a conserved putative transmembrane protein, is a novel 
intracellular regulator of STING-mediated signalling. We show that TMEM203 binds to, co-
migrates to the lysosome and functionally cooperates with STING following cell stimulation, 
which in turn controls the activation of TBK1, IRF3 and the induction of target genes in 
macrophages, including interferon-β. Using Tmem203 knockout bone marrow-derived 
macrophages and transient knockdown of TMEM203 in human monocyte-derived 
macrophages, we show that this protein is required for cGAMP induced STING activation. 
Unlike STING, TMEM203 mRNA levels are elevated in T cells from patients with SLE, a 
disease characterised by the overexpression of type I interferons. Moreover, TMEM203 
mRNA levels are associated with disease activity, as measured by C3 serum levels.  
Identification of TMEM203 sheds new light into the control of STING mediated innate immune 
responses, providing a potential novel mechanism for therapeutic interventions in STING 
associated inflammatory diseases. 
 
Keywords: 
TMEM203, STING, cGAMP, type I interferon 
Introduction: 
Innate immune sensing of microbial infections involves pathogen pattern recognition receptors 
(PPRs), such as Toll-like receptors (TLRs). Many TLR-dependent and –independent innate 
signalling systems, including NOD-like receptors and systems recognising intracellular DNA 
(1, 2) activate the TBK1/IRF3 axis, a pathway of fundamental importance in immune defence 
in both bacterial and viral diseases (3). Activation of this pathway, which is of great 
phylogenetic antiquity (4), results in the production of interferon-β, a cytokine critical for host 
defence against both viruses and bacteria. As increasing evidence links the PPR/TBK1/IRF3 
axis to autoimmune disease (including SLE) (5, 6), vaccine responses (7) and the 
development of malignancy (8–10), the identification of regulators of this pathway may reveal 
novel therapeutic targets. 
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One important component mediating the activation of the TBK1/IRF3 pathway is the 
endosomal multi-transmembrane protein, STimulator of INterferon Genes (STING) (2, 11). 
STING is activated by the double-stranded DNA (dsDNA) sensor IFI16, or by direct binding to 
bacteria-secreted cyclic dinucleotide c-di-AMP, c-di-GMP and 3’3’-cGAMP, as well as cGAS-
catalysed (12, 13) mammalian ligand 2’3’-cGAMP. Its critical role is proven both by the lack of 
interferon induction following viral, bacterial or synthetic DNA stimulation in STING deficient 
cells (2, 14), and by the increased sensitivity of STING deficient mice to DNA viruses such as 
HSV-1 (2). Constitutively-activated STING variants have been found in patients diagnosed 
with severe symptoms of type I interferonopathy and leading to diseases such as STING-
associated vasculopathy with onset in infancy (SAVI) (15), systemic lupus erythematosus 
(SLE) (5, 6, 16), and familial chilblain lupus (FCL) (17). The importance of STING activity in 
health and disease has also been the subject of several recent reviews (3, 18, 19). 
Following STING activation, the serine/threonine kinase TBK1 is recruited to the cytosolic face 
of the endo-lysosome/endoplasmic reticulum (ER) (20). At these intracellular vesicles, STING 
is targeted for K27-linked ubiquitination by AMFR, triggering its activation and the subsequent 
phosphorylation of the transcription factor IRF3 (21). Once phosphorylated, IRF3 dimerises 
and translocates to the nucleus where it drives the expression of genes containing IRF binding 
sites in their promoter, predominantly the type I interferons IFN-α and IFN-β (20). Post-
activation, STING is sorted to the endo-lysosomes where it is targeted by LC3 and autophagy-
related protein 9a (Atg9a) to attenuate its functions (22, 23). 
Whilst most studies have described STING as a critical component in cytosolic nucleic acid 
recognition, STING has also been shown to play a role in augmented IRF3 activation and type 
I interferon (IFN-I) induction upon concomitant ER stress and LPS stimulation (2, 24) via late-
TLR4 signalling (25). Despite the fundamental importance of STING in both anti-bacterial and 
anti-viral immunity, its partners remain largely unknown, with many aspects of its mechanism 
of action still being poorly understood. 
In previous functional screens discovering novel regulators of inflammation (26, 27), we 
reported the identification of TMEM203 as a previously unknown proinflammatory gene in 
mouse macrophages (26). Here we demonstrate that TMEM203, a protein that was recently 
shown to be endosomal and interacts with the pleiotropic inositol phosphate signalling 
pathway protein IP3R (28), is associated with SLE disease activity, forms a functional and 
ligand-dependent complex with STING and is a novel regulator of signalling pathways 
activated in response to diverse bacterial and viral stimuli, including cyclic dinucleotides.  
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Results: 
TMEM203 is an evolutionarily conserved putative transmembrane protein, regulated by 
inflammatory stimuli 
We have previously identified multiple regulators of inflammatory signalling in macrophages 
by genome-wide expression screening for genes which drove Cxcl2 expression when 
transfected into RAW 264.7 cells (26); TMEM203 was one such protein. Multiple alignment of 
TMEM203 orthologues from a wide range of species demonstrated that TMEM203 is an 
evolutionally highly conserved gene (Fig. 1A) encoding a 136 amino acid protein, with the 
mouse and human orthologues being 98% identical. Interestingly, a survey of the GenBank 
database revealed that only a single copy of this gene is present in both invertebrate and 
vertebrate species; with TMPred (29) predicting four putative membrane-spanning helices 
(Fig. 1A, TM1-4). One distantly related homologue of TMEM203 has been described so far, 
the 133 amino acid protein TMEM60 with about 21% identity (30). 
Dysregulated expression of key innate immune signalling molecules has previously been 
linked to the development of human pathologies, including systemic lupus erythematous (SLE), 
an inflammatory disease often characterised by the recruitment of immune cells, including T 
lymphocytes and their excessive type I interferon production in the affected tissues. Thus, we 
have analysed the mRNA levels of two well characterised intracellular signalling regulators, 
MAVS (mitochondrial antiviral signalling protein) and STING (Stimulator of Interferon Genes), 
as well as TMEM203 in T cells isolated from the blood of recently diagnosed, treatment naïve 
SLE patients. Both MAVS and STING have previously been implicated in driving interferon 
production in SLE (5, 31, 32). We found significantly reduced, almost abolished MAVS 
expression, with marked upregulation of TMEM203 (Mean 13.83 ± SD 6.52 fold induction, 
lower:upper interquartile = 8.59:18.84) (Fig. 1B). Further, TMEM203 mRNA levels inversely 
correlated with the plasma levels of complement factor C3, a clinically used marker of 
activated innate immunity. Taken together, this suggests that TMEM203 may play a role in the 
development of this disease (Fig. 1C) and that this activity might be coupled to excessive 
production of type I interferon. 
A search in the transcriptome database thebiogps.org (33) indicated that TMEM203 is highly 
expressed in myeloid cells, including macrophages. Since our expression screen showed that 
TMEM203 may act as a signalling regulator in myeloid cells (26), we first tested how 
chemokine expression in murine macrophages is controlled by TMEM203. Compared to 
controls, Cxcl2 promoter activity in LPS stimulated RAW 264.7 cells was enhanced by the 
overexpression of Tmem203 (Fig. 1D), whilst being impaired by the siRNA-mediated 
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downregulation of Tmem203 (Fig. 1E), suggesting that TMEM203 is likely to act downstream 
of Toll-like receptors (TLRs) and/or other innate immune sensors.  
We next characterised the molecular pathways for Tmem203 action, using Cxcl2 promoter 
activity as a surrogate of the activation of canonical TLR pathways (34). Whilst LPS-induced 
activation of a Cxcl2-luciferase reporter in RAW 264.7 cells is blocked (Fig. 1F), the 
Tmem203-induced Cxcl2 activation is not inhibited by the expression of the dominant negative 
forms of Irak1, Trif, MyD88, Tram, Mal and Traf6 (Fig. 1G). Similarly, pharmacological MAPK 
inhibitors impair LPS-, but not overexpressed (OE) Tmem203-induced Cxcl2 promoter 
activities (Fig. S1). Therefore, we concluded that whilst TMEM203 is a novel pro-inflammatory 
mediator/effector, it is likely to act independently from the canonical TLR and MAPK networks. 
We therefore explored whether TMEM203 acts on the non-canonical inflammatory pathway, 
since LPS also induces the TRIF-TRAM/TBK1/IRF3 pathway via endosomal “late signalling”, 
leading to activation of multiple inflammatory cytokines, including interferons (35–37). The 
TBK1/IRF3 axis is known to couple to the adaptor protein STING, a critical regulator of 
cytosolic double-stranded DNA detection mechanism (38–40), and whose activities are mostly 
independent of MAPK and canonical TLR mediators (20, 39, 41). Activation of STING induces 
TBK1 phosphorylation (20) which subsequently induces IRF3 or NF-κB to elicit the type I 
interferon response and a variety of pro-inflammatory genes including TNF, IL-6, and several 
chemokines (12, 20, 42).  
Since Shambharkar et al (28) previously reported that TMEM203 is localised on ER 
membranes, and that our above data suggested that TMEM203 is closely related to 
chemokine expression and SLE disease indications, we hypothesised that TMEM203 may 
regulate STING-mediated signalling events. Therefore, a Tmem203 overexpressing plasmid 
construct and siRNA against the individual STING signalling effectors were co-transfected into 
RAW 264.7 cells, followed by the measurement of Cxcl2 promoter activities. As Tmem203 
overexpression resulted in elevated Cxcl2 activity and the simultaneous suppression of Sting 
or its downstream regulators significantly reduced it (Fig. 1H), we concluded that TMEM203 
potentially acts upstream or in parallel to a STING-dependent signalling pathway. 
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Figure 1: TMEM203 is an evolutionarily conserved, SLE associated signalling mediator. 
1A. Alignment of TMEM203 orthologues: Vertebrate and invertebrate homologues of the 
mouse Tmem203 proteins were identified by BLAST search in the GenBank database. The 
collected sequences were aligned using the Clustal W algorithm. Four transmembrane regions 
(TM1-4) were predicted by TMpred (29). Abbreviations: H.h.: Homo sapiens, P.t.: Pan 
trogloides, M.m.: Mus musculus, G.g.: Gallus gallus, X.l.: Xenopus laevis, T.n.: Tetraodon 
nigroviridis, D.r.: Danio rerio, B.f.: Branchiostoma floridae, S.p.: Strongylocentrotus purpuratus, 
D.m.: Drosophila melanogaster, A.e.: Aedes aegypti, B. m.: Bombyx mori, C.c.: Caligus 
clemensi, L.s.: Lepeophtheirus salmonis, A.m.: Apis mellifera, C.f.: Camponotus floridanus, 
H.m.: Hydra magnipapillata, C.i.: Cionia intestinalis.  
1B. C. TMEM203 level is elevated in a cohort of SLE patients. (B) MAVS, TMEM203 and 
STING mRNA levels in PHA-L -activated T cells were assessed by RT-qPCR from a cohort of 
treatment-naïve systemic erythematous lupus (SLE) patients in comparison to cells from 
healthy individuals. (C) Spearman correlation coefficient of C3 complement plasma level was 
assessed against fold TMEM203 mRNA induction in SLE patients (95% confidence interval: 
dash lines). Data is presented as mean ± SD, one dot per person. 
1D. Overexpression of Tmem203 augments LPS-induced Cxcl2 activation. RAW 264.7 
cells were transfected with the Cxcl2-pLuc and EF1-rLuc reporters, and with Tmem203 
expression plasmid (dashed line) or empty control vector (solid line). Cells were stimulated 
with the stated concentration of LPS for 6 hours. Two-way ANOVA with Sidak correction was 
performed to ascertain the impact of Tmem203 overexpression on LPS induced cxcl2 
activation (****: p< 0.0001). Data is presented as mean ± SEM, n=3. 
1E. Knockdown of Tmem203 impairs LPS-induced Cxcl2 activation. RAW 264.7 cells 
were transfected with the Cxcl2-pLuc and EF1-rLuc reporters, and with siRNA against 
Tmem203 (dashed line) or non-targeting si-scrambled (solid line). Cells were stimulated with 
the stated concentration of LPS for 6 hours. Two-way ANOVA with Sidak correction was 
performed to ascertain the impact of siTmem203 treatment on LPS induced cxcl2 activation 
(**: p<0.01, ***: p<0.001). Data is presented as mean ± SEM, n=3. 
1F. Dominant negative signalling molecules impair LPS-induced Cxcl2 promoter 
activity. RAW 264.7 cells were transfected with the Cxcl2-pLuc and EF1-rLuc reporters, and 
the indicated expression plasmids encoding for dominant negative (DN) mutants of known 
pro-inflammatory molecules (mouse Irak1, Trif, MyD88, Tram, Mal and Traf6, respectively). 
LPS (100 ng/ml, 6 hours) was used as a positive control to test for the inhibitory activity of the 
DN constructs. Data is presented as mean ± SD, n=2. 
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1G. Dominant negative signalling molecules fail to inhibit Tmem203 induced Cxcl2 
promoter activity. RAW 264.7 cells were transfected as in F and the ability of the DN 
constructs to block overexpressed Tmem203 -induced Cxcl2 activation was tested. Data is 
presented as mean ± SD, n=2. 
1H. Tmem203 induces Cxcl2 promoter via the Sting/Tbk1/Irf3 pathway. RAW 264.7 cells 
were transfected with the Cxcl2-pLuc, TK-rLuc reporters and Tmem203 expression plasmid, 
together with scrambled siRNA (siNC) or an siRNA against Irf3, Tbk1 or Sting. Data was 
analysed by one-way ANOVA (p<0.05: *, p<0.01: **, p <0.001: ***). Data is presented as mean 
± SEM, n=3. 
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TMEM203 co-localises and interacts with STING 
To establish whether TMEM203 co-regulates STING, Tmem203 expression levels were 
examined in mouse bone marrow-derived macrophages (isolated from C57/BL6 mice) after 
stimulation with LPS, endogenous STING ligand 2’3’-cGAMP (38) or microbial secreted 
STING ligand 3’3’-cGAMP (43). Each tested stimuli rapidly induced Tmem203 mRNA levels, 
albeit with different kinetics (Fig. 2 A, B, C).  
Based on our observation that suppression of STING expression impaired TMEM203 induced 
Cxcl2 activation (Fig. 1H) and that STING and TMEM203 are both localised in intracellular 
membranes (28, 44), we questioned whether STING and TMEM203 directly interact and co-
regulate the activation of an inflammatory response. Co-localisation of STING and TMEM203 
within punctate, intracellular structures was detected in HeLa cells co-transfected with GFP-
Sting and mCherry-Tmem203, respectively (Fig. 2D). The observed interaction between 
TMEM203 and STING was further confirmed by co-immunoprecipitation of Myc-Sting and 
Flag-Tmem203 in HEK293T cells (Fig. 2E), indicating that a stable molecular complex is 
formed upon the contact of these two proteins.  
To further validate the association of TMEM203 and STING, we used the Yellow Fluorescence 
Protein (YFP, Venus derivative) fragment complementation assay (PCA), which is based on 
expressing each putative binding partner in fusion with either the N-terminal (V1) or C-terminal 
(V2) portion of YFP (45–47) (Fig. 2F). When the two test proteins interact, the V1 and V2 parts 
of YFP fluorophore self-assembles in a cyclisation reaction which is essentially irreversible 
(48). This stable fluorescent signal can be detected by flow cytometry or fluorescence 
microscopy. We used this technique to ask whether TMEM203 and STING can interact 
intracellularly (Fig. 2F). As expected from the distribution of TMEM203 and STING alone, a 
punctate membrane / vesicular distribution of fluorescence was observed by confocal 
microscopy (Fig. 2G). Interestingly, a similar distribution of TMEM203 dimer (or oligomer) was 
also observed (Fig. 2H). As TMEM203 and STING are each predicted to contain four 
transmembrane domains, the positioning of the V1 or V2 PCA tags enabled us to map the 
relative orientation of the C- and N-termini of these proteins. In agreement with the proposed 
schematic model in Fig. 2F, TMEM203 and STING with either N-terminus and C-terminus 
tags were transfected into HEK293 cells and mean GFP signal was analysed by FACS. 
TMEM203 and STING can lead to the formation of a fluorescent complex (Fig. 2I, 2nd & 3rd 
bar), while a strong signal was also seen by TMEM203 dimerisation (Fig. 2I, 4th bar). 
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Figure 2. TMEM203 co-localises and interacts with STING. 
2A. B. C. Tmem203 expression is transiently induced by inflammatory stimuli. Murine 
bone marrow-derived macrophages were stimulated with LPS (A), 2’3’-cGAMP (B) or 3’3’-
cGAMP (C) for the time indicated. The expression of Tmem203 was determined by RT-qPCR. 
(Data is presented as mean ± SD for 2 independent experiments). 
2D. Tmem203 co-localises with Sting. HeLa cells were co-transfected with Sting-GFP and 
mCherry-Tmem203 expression plasmids and their localisation was visualised by fluorescence 
microscopy under 63X magnification. n=15 images (total>30 cells) from 2 independent 
experiments were processed, a set of representative images is shown here.  
2E. Tmem203 co-precipitates with Sting. HEK293 T cells were transfected with either empty 
vector, Flag-Tmem203 or Myc-Sting. Tmem203-containing complexes were immuno-
precipitated (IP) using anti-Flag coated beads and blotted for Myc and Flag, as indicated. 
Lysates were also immunoblotted for Myc and Flag. Immunoblots (IB) shown are from a single 
experiment and are representative of two independent experiments. 
2F. Illustration of Tmem203-Sting interaction by PCA. Tmem203 was tagged at its N 
terminus with the V1 fragment of Venus yellow fluorescent protein, whilst Sting was tagged at 
its N-terminus with the V2 Venus fragment to test for a molecular interaction between these 
proteins in live cells. Both Tmem203 and Sting proteins were predicted to encode for four 
transmembrane domains (28, 76). Thus, this arrangement was predicted to localise the V1 
and V2 tags to the same side of the lipid membrane.  
2G. H. Tmem203 and its complex with Sting is located in the cytoplasm, in perinuclear 
structures. HeLa cells were transfected with the above-described Venus fusion protein 
expression plasmids. The ‘Venus’ fluorescent signal, demonstrating TMEM203-STING 
interaction (G) or TMEM203 dimerisation (H) was visualised in live cells at 80X magnification, 
scale bar = 20 µm. Two experiments, 30 cells each. 
2I. Tmem203 forms dimers and interacts with Sting in live cells. HEK293 T cells were co-
transfected with the indicated fusion protein expression vectors; Venus fluorescence signal 
generated by Tmem203 and Sting interaction was detected by flow cytometry. Relative 
geometric mean fluorescence intensity was plotted compared to the control single transfection 
of V2 construct (V2_ZIP). Data is presented as mean ± SEM, n=4. 
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The TMEM203-STING complex is localised in the ER and lysosomes 
To further study the localisation of TMEM203, HeLa cells were transiently transfected with 
mCherry-Tmem203. TMEM203 was predominantly found in perinuclear membrane structures 
in accordance with a previous report of ER localisation (Fig. 3A) (28). Stimulation with LPS 
led to TMEM203 translocation to perinuclear, punctate membranes or vesicles (Fig. 3A). A 
more detailed analysis revealed a transient co-localisation between TMEM203 and the 
lysosomal marker LAMP1 at 30 mins stimulation with LPS in HeLa cells (Fig. 3B). This rapid 
ER-to-vesicle translocation of TMEM203 correlates with the kinetics of translocation seen for 
STING during activation (49). To study the localisation of the TMEM203-STING complex, we 
co-transfected the previously described Venus PCA constructs of these two proteins (Fig. 2F) 
into HeLa cells and co-stained with either cell permeable, lysosome- or ER- specific 
fluorescent dyes. The STING-TMEM203 complex was mainly expressed on lysosomal 
membranes rather than the ER (Fig. 3C-E), a distribution consistent with the previously 
described localisation pattern of activated STING (44). We therefore speculated that co-
expression of TMEM203 and STING may pre-activate or sensitise the STING pathway, thus 
leading to a lysosomal translocation, even in the absence of ligands. In HeLa cells, which 
express lower levels of STING than the RAW 264.7 cells used in initial screening (26), 
overexpression of TMEM203 alone did not elevate proinflammatory activities, as measured 
by the activation of a previously described (50) luciferase reporter, but it augmented 
overexpressed STING-induced responses (Fig. 3F). Constitutive overexpression of Tmem203 
(Fig 3 - S1) in RAW 264.7 cells potentiated STING-ligand induced interferon activation (Fig. 
3G). In summary, our data demonstrate that TMEM203 accompanies STING to transiently 
translocate to the lysosomes and that this co-expression sensitises cells to interferon and 
chemokine activation. 
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Figure 3. Inflammation induces TMEM203 trafficking and augments STING activity. 
3A. LPS induced perinuclear translocation of Tmem203. HeLa cells were transfected with 
Tmem203-mCherry fusion protein expression plasmid and stimulated with 1 µg/ml LPS for the 
stated length of time. Two independent experiments, 20 cells each. 
3B. Tmem203 transiently co-localises with LAMP1 in LPS induced cells. HeLa cells were 
transfected with Tmem203-mCherry fusion protein expression plasmid and stimulated with 1 
µg/ml LPS for indicated time. LAMP1 localisation was visualised using Alexa Fluor® 488 
conjugated anti-mouse secondary antibody. Images were taken under oil immersion at 63X 
magnification. Three independent experiments, 15 cells each. 
3C-E. Co-expressed Sting – Tmem203 localises to lysosomes. HeLa cells were co-
transfected with the V1_Sting WT and V2_Tmem203 WT prior to ER (C) or lysosome (D) 
staining; fluorescence signal was detected under confocal microscopy at 80X. Images are 
representative of two independent experiments. (E) Overlay of Tmem203-Sting signals and 
organelle signals were quantified with Fiji and co-localisation was calculated as the percentage 
of organelle with positive Tmem203-Sting detection. One dot per cell analysed from two 
independent experiments. Data is presented as mean ± SEM, scale bar = 20 µm. 
3F. Tmem203 augments Sting induced IL-8 activation. HEK293 T cells were co-transfected 
with IFN-β reporter and plasmids expressing Sting, Tmem203, or controls. Data are expressed 
as fold change in reporter induction relative to the control plasmid, with (grey bars) or without 
(black bars) stimulation of DMXAA (100 µg/ml, 6 hrs). Data was analysed by 2-way ANOVA 
(p<0.0001: ****). Data is presented as mean ± SEM, n=3. 
3G. Tmem203-overexpression augments Ifnb activation in RAW 264.7 cells. Vector or 
Tmem203 overexpression (OE Tmem203) transfected RAW 264.7 cells were stimulated with 
3’3’-cGAMP for the time indicated. The expression of Tmem203 and Ifnb was determined by 
quantitative RT-qPCR. Data is presented as mean ± SD for 2 independent experiments. 
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TMEM203 downregulation impairs cGAMP-induced STING-mediated type I interferon 
expression 
STING predominantly mediates type I interferon activation in response to pathogen-
associated cyclic-dinucleotide production in the cytoplasm (38–40, 51).  Building on these 
findings, we investigated the importance of TMEM203 in mediating STING activation in human 
monocyte-derived macrophages (MDMs). CD14 positive human monocytes (Fig. S2 A) were 
isolated from whole blood and differentiated into MDMs (Fig. S2 B) by M-CSF. MDMs were 
transfected with control or TMEM203 targeting siRNA, followed by a 3-hour stimulation of 
these cells with 2’3’-cGAMP or 3’3’-cGAMP, 48 hours post-transfection. RT-qPCR analysis of 
TMEM203 mRNA levels confirmed a highly robust (>70%) knockdown in siTMEM203-targeted 
MDMs (Fig. 4A & 4B), which was accompanied by a significant inhibition of cGAMP-induced 
IFN-I expression in human MDM samples obtained from a cohort of healthy individuals (Fig. 
4C & 4D, IFN-β). Whilst the amount of IFN-β mRNA produced in these samples showed 
donor-specific variation upon ligand stimulation (Fig. S2 C&D), siTMEM203 treatment in each 
case reduced 2’3’-cGAMP and 3’3’-cGAMP -induced IFN-β mRNA levels by approx. 50% (Fig. 
4C & 4D). In contrast, IL-8 mRNA was not induced under both stimulation conditions (0-3 fold, 
depending on the specific donor or MDM isolation, not shown); although its levels were also 
reduced by TMEM203 suppression in response to 2’3’-cGAMP treatment (Fig. 4C). 
To expand on the above findings from primary human macrophages, we investigated whether 
TMEM203 displays similar STING regulatory behaviour in mouse macrophages. siRNA 
knockdown of Tmem203 or Sting was performed in immortalised bone marrow-derived 
macrophages (iBMDMs) followed by 3 h stimulation with the physiological STING ligand 2’3’-
cGAMP or the synthetic ligand DMXAA (52, 53), that selectively targets the mouse but not the 
human protein. Efficient suppression of both Tmem203 and Sting was confirmed by RT-qPCR 
analysis (Fig. 4E-F). Similarly to MDMs, 2’3’-cGAMP robustly induced IFN-I expression in 
iBMDMs (Fig. S2 E) and this was impaired by Tmem203 or Sting knockdown (Fig. 4G). 
However, IFN-I induction by DMXAA was only reduced by the knockdown of Sting but not 
Tmem203 (Fig. 4G), suggesting that Tmem203 regulation of Sting may be ligand dependent. 
To further test this, we used primary bone marrow-derived macrophages (BMDMs) isolated 
from WT or CRISPR-Cas9 –targeted Tmem203 knockout mice (Fig. S2 F) and stimulated 
them with DMXAA or 2’3’-cGAMP. In controls, both STING ligands induced a marked Ifnb1 
upregulation (Fig. S2 G), but only 2’3’-cGAMP and not DMXAA -mediated Ifnb1 expression 
was reduced by Tmem203 deficiency (Fig. 4H). From the above data we conclude that 
TMEM203 is a critical regulator of STING-induced type I interferon production and that its 
suppression impedes this process in response to specific STING ligands. 
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Figure 4. TMEM203 downregulation impairs cGAMP-induced STING-mediated type I 
interferon expression. 
4A. B. Efficient TMEM203 knockdown in human monocyte derived macrophages 
(MDMs). MDMs were transiently transfected by scrambled control (siCtrl) or TMEM203 
targeting siRNA. Post transfection, MDMs were left stimulated with +/- 4 µg/ml 2’3’-cGAMP (A) 
or 1 µg/ml 3’3’-cGAMP (B) for 3 hours. TMEM203 knockdown was quantified by RT-qPCR. 
Multiple Student’s t-tests with Holm-Sidak corrections were performed to ascertain the impact 
of siTMEM203 treatment on TMEM203 mRNA levels (p <0.0001: ****). Data is presented as 
mean ± SEM, n=10 (A) and n=4 (B). 
4C. D. TMEM203 knockdown impairs 2’3’-cGAMP (C) and 3’3’-cGAMP (D) induced IFN-
β production in MDMs. 2’3’-cGAMP (4 µg/ml) or 3’3’-cGAMP (1 µg/ml) –stimulated (3h) IFN-
β production of siCtrl vs. siTMEM203 transfected MDMs from 4 donors was compared by 
normalizing IFN-β levels of siTMEM203 treated cells to the siCtrl treatment for each individual. 
Student’s t-test was performed to ascertain the impact of siTMEM203 treatment (p <0.01: **, 
p <0.001: ***, p <0.0001: ****). Data is presented as mean ± SEM, n=4. 
4E. F. Efficient Tmem203 (E) and Sting (F) knockdown in immortalised mouse bone 
marrow-derived macrophages (iBMDMs). iBMDMs were transiently transfected by 
scrambled control (siCtrl), Tmem203, or Sting targeting siRNA. Post transfection, cells were 
left stimulated with +/- 25 µg/ml DMXAA or 20 µg/ml 2’3’-cGAMP for 3 hours. Tmem203 and 
Sting knockdown was quantified by RT-qPCR. Multiple Student’s t-tests with Holm-Sidak 
corrections were performed to ascertain the impact of siTmem203 and siSting treatment on 
Tmem203 and Sting mRNA levels, respectively (p <0.01: **, p <0.0001: ****). Data is 
presented as mean ± SEM, n=4. 
4G. 2’3’-cGAMP, but not DMXAA, -induced Ifnb1 expression is impaired by Tmem203 
knockdown in iBMDMs. IFN-β induction by DMXAA (25 µg/ml) or 2’3’-cGAMP (20 µg/ml) 
stimulation (3h) in the siTmem203 or siSting transfected iBMDMs was compared to that in the 
siCtrl treated cells. One-way ANOVA test was performed to ascertain the impact of 
siTmem203 / siSting treatment on Ifnb1 mRNA levels compared to the siCtrl group (p <0.05: 
*, p <0.001: ***, p <0.0001: ****). Data is presented as mean ± SEM, n=4. 
4H. 2’3’-cGAMP, but not DMXAA, -induced Ifnb1 expression is impaired by Tmem203 
knockout in bone marrow-derived macrophages (BMDMs). BMDMs derived from WT or 
Tmem203 knockout C57BL/6 mice were stimulated with DMXAA (50 µg/ml) or 2’3’-cGAMP 
(10 µg/ml) for 3 h before Ifnb1 expression levels were analysed by RT-qPCR. Multiple 
Student’s t-tests with Holm-Sidak corrections were performed to ascertain the impact of 
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Tmem203 knockout on IFN-β mRNA levels (p <0.05: *, one dot per mouse). Data is presented 
as mean ± SEM, n=6 
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TMEM203 levels regulate TBK1/IRF3 activation downstream of STING 
To further characterise the functional contribution of TMEM203 to cGAMP-induced STING 
signalling events, activation of TBK1 and IRF3 were compared between control and 
TMEM203-overexpressing or knockout RAW 264.7 cells. Each of these signalling molecules 
have previously been shown to be phosphorylated (and thus activated) in a STING-dependent 
manner, including responses to cytosolic dsDNA sensing (20, 54). Whilst CRISPR/Cas9-
mediated Tmem203 knockout in RAW 264.7 cells (Fig. S3 A) resulted in an impaired Tbk1/Irf3 
phosphorylation (Fig. 5A), Tmem203 overexpression (Fig. S3 B) augmented Tbk1/Irf3 
activation after 3’3’-cGAMP stimulation (Fig. 5B). Similar TMEM203-dependent changes were 
seen in these cells after human simplex virus-1 (HSV-1) infection (Fig. 5C), a dsDNA virus 
known to activate the STING/TBK1/IRF3 signalling axis (55–58). Considering that the 
phosphorylation level of Tbk1 and Ifr3 only signatures the initiation of type I interferon 
expressions, we further quantify Sting activation by analysing Ifnb1 secretion level in the 
Tmem203 overexpressing and knockout cells. Consistently, HSV-1 stimulated Ifnb1 secretion 
is enhanced in Tmem203 overexpressing cells (Fig. 5D right) while it is impaired in Tmem203 
knockout cells (Fig. 5D left), confirming the functional significance of Tmem203 in the 
regulation of STING-interferon signalling. 
Finally, we analysed IRF3 activation downstream of STING by measuring the nuclear 
localisation of IRF3 in control and Tmem203-overexpressing macrophages. Activated STING 
induces TBK1-IRF3 activation leading to nuclear translocation of IRF3 that is critical for the 
initiation of transcription of the type I interferon genes (20). Elevated Tmem203 expression in 
RAW 264.7 cells indeed led to an enhanced, 3’3’-cGAMP induced IRF3 nuclear localisation 
(Fig. 5E & 5F) in line with the timeframe observed for IRF phosphorylation (Fig. 5B).  
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Figure 5: TMEM203 level regulates TBK1/IRF3 activation downstream of STING. 
5A. CRISPR/Cas9-mediated Tmem203 knockout resulted in reduced TBK1 and IRF3 
phosphorylation upon STING stimulation. Vector or CRISPR/Cas9-mediated Tmem203 
knockout (KO Tmem203) RAW 264.7 cells were stimulated with 3’3’-cGAMP (1 µg/ml) for the 
time indicated. Activation of Tbk1 and Irf3 was examined by western blot analysis. Membranes 
were blotted with anti-phospho-Tbk1 (-Tbk1), anti-total Tbk1 (tTbk1), anti-phospho-Irf3 (p-Irf3) 
and anti-total Irf3 (t-Irf3) as indicated (n=3). 
5B. Increased TBK1-IRF3 activation in Tmem203-overexpressing RAW 264.7 cells in 
response to STING stimulation. Vector- or Tmem203-overexpressing (OE Tmem203) RAW 
264.7 cells were stimulated with 3’3’-cGAMP (1 µg/ml) for the time indicated. Activation of 
Tbk1 and Irf3 was examined by western blot analysis. Membranes were blotted with anti-
phospho-Tbk1 (-Tbk1), anti-total Tbk1 (tTbk1), anti-phospho-Irf3 (p-Irf3) and anti-total Irf3 (t-
Irf3) as indicated (n=3). 
5C. Increased TBK1-IRF3 activation in Tmem203-overexpressing RAW 264.7 cells in 
response to HSV infection. Vector- or Tmem203-overexpressing RAW 264.7 cells were 
infected with HSV-1 for the time indicated. Activation of Tbk1 and Irf3 was examined by 
western blot analysis. Membranes were blotted with anti-phospho-Tbk1 (-Tbk1), anti-total 
Tbk1 (tTbk1), anti-phospho-Irf3 (p-Irf3) and anti-total Irf3 (t-Irf3) as indicated (n=3). MOI=0.2. 
5D. Ifnb cytokine secretion is impaired in Tmem203 knockout RAW 264.7 cells (left) and 
is enhanced in Tmem203-overexpressing cells (right) in response to HSV infection. 
CRISPR/Cas9-mediated Tmem203 knockout (or Vector) and Tmem203-overexpressing (or 
Vector) RAW 264.7 cells were infected with HSV-1 for 6 hours and Ifnb1 secretion was 
measured by ELISA. Data is presented as mean ± SEM, n=3. 
5E & F. Tmem203 overexpression enhances IRF3 nuclear accumulation in 
macrophages in response to STING stimulation. Vector- and Tmem203-overexpressing 
RAW 264.7 cells were stimulated with 1 µg/ml 3’3’-cGAMP for 6 hours. Subcellular localization 
of Irf3 was determined by Irf3 intracellular staining, and confocal fluorescence images were 
captured (F). Scale bar is 10 µm. Average Irf3 nuclear fluorescence intensity of 50-200 cells 
was quantified using ImageJ (F). Data is presented as mean ± SEM. 
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Transmembrane domains of STING are required for the formation of its complex with 
TMEM203 
Having demonstrated the functional significance of TMEM203-mediated regulation of STING, 
we sought to further explore the mechanisms by which these two proteins interact and 
investigate the underlying mechanisms of selective TMEM203-mediated regulation of STING 
activation. Since TMEM203 regulates cGAMP-, but not DMXAA-induced STING activation in 
macrophages, we proposed that these ligands may differentially influence the physical contact 
between TMEM203 and STING. We established the Renilla fragment complementation assay 
(Renilla PCA), which is based on expressing Tmem203 or Sting in fusion with either the small 
part (1.1) or the large part (2.1) of an engineered Renilla luciferase, NanoBit (Fig. 6A). The 
association of TMEM203 and STING causes a reversible assembly of Renilla formation, which 
then catalyses the breakdown of a luciferase substrate. A robust interaction between 
TMEM203 and STING was observed upon co-transfecting the Renilla PCA fusion constructs, 
and their strong association was demonstrated by comparison to the Rel A-IκBa complex 
which has been reported to form a stable complex in resting cells (Fig. 6B). Next, we co-
expressed 2.1 N Sting and 1.1 C Tmem203 in HEK293 T cells that were stimulated with either 
2’3’-cGAMP or DMXAA. We detected a rapid, time-dependent reduction of the TMEM203-
STING complex following cGAMP treatment, in contrast to an enhanced association of these 
proteins upon DMXAA treatment (Fig. 6C). This opposing effect of the two STING ligands on 
STING-TMEM203 association is likely to underlie the differential regulation of STING 
signalling by TMEM203 as demonstrated in BMDMs (Fig. 4G & H). The different association 
of TMEM203-STING by the two ligands may potentially affect the binding of STING’s signalling 
effector TBK1 to this complex. However, further experiments are required to understand the 
mechanism of this opposite structural change and how it reflects on immune regulation of 
STING-TMEM203 complex.  
TMEM203 is a 136 amino acid transmembrane protein with no obvious regulatory domains at 
the exposed short cytoplasmic regions. The protein sequence is highly conserved across 
vertebrates with only a three amino acid difference in the sequence between the human and 
the mouse genes (28) (Fig. 1A). Thus, we speculated that the interaction between STING and 
TMEM203 is likely to be coordinated by STING, which contains complex regulatory domains. 
Although human and mouse STING are only 81% similar in primary sequence and 68% similar 
in amino acid composition (13), functional domains in STING are nonetheless spatially and 
structurally conserved across the two species. Previous studies on the structure of STING 
have identified the C-terminal cytoplasmic domain as the site for protein-protein interactions 
and ligand binding, whereas the N-terminal transmembrane (TM) domains are mainly thought 
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to be responsible for membrane anchorage (59). The cytoplasmic region of STING 
(approximately amino acids 153-378 in mouse) comprises of three domains: the dimerization 
domain (DD) (or helices α-5/α-6) formed by amino acids ~155-180; the cyclic dinucleotide 
binding domain (CBD) formed by amino acids ~153-340; and the cytoplasmic-terminal tail 
domain (CTT) formed by amino acids ~340-378 (amino acids ~340-379 in human) (4, 60). The 
CTT is involved in TBK1 / IRF3 binding and activation and is essential for type I interferon 
induction (20). To identify the molecular domains of STING required for its interaction with 
TMEM203, we created mutant Sting constructs that contain deletions of TM, CBD, or the CTT 
domain (Fig. 6D). Co-immunoprecipitation of HA-tagged WT or mutant Sting with Flag-
Tmem203 from HEK293 T lysates showed that the STING – TMEM203 complex is formed in 
the presence of STING’s TM domains (Fig. 6E, lines 1-3, 5), whereas the presence of CBD 
alone led to a very weak STING – TMEM203 interaction (Fig. 6E, lines 4, 6). 
To substantiate these findings, 141A, 184L, 243V and 344A Sting truncations were created 
(Fig. 6F), expressing TM domains only (TM), TM and dimerisation domain (TM+DD), a 
disrupted cyclic dinucleotide binding domain (d-CBD), or CTT deleted STING (ΔCTT), 
respectively. Both the mutant and WT Sting were fused with the YFP expression plasmids and 
their expression was tested by Western blot. Compared to the WT Sting, TM and ΔCTT 
mutants (Fig. 6G, line 3 & 6) showed enhanced protein expression whereas the TM+DD and 
d-CBD mutants showed reduced expression (Fig. 6G, line 4-5). Next, we fused the mutants 
and WT Sting with V1 fragment of the previously described split YFP (Fig. 2F) which were co-
transfected with the complementary V2-tagged Tmem203 expression plasmid into HEK293 T 
cells; fluorescent signal was quantified by flow cytometry (Fig. 6H). To ensure the 
overexpression of Tmem203 or Sting does not induce a non-specific ER stress response (61), 
the level of spliced XBP1 gene was assessed in HEK293 T cells, transfected with 
pcDNA3.1(control) or Tmem203 - Sting PCA constructs. No significant increase of XBP1 
splicing was detected by RT-qPCR in Tmem203 and Sting expressing cells (Fig. S4 A-C). 
Compared to the WT Tmem203 – WT Sting interaction, a stronger protein interaction was 
observed between Tmem203 and Sting TM, TM+DD, and ΔCTT, respectively (Fig. 6F). 
However, d-CBD Sting showed an impaired interaction with Tmem203 due to reduced protein 
expression levels (Fig. 6F & 6G, d-CBD), potentially caused by degradation of dysfunctional 
Sting protein. Of note, while the enhanced interaction between Tmem203 and Sting TM mutant 
was paralleled with high expression of this truncated Sting protein, the TM+DD mutant 
exhibited similar association at a much lower Sting protein expression level (Fig. 6F & 6G, 
TM+DD). Furthermore, the Tmem203 – Sting TM complex showed a more equal localisation 
between the ER and lysosomes (Fig. 7 A-C), compared to the Tmem203 – WT Sting complex 
(Fig. 3 C-E), likely due to the loss of STING’s regulatory site for post-translational modification 
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required to direct its trafficking. This also suggests that TMEM203 may rely on STING to 
relocate from the ER to other intracellular structures. Therefore, we conclude that interaction 
with TMEM203 is dependent on the N-terminal transmembrane domain of STING and its 
dimerisation domain is potentially a significant regulator of their interaction.  
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Figure 6: Molecular determinants of Tmem203-Sting complex formation. 
6A. Detection of Tmem203-Sting interaction by Renilla PCA. Tmem203 was tagged at its 
C terminus with the 1.1 (small) fragment of Renilla luciferase reporter, whilst Sting was tagged 
at its N-terminus with the 2.1 (large) Renilla fragment to test for a molecular interaction 
between these proteins in live cells.  
6B. Tmem203 and Sting interact in live cells. HEK293 T cells were co-transfected with the 
indicated fusion protein expression vectors; Renilla luciferase signal was detected by Nano-
Glo live cell luciferase assay. Relative luminescence intensity was plotted compared to the 
negative control transfection of Nano-BIT construct. Data is presented as mean ± SEM, n=3. 
6C. Tmem203-Sting interaction is differentially regulated by DMXAA and 2’3’-cGAMP. 
TMEM203 and STING were tagged at its N terminus with the 1.1 and 2.1 fragment of Renilla 
luciferase, respectively, to test for a molecular interaction between these proteins in live cells 
(upper). Tmem203 and Sting were transfected into HEK293 T cells for 24 h and were then 
stimulated with DMXAA (50 µg/ml) and 2’3’-cGAMP (10 µg/ml) for the indicated time. Relative 
luciferase activity was assessed according to Hoechst (cell numbers) and calculated relative 
to early 2.5 stimulation time point. Data is presented as mean ± SEM, n=4. 
6D. E. Tmem203 co-precipitates with Sting N terminal transmembrane region. (D) WT 
and five mutant Sting constructs were created as indicated and fused with HA tags. WT Sting, 
aa 1-378; TM = transmembrane domain, aa 1-153; ΔCTT = Sting without cytoplasmic tail, aa 
1-340; ΔTM = Sting without transmembrane domain, aa 147-378; ΔCBD = Sting without cyclic-
dinucleotide binding domain (CBD), aa 1-153 & 340-378; CBD = CBD domain of Sting, aa 
147-340. (E) HEK293 T cells were transfected with either empty vector, Flag-Tmem203 or 
HA-Sting (WT / mutants). Tmem203-containing complexes were immuno-precipitated (IP) 
using anti-Flag coated beads and blotted for Flag and HA, as indicated. Lysates were also 
immunoblotted (IB) for Flag and HA. Immunoblots shown are from a single experiment and 
are representative of two independent experiments. 
6F. Sting truncation mutants. 4 serial truncation mutants were individually created on the 
WT Sting after the N-terminal transmembrane domains (TM), after the dimerisation domain 
(TM+DD), inside the cyclic dinucleotide binding domain (d-CBD), and before the C-terminal 
cytoplasmic terminal tail (ΔCTT).  
6G. C-terminal truncations alter Sting protein expression. HEK293 T cells were 
transfected with the YFP fusion vectors expressing Sting WT and mutants as indicated. YFP-
Sting protein levels were examined by western blot analysis. Membranes were blotted with 
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anti-GFP and anti-PDHX (housekeeper) as indicated. Relative expressions of mutant Sting 
were compared to the WT expression. Data is presented as mean ± SEM, n=5. 
6H. Tmem203-Sting association is not eliminated by C-terminal truncations of Sting. 
HEK293 T cells were co-transfected with the Tmem203 and Sting WT/mutants cloned into the 
Venus vector system as described in Figure 2F; Venus fluorescence signal was detected by 
flow cytometry. Relative mean fluorescence intensity was plotted compared to the control 
Sting WT – Tmem203 interaction. Data is presented as mean ± SEM, n=4-7. 
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Figure 7: C-terminal region of STING is required for preferential localisation of the 
STING-TMEM203 complex to the lysosome. 
7A-C. Localisation of TM Sting – WT Tmem203. HeLa cells were co-transfected with the 
V1_TM Sting and V2_WT Tmem203 prior to ER (A) or lysosome (B) staining; fluorescence 
signal was detected under confocal microscopy at 80X. Images are representative of two 
independent experiments. (C) Overlay of Tmem203-Sting signals and organelle signals were 
quantified with Fiji and co-localisation was calculated as the percentage of organelle with 
positive Tmem203-Sting detection. One dot per cell analysed from two independent 
experiments. Data is presented as mean ± SEM, scale bar = 20 µm. 
7D: Proposed molecular model for TMEM203 action. In the absence of immune stimuli, the 
type I interferon promoter has no transcriptional activity. Pathogen-released 3’3’-cGAMP or 
cGAS-produced 2’3’-cGAMP can induce the canonical STING pathway, resulting in TBK1-
IRF3 interaction and subsequent type I interferon expression. Internalised LPS-bound TLR4 
activates the “late signalling” events which induce TMEM203-STING interaction in the ER, 
leading to STING-TBK1-IRF3 activation and type I interferon expression. CDN = cyclic 
dinucleotide; cGAMP = cyclic GMP-AMP; cGAS = cyclic GMP-AMP synthase; ER = 
endoplasmic reticulum; IRF3 = interferon regulatory factor 3; LPS = lipopolysaccharide; 
STING = Stimulator of Interferon Genes; TLR4 = Toll-like receptor 4; TBK1 = TANK binding 
kinase; TMEM203 = transmembrane protein 203. 
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Discussion: 
In this study, we show that a novel inflammatory regulator, TMEM203 forms part of a functional 
signalling complex with STING, thus regulating the activity of the effector kinase TBK1 and 
the transcription factor IRF3, leading to activation of type I interferon expression. TMEM203 
acts independently of the canonical PRR systems and the STING/TMEM203 complex 
localises in cytoplasmic punctate membranes. Our experiments aiming to further dissect the 
underlying molecular mechanisms in human and mouse macrophages revealed that 
TMEM203 regulates STING in a ligand-dependent manner. Upon STING activation by cyclic 
dinucleotides and HSV-1 but not by DMXAA, TMEM203 promotes the activation of TBK1 and 
IRF3. Finally, our data on different truncated forms of STING reveal that its N-terminal 
transmembrane domain itself is sufficient to form a complex with TMEM203 and that this 
interaction is regulated by the α-helix / dimerisation domain on STING. Supported by the 
mechanistic studies presented here, we propose a model (Fig. 7D) by which TMEM203-
STING acts and promotes the TBK1-IRF3-interferon activation.  
Whilst detailed structural studies will be required to shed light on the exact molecular 
mechanisms by which TMEM203 regulates STING activity, our data demonstrates the first 
time the important role for TMEM203 in ligand-dependent STING activation. In three primary 
and established macrophage systems, immuno-stimulation by cGAMP was impeded by the 
reduction/loss of TMEM203, whilst DMXAA induced IFN-β expression only changed in parallel 
to Sting but not Tmem203 RNA levels. The mouse-specific ligand DMXAA binds to STING via 
mechanisms similar to cGAMP but different amino acids are involved. Point mutations of 
hSTING S162A and E260I render it sensitive to DMXAA (64, 65). Upon ligand binding, STING 
dimer switches from an open-inactive to a close-active conformation, the binding pocket being 
much tighter in the presence of 2’3’-cGAMP versus DMXAA (64). This model is further 
supported by our finding that DMXAA strengthens TMEM203-STING association while 
cGAMP weakens it. 
Our data also highlights the role for TMEM203 in directing STING between intracellular 
compartments. Whilst TMEM203 overexpression alone did not strongly enhance type I 
interferon expression in the mechanistic studies presented here, it has nevertheless promoted 
vesicular translocation of STING and its downstream IFN-β transcriptional activities. Recent 
literature suggests that the N-terminal of STING is indispensable for its translocation from the 
ER to other membranes during stimulation (59). Thus, the association of this domain with 
TMEM203 may provide a mechanistic explanation for the importance of this STING domain.  
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Host innate immunity is governed by a complex network of proteins cooperating in response 
to a variety of pathogens and autoimmune stimuli. Apart from the four well-established PRR 
systems controlled by TLR, C-type lectin receptors, NOD-like receptors and RIG-I-like 
receptors, innate immune signalling also utilises a range of accessory/adaptor proteins to 
maintain the homeostasis of inflammation. STING is one of the major intracellular sensors of 
cytoplasmic double-stranded DNA and is a critical switch to initiate type I interferon production. 
Recent work in mouse models of SLE have demonstrated that STING is required for 
homeostatic expression of negative regulators of immune activation (6); whilst analysis of 
human monocytes from SLE patients revealed a hyperactive STING signalling that is 
regulated by the interferon induced gene, IFIT3 (31). Analysis of T cells (a critical source of 
Type I interferon in this disease (62, 63)) from a cohort of SLE positive, treatment naïve 
patients revealed unaltered STING and an elevated level of TMEM203 with a concurrent 
suppression of MAVS RNA levels, suggesting that TMEM203 may be an important, novel 
player in the pathology of SLE. 
The physiological significance of STING has been demonstrated during HSV, adenovirus 
(ADV), human papillomavirus (HPV) and negative-stranded RNA viruses such as vesicular 
stomatitis virus (VSV) infections (2, 44, 66). Gain-of-function STING variants lead to auto-
immune, inflammatory diseases such as SAVI and FCL, manifesting symptoms of type I 
interferonopathy (15, 17). STING mediated signalling is known to involve TBK1/IRF3 and NF-
κB; targeting STING activity for therapeutic purposes nonetheless thus far focussed on 
inhibiting downstream interferon receptors, and JAK/STAT (15, 17, 67). Several cancer 
adjuvants showed promising anti-tumour effects in early clinical trials but none has yet 
progressed to the clinic (68, 69). Therefore, revealing TMEM203 as a novel STING-centred 
signalling regulator is of significant interest to both basic research to the understanding of 
diseases of interferon dysregulation, and to the development of therapeutics and adjuvants 
modifying interferon induction.  
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Methods: 
Plasmids: 
- Expression vectors 
Tmem203 expression constructs were generated using standard molecular biological 
techniques. For details of other inserts used, see (50). 
- Reporter vectors 
pGL4.cxcl2 reporter vector, which contain the mouse cxcl2 promoter in pGL4 (Promega) have 
been previously described (50). Similarly, the IL8-luc has previously been reported (70). As an 
internal control, pGL4.EF1.rLuc was used; this was constructed by PCR amplification of the 
human EF1 promoter from pEF-BOS (71) and inserted into pGL4 at the Nhe I site. Sequences 
of all vectors used were confirmed by sequencing. Plasmid vectors for studies of the 
TMEM203/STING complex by EYFP-PCA have been reported previously (72). For Renilla-
PCA, plasmids from the NonBIT-PPI (Promega) were used. Plasmids used in co-
immunoprecipitation were cloned into pXJ40 vector (73) which contains CMV enhancer/ 
promoter. HA tag sequence is MVPYDVPDYAGS, Flag tag sequence is MDYKDDDDKG, Myc 
tag sequence is EQKLISEEDL. Sequences of all vectors used were confirmed by sequencing.  
SLE cohort 
A cohort of patients diagnosed with SLE on the basis of the 1997 updated criteria of the 
American College of Rheumatology (74) were examined in this study and patient samples 
were followed-up at the Department of Rheumatology and Immunology, University of Szeged, 
Hungary. Patients aged 18-80 years with clinical disease activity in at least one organ system 
were eligible for the study. Exclusion criteria included the presence of an overlapping 
connective tissue disease, an infectious or other inflammatory process, and corticosteroid 
treatment with a prednisolone dose higher than 10 mg/day. The most important demographic 
characteristics and disease activity parameters of the cohort are presented in Table S1. All 
subjects gave informed consent to donate blood for research purposes prior to starting 
treatment of SLE. SLEDAI2K, anti-DNA, C3 and C4 complement levels in the patient serum 
were measured as part of the assessment of disease activity during lupus flare. The study was 
approved by the Human Investigation Review Board of the University of Szeged, Albert Szent-
Györgyi Health Centre (reference number 2833/2011). 
Study Ethics 
All human tissue samples were collected under protocols approved by the University of 
Szeged Review Board (Ref No 2833/2011) and conformed to the declaration of Helsinki 
(World Medical Association. 1964. Declaration of Helsinki). Human blood was taken and used 
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under protocols approved by the University of Sheffield Research Ethics Committee (UREC) 
(Ref. SMBRER310). All participants gave written informed consent. 
 
Isolation of primary macrophages 
Peripheral blood mononuclear cells (PBMCs) were isolated from total blood using standard 
Ficoll-Pague gradient (GE Healthcare). Monocytes were isolated by positive selection using 
CD14-targeting magnetic microbeads (Miltenyi Biotec) according to manufacturer’s 
instructions. The purified cell population was found to contain over 90% CD14-positive 
monocytes. To differentiate human monocytes into human monocyte-derived macrophages 
(MDMs) 250,000 cells were seeded in a 12 well plate in 1.5 ml complete RPMI (1% PS, 1% 
L-G and 10% LE HI FBS) supplemented with 100 ng/ml human recombinant M-CSF 
(PeproTech). MDMs were fully differentiated at the seventh day of incubation (37 ℃ 5% CO2) 
and used for further experimental purposes. At day 7 of M-CSF incubation, fresh complete 
RPMI medium was supplied before further treatment.  
Mice hind limbs were a gift from MRC Harwell, Oxford. Bone marrow were eluted from 
mice bones are were cultured in DMEM (10% low endotoxin FCS (Biowest); 1% Penicillin-
Streptomycin; 10% L929 conditioned medium) for 5 days to be differentiated into primary bone 
marrow-derived macrophages (BMDMs). Cells were seeded in 12 well plates for further 
experiments.  
 
Isolation and analysis of T cells: 
PBMCs were isolated from SLE and healthy donors using Ficoll (GE Healthcare) gradient 
centrifugation. PBMCs were stimulated with 1 μg/mL Phytohaemagglutinin (PHA-L, Sigma-
Aldrich) and were cultured for 72 hours in RPMI-1640 medium (Gibco®) supplemented with 
10% fetal bovine serum (FBS) (Gibco®), 2 mM L-glutamine (Gibco®) and penicillin-
streptomycin (Sigma-Aldrich). Total RNA was extracted from activated T cells (1-3 × 106 cells) 
using PerfectPure RNA Cultured Cell kit (5 Prime) according to the manufacturer’s instructions 
with on-column DNase digestion. For cDNA synthesis, 1 μg of total RNA / reaction was reverse 
transcribed using RevertAid Reverse Transcriptase (Thermo Fisher Scientific Inc.) in the 
presence of 1.66 µM of oligo(dT)18 and random hexamer primers, 0.5 mM dNTP, 10 U 
RiboLock RNase Inhibitor and 200 U RevertAid H Minus Reverse Transcriptase for 60 min at 
42°C then heated for 10 min at 70°C. Quantitative PCR was carried out using TaqMan 
Universal mastermix II (Applied Biosystems®) in 10 µl reaction volumes in duplicates using 
Roto-Gene Q real-time PCR cycler (Qiagen). The following Taqman® Gene Expression 
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Assays (Applied Biosystems®) were used: (Hs01060665_g1 for ACTB, Hs01057884_s1 for 
TMEM203, Hs00736955_g1 for TMEM173, Hs00920075_m1 for MAVS with a Roto-Gene Q 
instrument (Qiagen). Quantitative real-time PCR data were analysed using the Rotor Gene 
software (v6.1 build 93). 
 
Cell cultures, transient transfection 
RAW 264.7 cells were purchased from ATCC (Cat. No: TIB-71). RAW 264.7 cells were 
plated overnight and the next day transfected using DharmaFECT transfection reagents 
(Dharmacon, GE Healthcare) according to the manufacturer’s guidelines. Cells were further 
treated 24 h post plasmid transfection or 48 h post siRNA transfection. All transfections were 
performed in 96-well plates, unless stated otherwise.  
Differentiated human monocyte-derived macrophages (MDMs) were transfected with On-
target Plus siRNAs smartpool (Dharmacon, GE Healthcare) against human TMEM203 or non-
targeting control siRNA using Viromer green transfection reagent (Lipocalyx) at a final 
concentration of 12.5 nM. Transfection lasts 48 h before cells are used for other purposes.  
Immortalised bone marrow-derived macrophages (iBMDMs) cell line was generated by 
David Brough’s lab (University of Manchester) using the method described by (75). Cells 
(75,000 in 0.5 ml) were seeded overnight to allow attachment and were transfected with siRNA 
pool (Dharmacon, GE Healthcare) against mouse Tmem203 or Sting or non-targeting control 
siRNA using the same Viromer green transfection method as described for MDMs. Cells were 
assayed 48 h post transfection. 
HeLa cells (200,000) were plated in 35mm glass-bottom petri dish to attach overnight and 
the next day were transfected with Lipofectamine 3000 according to the manufacturer’s 
protocol. Cells were used 18-24 h post plasmid transfection. 
For Renilla and Venus protein complementary assay, HEK293 T cells were transfected 
using PolyFECT (Qiagen) according to manufacturer’s guidelines. Equal quantities were used 
for co-transfecting plasmids. Transfection lasts 18-24 h before cells are used in further 
treatments.  
RAW 264.7 and iBMDMs were maintained in Dulbecco’s Modified Eagle’s medium 
(DMEM) supplemented with 1% Penicillin-Streptomycin (PS) (Gibco), 1% L-glutamine (L-G) 
(Gibco) and 10% low-endotoxin heat-inactivated fetal bovine serum (LE HI FBS) (Biowest). 
Human MDMs were maintained in RPMI-1640 medium supplemented with 1% PS, 1% L-G 
and 10% LE HI FBS. HeLa cells were maintained in DMEM supplemented with 1% PS, 1% L-
G, 1% non-essential amino acids and 10% HI FBS. HEK293 T cells were maintained in DMEM 
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supplemented with 1% PS, 1% L-G and 10% HI FBS. All cells were kept at 37 ℃ and 5% CO2; 
all established cells were used at 30 or lower passages.  
 
Generation of CRISPR/Cas9 Tmem203 Knockout RAW 264.7 cells 
Four suitable sgRNA oligos were designed and used in the generation of pGL3-U6 
sgRNA-Puromycin expression vectors. Vectors were transformed into E.coli DH5α and 
positive clones were screened on Ampicillin selection plates. Identified clones containing 
correct insertion of sgRNA oligos were further confirmed by sequencing using the primer: 5’-
cgattagtgaacggatctcgacg-3’. Transfection of RAW 264.7 with pGL3-U6 sgRNA expression 
vectors was carried out using Lipofectamine 2000 according to the manufacturers’ instructions. 
6h post-transfection, media was replaced with RPMI complete medium. Antibiotic selection 
using Puromycin (2 μg/ml) and Blasticidin (10 μg/ml) was started at 24 hours (h) post-
transfection and continued for a total of 72 h before passaging cells for downstream 
applications. Clonal isolation was performed, and successful clones that consistently showed 
3-4 folds decrease in Tmem203 expression determined by quantitative real-time PCR. These 
colonies were selected for establishment of a stable cell lines along with CRISPR-Cas 9 
control group using selective medium containing Puromycin (2 μg/ml) and Blasticidin (10 
μg/ml). 
 
Generation of Tmem203 Stably Expressing RAW 264.7 cells 
Mouse Tmem203 cDNA was cloned into the pcDNA 3.0 vector between the Hind III and 
BamHI restriction sites. The construct was then transfected into RAW 264.7 cells using 
Lipofectamine (Invitrogen) according to the manufacturer’s instruction. 18-24h after the 
transfection, RPMI-1640 medium supplemented with 10% FCS, Penicillin/ Streptomycin and 
500μg/ml G418 was added to initiate the selection of stably expressing Tmem203 cells. 
Clones were selected for further culture after two weeks of selection. qPCR was carried out to 
confirm the level of overexpression.  
 
STING ligand stimulation: 
RAW 264.7 cells were transfected with 1μg 3’3’-cGAMP using Lipofectamine LTX 
(Invitrogen) according to the manufacturer's instructions. 
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For MDM, immortalised BMDM (iBMDM) and BMDM stimulation, macrophages were 
stimulated with 2’3’-cGAMP, 3’3’-cGAMP or DMXAA at the indicated doses and time. 2’3’-
cGAMP was delivered with fresh medium (control treated with fresh DMEM only); 3’3’-cGAMP 
was delivered with 20 mins incubation of reversible Digitonin permeabilisation method as 
described in by Woodward and colleagues (2010 Science 328(5986): 1703-5) (control treated 
with ligand free Digitonin buffer); DMXAA is reconstituted in DMSO and delivered to cells with 
fresh medium (control treated with DMSO only medium). All ligands were purchased from 
Invivogen. 
 
HSV-1 infection 
RAW264.7 cells (control and Tmem203-overexpression / CRISPR-Tmem203 knockout) 
were grown in RPMI 1640 medium (Hyclone) supplemented with 10%(v/v) FBS (Sigma) and 
seeded to 50% confluency in 6 well plates and allowed to rest overnight. Cultures were then 
replaced with antibiotic free media before infection with HSV-1 virus at MOI of 0.2. Cell lysates 
were obtained at 0, 1, 3 and 6 hr post infection for western analyses. Cells were harvested at 
0 and 6hr post infection for RNA extraction and cell culture supernatants were subjected to 
ELISA. 
 
Enzyme-linked immunosorbent assay (ELISA) 
IFN-β ELISA kit (PBL Interferon Source) were used for the measurement of IFN-β 
concentrations according to the manufacturer’s protocol. The concentration was determined 
by reading the absorbance at 450 nm using the BioTek® Microplate Reader. 
 
Standard and quantitative real-time PCR 
Following experiments, RAW 264.7 cells were lysed using Isol (5 prime) and then 
chloroform extracted prior to RNA isolation on RNeasy Mini columns, including DNase 
digestion (Qiagen). cDNA was made from total RNA with Maxima First Strand cDNA Synthesis 
Kit for RT-qPCR (Thermo scientific) according to the manufacturer’s protocol. Quantitative 
real-time PCR (qPCR) was performed with the PerfeCTa qPCR FastMix (Quanta Biosciences) 
in 20 μl reaction volumes in duplicate wells and cycled in a StepOnePlus™ Real-Time PCR 
cycler. The following TaqMan® Gene Expression Assays (Applied Biosystems®) were used: 
IFN-β (Hs01077958_s1), TNF (Hs00174128_m1). 
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For analysis of mRNA levels in MDM, BMDMs, iBMDMs, and ER stress response in 
HEK293 T cell: Following treatment, cells were washed with PBS and harvested for total RNA 
extraction on ReliaPrep Cell Isolation columns (Promega) following the manufacturer’s 
instructions. Complementary DNA was made from 500 ng total RNA (Biorad iScript cDNA 
synthetic kit) for gene expression analysis. Real-time quantitative PCR was performed using 
Primerdesign SYBR green mastermix in 10μl reaction volume in triplicate wells and quantified 
in Biorad CFX384 TouchTM real-time PCR cycler. Primers for amplification of human genes 
were as follows (Forward and Reverse):  
Human:  
IFN-β: 5’-AAGCAGCAATTTTCAGTGTCAGA–3’ and 5’-CCTCAGGGATGTCAAAGTTCA–3’; 
IL-8: 5’-TGCCAAGGAGTGCTAAAG–3’ and 5’-CTCCACAACCCTCTGCAC–3’; TMEM203 5’-
GTCTTCGAGATGCTGTTGTGC–3’ and 5’-ACGTAATGAGGCCGAACCAG–3’; Total XBP1 
5’-TGGCCGGGTCTGCTGAGTCCG–3’ and 5’-ATCCATGGGGAGATGTTCTGG–3’; Spliced 
XBP1 5’-CTGAGTCCGAATCAGGTGCAG–3’ and 5’-ATCCATGGGGAGATGTTCTGG–3’; 
Non-spliced XBP1 5’-CAGCACTCAGACTACGTGCA–3’ and 5’-
ATCCATGGGGAGATGTTCTGG–3’; β-actin 5’-GGATGACAGAAGGAGATCACTG–3’ and 5’-
CGATCCACACGGAGTACTTG–3’. 
Mouse: 
Sting: 5’- GCTGGCATCAAGAATCGGGT–3’ and 5’- TACTCCAGGATACAGACGCC–3’; 
Tmem203: 5’- CCCTGTTGGTGTTCTCCGTA–3’ and 5’- GCACAAAGACGTTCCACCAG–3’; 
Ifnb1: 5’- TGTCCTCAACTGCTCTCCAC–3’ and 5’- CATCCAGGCGTAGCTGTTGT–3’; Cxcl2: 
5’- ATCCAGAGCTTGAGTGTGACG–3’ and 5’- TTTGACCGCCCTTGAGAGTG–3’; β-actin: 
5’-GGGACCTGACAGACTACCTCATG–3’ and 5’-GTCACGCACGATTTCCCTCTCAGC–3’; 
 
Site-directed Mutagenesis and molecular cloning 
Single-amino acid mutation was performed using Agilent QuikChange Mutagenesis kit 
following the manufacturer’s protocol. Forward and reverse primers were designed to 
substitute the target tri-nucleotide with a stop codon to generate truncation mutations in Sting 
coding region (ENSMUSG00000024349; NP_082537.1, Q3TBT3). Reverse primers are 
complementary to the forward primers. Primers were purchased from Sigma Aldrich. Sting 
mutants used in co-immunoprecipitation were generated by standard PCR with respective 
primers using AccuPrime™ Taq DNA Polymerase system from Thermo Scientific following 
manufacturer’s instructions. EcorV site was introduced to facilitate ligation between internal 
deletion sites. Fidelity of the constructs were confirmed by Sanger sequencing. 
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Mutations and primers are described below: 
Sting mutants for co-immunoprecipitation: 
Gene Mutation Mutagenesis Primer Sequences 
Sting 
WT 
WT 
aa 1-379 
Forward: 5’-
AAAAAGCTTATGCCATACTCCAACCTGCATCCAGCCATCCCACGGC-3’ 
Reverse: 5’AAACTCGAGTCAGATGAGGTCAGTGCGGAGTGGGAGAGGCTGA-3’ 
TM TM1 – TM4 
aa 1-146 
Forward: 5’-
AAAAAGCTTATGCCATACTCCAACCTGCATCCAGCCATCCCACGGC-3’ 
Reverse: 5’-AAACTCGAGTCAGACTGCAGAGACTTCCGCTGG-3’ 
ΔCTT TM1 – CBD 
aa 1-338 
Forward: 5’-
AAAAAGCTTATGCCATACTCCAACCTGCATCCAGCCATCCCACGGC-3’ 
Reverse: 5’-AAACTCGAGTCACTCCTTTTCTTCCTGACGAATGTGCC-3’ 
ΔTM CBD – CTT 
Aa 147-379 
Forward: 5’-GGGAAGCTTATGTGTGAAGAAAAGAAGTTAAATGTTGCCCACGG-3’ 
Reverse: 5’-AAACTCGAGTCAGATGAGGTCAGTGCGGAGTGGGAGAGGCTGA-
3’ 
ΔCBD Internal 
deletion of 
CBD 
Aa 1-146, 
340-379 
Forward: 5’-AAGATATCGAGGTTACCATGAATGCCCCCATGACCTCAGTGGCA-3’ 
Reverse: 5’-
AAGATATCGACTGCAGAGACTTCCGCTGGAGTCAAGCTCTGAAGG-3’ 
CBD CBD only 
Aa 147-379 
Forward: 5’-GGGAAGCTTATGTGTGAAGAAAAGAAGTTAAATGTTGCCCACGG-3’ 
Reverse: 5’-AAACTCGAGTCACTCCTTTTCTTCCTGACGAATGTGCC-3’ 
 
Sting truncation mutants used in protein complementation assays and Western blotting 
were generated using QuikChange II Site-Directed Mutagenesis kit following the 
manufacturer’s guidelines. Gateway Entry clones were used in mutagenesis reaction to induce 
point mutations and the correct gene-encoding sequence were fused into desired EYFP-PCA 
(as described above) or EYFP expression clones to express the gene of interests. Plasmids 
were transformed into NEB® 5-alpha Competent E. coli (high efficiency) cells and selected by 
50 µg/ml Kanamycin (Entry clones) or 100 µg/ml Ampicillin (Destination clones) during 
amplification. Plasmid were isolated from bacteria cultures on GenElute plasmid DNA 
midiprep kit (Sigma Aldrich) according to the manufacturer’s protocol. Mutagenesis were 
confirmed by Sanger sequencing (Source Bioscience, Birmingham). 
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Sting truncation mutants: 
Gene Mutation Mutagenesis Primer Sequences 
 
141A 
GCG->TGA 
A -> STOP 
Forward 5’ CAGAGCTTGACTCCATGAGAAGTCTCTGCAGTC 3’ 
Reverse 5’ GACTGCAGAGACTTCTCATGGAGTCAAGCTCTG 3’ 
 
184L 
CTA->TGA 
L -> STOP 
Forward 5’ CGAATGTTCAATCAGTGACATAACAACATGCTC 3’ 
Reverse 5’ GAGCATGTTGTTATGTCACTGATTGAACATTCG 3’ 
 
243V 
GTC->TGA 
V -> STOP 
Forward 5’ GTTTATTCCAACAGCTGATACGAGATTCTGGAG 3’ 
Reverse 5’ CTCCAGAATCTCGTATCAGCTGTTGGAATAAAC 3’ 
 
344A 
GCC->TGA 
A -> STOP 
Forward 5’ GAGGTTACCATGAATTGACCCATGACCTCAGTG 3’ 
Reverse 5’ CACTGAGGTCATGGGTCAATTCATGGTAACCTC 3’ 
 
Protein complementary assay 
To determine protein interaction using split Venus protein complementary assay (PCA), 
125,000 HEK293 T cells were seeded in 24 well plates and transfected with 500 ng total 
plasmid per well. Post transfection, cells were harvested in FACS buffer (5% (v/v) FBS-PBS) 
and assessed by flow cytometry (BD Bioscience LSRII). Cell viability was determined by TO-
PRO-3 (0.002 nM, Thermo Fisher) negativity. Geometric means of GFP determined in the 
alive cells were compared to the selected control samples.  
For split Renilla PCA, 25,000 HEK293 T cells were seeded in 96 well plates and 
transfected with 100 ng total plasmid per well. Post transfection, Renilla signal was analysed 
using Nano-Glo® Luciferase Assay System (Promega). Cells were stimulated with STING 
ligands for indicated time when Renilla activities were measured accordingly. Cells were also 
stained with Hoechst33324 (0.002 nM, ThermoFisher) to indicate cell number for 
normalisation. Cells were maintained at 37℃ throughout the experiment. 
Immunostaining and confocal microscopy: 
HeLa cells were transiently transfected with 2 μg of Tmem203-mCherry for 48 hours 
using Metafectene™ (Biontex) according to the manufacturer’s recommendations. HeLa cells 
were then seeded onto UV-irradiated coverslips in a 6-well plate (2ml at 2 × 105 per ml) and 
treated with 1μg/ml LPS for 30 and 60 minutes as indicated. Cells were fixed with 
methanol/acetone at a 1:1 ratio and stained with an anti-TBK1 (Alexis Biochemicals) antibody 
or an anti-IRF3 (C20, SC-15991, Santa Cruz) antibody as indicated. Localisation of TBK1 and 
IRF3 was visualised using Alexa Fluor 488 conjugated anti-mouse and anti-goat secondary 
antibodies respectively (Molecular Probes). LAMP1, (H5G11, SC-18821, Santa Cruz) 
localisation was visualised using Alexa Fluor 488 conjugated anti-mouse secondary antibody 
(Molecular Probes).  
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For live cell imaging of Tmem203-Sting organelle localisation, attached HeLa cells were 
transfected with 750 ng of each V2_Tmem203 and V1_Sting (WT or mutant) for 18-24 hours 
using Lipofectamine 3000 according to the manufacturer’s guidelines. Post transfection, 
samples were washed three times with PBS and were stained for 10 mins with ER or lysosome 
Cytopainter staining kit (Abcam) at 1/5 and 1/3 of manufacturer’s recommended 
concentrations, respectively. Cells were then washed three times with PBS and were 
maintained in colourless DMEM medium (1% PS and 10% HI FBS) until imaging. Images were 
acquired by confocal microscopy on a Zeiss LSM 510 META with 40X inverted water-lens 
(Molecular Probes). Images were analysed by Fiji. ROI was selected around the organelles to 
calculate the number of pixels of the organelle, Sting-Tmem203 fluorescence and co-localised 
signals. The percentage of localisation was calculated as the ratio of number of co-localised 
pixels to number of pixels occupied by the organelle.  
RAW 264.7 macrophages stably expressing Tmem203 or empty vector were grown on 
coverslips and transfected with 1 µg 3’3’-cGAMP for 6h, along with controls. Cells were fixed 
with 3.7% (v/v) formaldehyde for 15 minutes (min) at 37°C. Fixed cells were washed twice 
with PBS, twice with 4mM NH4Cl in PBS, twice with PBS and then permeabilised with 0.2% 
(v/v) Triton X‐100 (BioRad) in PBS for 15 min at room temperature. Blocking was carried out 
with 2% (w/v) bovine serum albumin and 7% (w/v) FBS in PBS for 60 min at room temperature. 
Cells were incubated with rabbit anti‐IRF3 antibody (Cell Signaling Technology) in blocking 
solution overnight. Samples were washed three times with 0.1% (v/v) Triton X‐100‐containing 
PBS before incubation with Alexa Fluor 546‐conjugated donkey anti‐rabbit IgG for 60 min, 
washed three times with 0.1% (v/v) Triton X‐100‐containing PBS and incubated with DAPI for 
5 min, washed twice and mounted using Fluorsave. Confocal fluorescence images were 
captured on a Zeiss LSM510 META microscope. 
Human MDMs were seeded in 8 well chamber slides (40,000) and were washed twice 
with PBS and fixed with 4% (v/v) formaldehyde for 30 min at 37°C. Fixed cells were washed 
3 times with PBS and then permeabilised with 0.1% Triton X-100 – PBS for 15 mins. Cells 
were then washed 3 times with PBS and blocked with 2% bovine serum albumin (BSA)-PBS 
for 1 h at room temperature. Cells were washed with PBS and incubated with mouse anti- 
human CD68 (Dako) (1:100 in 1% BSA-PBS) at 4°C overnight. Cells were then washed 3 
times with PBS and reacted with AlexaFluor 488-conjugated goat anti-mouse secondary 
antibodies. Nuclei were visualised with DAPI (1:1000 PBS) (ThermoFisher). Cells were 
imaged on a LEICA AFI6000 Time-Lapse microscope at 10X magnification. 
 
Western-blotting and immunoprecipitation analysis 
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Post treatment, cells were washed twice with PBS and harvested in RIPA buffer (Sigma 
Aldrich) and phosphatase inhibitors (Roche). The samples were vortexed on ice and sonicated 
for 15 mins in ice cold water. Protein concentrations were determined by Pierce BCA assay 
(Thermo Fisher). 10 μg proteins were diluted with equal volume of 2x Laemmli reducing buffer 
(4% SDS (w/v), 10% (v/v) 2-mercaptoethanol, 20% (v/v) glycerol, 0.0004% (w/v) bromophenol 
blue, 0.125M Tris-HCl, pH 6.8) to separate on 4-12% NuPAGE gels (Life Technologies), then 
transferred on nitrocellulose or PVDF membrane.  
TBK1 protein and its phosphorylated form were blocked with TBST (TBS + 0.05% (v/v) 
Tween-20) and 3% (w/v) cold fish gelatin (Sigma), then reacted with specific rabbit antibodies 
(Cell Signalling #3013 and #5483, respectively) followed by anti-rabbit Ig-HRP (DAKO). All 
antibodies were diluted in 1.5% (w/v) cold fish gelatin-TBST. The chemi-illuminescent signal 
of EZ-ECL (Biological Industries) was detected on ChemiDoc™ XRS imager (Bio-Rad), and 
the band densities were quantified using the Image Lab™ Software. The relative pTBK1 levels 
were calculated by dividing the intensity of pTBK1 form by the intensity of total TBK1 in each 
sample. Western blot analysis was carried out with anti-pIRF3 (Ser396) (Cell Signalling 
Technology) for IRF3 phosphorylation, or anti-pTBK1 for TBK1 phosphorylation respectively.  
For detection of YFP-STING WT and mutants, membranes were blocked with TBST 
containing 10% (w/v) skimmed milk, then reacted with mouse monoclonal anti-GFP antibodies 
(Cusabio, CSB-MA000283) or mouse monoclonal anti-PDHX (housekeeper, Santz Cruz #Sc-
377255), followed by anti-mouse IgG-HRP (DAKO). All antibodies were diluted in 5% (w/v) 
milk-TBST. The chemi-illuminescent signal of EZ-ECL (Biological Industries) was detected on 
a Li-COR c-digit blot scanner and protein bands were quantified using Image Studio Digit 
software Ver 5.0. Band intensities were normalised against PDHX in the same sample. 
For immunoprecipitation experiments, HEK293 T cells were seeded at 5 × 105 per ml, 
in 10 ml, in 10 cm2 dishes and transfected with a total of 2g of plasmid for 18-24 hours. Cells 
were lysed on ice in radioimmunoprecipitation lysis buffer (1× PBS, 1% (v/v) Nonidet P-40, 
0.5% (w/v) Na-deoxycholate, 0.1% (w/v) SDS, 1 mM KF, 1 mM Na3VO4, 10 g/ml leupeptin, 
and 1 mM PMSF) followed by immunoprecipitation with anti-Flag (M2, F1804, Sigma) pre-
coupled to protein-G Sepharose beads (Sigma). Both immunoprecipitate samples and lysates 
were immunoblotted for Flag and Myc (Ab18185, Abcam). 
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Supplementary figure/table titles and legends: 
Figure S1 (relate to Figure 1): Tmem203 induced Cxcl2 activation is independent of 
MAPK pathways. The impact of MAPK inhibition on Tmem203 overexpression vs. LPS 
induced cxcl2 expression was investigated in RAW 264.7 cells transfected with the cxcl2-pLuc 
and EF1-rLuc reporters. LPS (100 ng/ml) was added for 3 hours and used to induce cxcl2 
luciferase reporter. Data is presented as mean ± SEM, n=3. 
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Figure S2 (relate to Figure 4): Interferon response in human and mouse macrophages. 
A. Assessment of high purity primary human monocyte isolated from whole PBMC. Post 
monocyte isolation, monocytes, B cells and T cells were stained with fluorescence-conjugated 
CD14, CD19 and CD3 antibodies, respectively. Over 90% purity of CD14 positive human 
monocytes were assessed by flow cytometry.  
B. Human monocyte-derived macrophages express CD68. CD14 positive monocytes were 
differentiated into macrophages with M-CSF incubation and purity was examined by blotting 
with anti-human CD68 and detected with Alexa Fluor® 488 conjugated goat anti-human. Scale 
bar = 100 µm. 
C. & D. TMEM203 knockdown reduces 2’3’-cGAMP (C) and 3’3’-cGAMP (D) induced IFN-
β expression in MDMs. IFN-β production of control vs. stimulated MDMs was compared in 
individual blood donor MDMs. Mean IFN-β mRNA levels (relative to β-actin) ±SEM are plotted 
from 3 biological replicates for each MDM culture.  
E. DMXAA (dark) and 2’3’-cGAMP (light) induces potent IFN-β mRNA increase in 
iBMDMs. IFN-β production of control vs. stimulated iBMDMs was compared. Mean Ifnb1 
mRNA levels (relative to b-actin) ± SEM are plotted from n=3. 
G. Genotype of Tmem203 gene in the WT and Tmem203 knockout mice. CRISPR-Cas9 
induced deletion mutation of 11 nucleotides of exon ENSMUSE00000665152 (WT Tmem203) 
to generate a knockout allele (H-Tmem203-DEL11-EM1-B6N) of C57BL/6 background mice. 
Genotyping information confirmed by Sanger sequencing, MRC Harwell Institute, Oxford. 
H. IFN-β response in BMDM stimulated with STING ligands. BMDM isolated from WT mice 
were stimulated with DMXAA (50 µg/ml) (dark) or 2’3’-cGAMP (10 µg/ml) (light) for 3 h. Mean 
IFN-β mRNA levels (relative to unstimulated controls, not shown) ± SEM are plotted from 3 
biological replicates for each BMDM culture. 
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Figure S3 (relate to Figure 5) – Establishing Tmem203 knockout and Tmem203 
overexpressing RAW 264.7 cell lines. 
A. CRISPR/Cas9 TMEM203 Knockout RAW 264.7 cell line. CRISPR-Cas9 –directed 
Tmem203 knockout in RAW 264.7 cell line (KO Tmem203) showed a 3-4 -fold decrease in 
Tmem203 (against β-actin mRNA) expression determined by RT-qPCR and the cell line was 
established for further experiments.  
B. Stable Tmem203 overexpression in RAW 264.7 cell line. Stable Tmem203 
overexpression in RAW 264.7 cell line (OE Tmem203) showed a robust 8-fold increase in 
Tmem203 (against β-actin mRNA) expression determined by RT-qPCR and the cell line was 
established for further experiments.  
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Figure S4 (relate to Figure 6): Overexpression of Tmem203 and Sting does not induce 
ER stress. 
S4. A-C. Venus PCA Tmem203 and Sting co-expression does not induce ER stress in 
HEK293 T cells. Co-transfection of Tmem203 (A) and Sting (B) Venus PCA constructs 
resulted in high expression of both genes but only little increase of XBP1 mRNA splicing (C). 
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Table S1 (relate to Figure 1): Clinical description of SLE patient cohort. A cohort of 20 patients 
were diagnosed with SLE and clinical data were acquired. Asterisks denote data being presented as 
Mean±SD (Lower:Upper interquartile range). Abbreviation: F=female; M=male; SLEDAI-2K=systemic 
lupus erythematosus disease activity index 2000; Anti-DNA=serum level of antibody to double-
stranded DNA; C3=serum C3 complement level; C4=serum C4 complement level; NA=not available. 
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Age at 
Sampling 
(Years) 
Gender SLEDAI-2K Anti-DNA 
IU/ml 
C3 
mg/dL 
C4 
mg/dL 
18 F 9 151 82 10 
42 F 23 151 84 11 
25 F 18 220 63 7 
46 F 12 12 141 29 
20 F 9 45 103 7 
63 F NA 74 131 11 
37 M 16 220 80 15 
36 F 16 220 59 15 
35 F NA 13 111 18 
49 M 16 18 135 23 
56 F 30 200 75 10 
54 F 15 200 53 11 
35 F 30 200 21 3 
31 F 18 NA NA NA 
45 F 8 14 41 10 
59 F 2 10 90 20 
37 F 19 220 67 12 
52 F 17 200 63 15 
38 F 6 41 116 23 
30 F NA NA NA NA 
N=20 F:18 
M:2 
*15.53±7.62 
(9:18) 
*122.72±87.63 
(29.5:200) 
*84.17±32.39 
(63:107) 
*13.89±6.41 
(10:16.5) 
      Normal range: 
 0-20 
Normal 
range: 
90-180 
Normal 
range: 
10-40 
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Chapter 3: Discussion and future work for TMEM203 
3.1 Discussion 
Maintaining tissue homeostasis relies on the complex network of inflammatory 
signalling events which respond to a wide spectrum of stimuli. Since the description of 
Toll-like receptors a century ago [275], numerous proteins have been identified in 
immune regulation and thus completing our knowledge of human physiology. Novel 
inflammatory mediators are continuing to be discovered for their potential in 
therapeutic development and academic interest. Unlike the TLR-dependent pathways, 
other pattern recognition receptors are less well-characterised and yet of significant 
physiological importance. For instance, the intracellular nucleic acid sensing adaptors 
MAVS and STING have become the centre of research since their discovery in 2005 
and 2008, respectively [276, 277]. These emerging inflammatory mediators have 
provided strong evidence supporting the endosomal TLRs and the cytosolic NLR-
inflammasome independent sensor of cytoplasmic nucleic acids, while it also 
emphasises the role for mitochondria and the ER in immune regulation. This also 
refined the function of Golgi vesicles and lysosomes which are indispensable 
signalling platforms downstream of MAVS and STING in addition to the role as 
transport for protein and enzyme cargos [278–280]. 
 
The initial purpose of the cDNA functional screen in LPS-induced RAW 264.7 murine 
macrophages was to identify novel inflammatory proteins with unclear roles in 
controlling innate immune response, which may mediate distinct impacts of TLR 
activation [131]. From the screen, Tmem203 was identified as an activator of the Cxcl2 
chemokine. At the beginning of Chapter 2, our preliminary study aimed to link 
Tmem203 to the canonical MyD88 or TRIF dependent pathways downstream of TLR4 
activation. However, our results suggested an alternative mechanism for Tmem203 
action. Tmem203 is a small protein with 4 transmembrane domains and no obvious 
N-terminal and C-terminal cytoplasmic regions, and therefore generating a specific 
and high affinity antibody for immunofluorescence studies was a challenge. Despite 
this limitation, we constructed the mCherry-fusion protein for Tmem203 and visualised 
its localisation in the punctate membrane structures in HeLa cells. These structures 
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highly resemble the endoplasmic reticulum. As our research continued, a paper 
published by Shambharkar and colleagues has confirmed the ER residency of 
Tmem203, yet the roles for this protein was mainly discussed in the context of calcium 
signalling and implications for spermiogenesis [132]. Although the paper did not 
discuss the relevance to immune regulation, it confirmed our findings of Tmem203 ER-
localisation, thus the potential to colocalise and interact with the nearby ER resident 
inflammatory mediators. We hypothesised that STING would demonstrate direct 
association with TMEM203. Although we considered MAVS as co-regulator for 
TMEM203, several publications have suggested that MAVS and STING crosstalk is 
not indispensable for their individual activation, suggesting that an interaction between 
mitochondria and the ER was not critical to MAVS’s activation, and it was very limited 
at the mitochondria-associated membrane regions [206]. Even though TMEM203 
could be part of signalling transduction between MAVS and STING, the role for 
TMEM203 in MAVS regulation could be minimal.  
 
We have used human primary monocyte-derived macrophages as a comparable cell 
model to study STING activation in human. However, we were aware that donor-
variation may exist in the expression level of TMEM203, STING and MAVS in primary 
cells isolated from different people. By analysing mRNA expression of these genes in 
MDMs from 9 individuals, a strong correlation was found between TMEM203 and 
STING but not with TMEM203-MAVS, although further studies of a large n>30 
population is required to understand the expression relation between these genes 
(Appendix A1.1, page 268).  Because of this donor-variation, we have also tested if 
siRNA transfection alone could induce immune response prior to further immune 
stimulations. For this, we have shown that non-specific siRNA transfection into MDMs 
does not induce potent type I interferon and IL-8 mRNA upregulation (Appendix A1.2, 
page 269), and the dose of siRNA transfection has been optimised in this primary cell 
type to ensure an even distribution of siRNA delivery in every cell (Appendix A1.3, 
page 270).  
 
In addition to the macrophages, we have used a number of other cell models for 
various purposes. HeLa cells were used for all imaging STING and TMEM203 
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expression and colocalization for their advantage of flat morphology. We have also 
optimised the staining concentration of ER and lysosome and doses of 
V1_Sting/V2_Tmem203 co-transfection to obtain an optimal fluorescent signal and 
cell viability in microscopy (Appendix A1.5-1.7, page 272-274). HEK293 cells were 
used to study STING wildtype and mutant interaction with Tmem203 as this cell line 
is known to express extremely low level of STING and cGAS [281], and thus avoiding 
the trouble of overexpressing this gene. Although both HeLa cells and HEK293 cells 
were sufficient models to study protein interactions, neither of these cells were well-
known to exhibit strong immune response as compared with immune cells, and 
therefore the studies involving STING-mediated immune response were conducted in 
macrophages.  
 
Our research has repeatedly revealed that TMEM203 enhances type I interferon 
expression via STING but not directly. As demonstrated in Chapter 2, Fig. 3G, Fig. 5B-
F, overexpression of Tmem203 only amplifies Ifnb1 expression and TBK1/IRF3 
activation in the presence of STING activation, and thus identified it as an enhancer 
but not an upstream activator for STING. The structure of TMEM203 does not possess 
functional domains to support ligand recognition and effector binding. Although data 
suggested that a multimeric TMEM203 structure exists, this does not rectify a lack of 
cytoplasmic region for functional interaction. This is also a potential reason that 
TMEM203 binds preferentially to the N-terminal transmembrane domains of STING, 
with STING acting as a signalling platform for TMEM203. However, TMEM203 
overexpression primes STING trafficking to lysosomal vesicles, which is a signal for 
STING activation and post-activation processing [280, 282, 283]. Although it was 
previously reported that STING translocation can be achieved in the absence of TBK1 
and IKK, a dsDNA stimulation was required to induce such dynamic [283]. Our 
evidence suggests a ligand-free, TBK-free translocation of STING-TMEM203 complex 
from the ER to lysosomal vesicles, being solely induced by the upregulation of 
TMEM203. It is unclear how an almost completely membrane-embedded protein is 
capable of directing the movement of protein complexes; the answer may relate to 
additional signalling cascades providing the trafficking machinery to facilitate their 
migration.  
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One possibility is related to calcium spikes which are strongly perturbed by TMEM203 
overexpression [132]. A novel area was explored by Kim et al. demonstrating a role 
for STING in regulating calcium response [284]. The experiments identified a calcium 
spike upon DMXAA and 3’-3’ cGAMP stimulations in RAW 264.7 cells. Whereas 
STING downregulation impairs calcium pulses induced by the ligands, the intracellular 
calcium chelator BAPTA-AM also inhibited DMXAA-induced STING activation. 
However, calcium mobilisation was not essential for cGAMP-induced STING 
activation, and distinct regulatory mechanisms between the two STING ligands was 
also indicated in our work (Chapter 2, Fig. 2G-H and Fig. 6C). Further to the authors’ 
suggestions that cGAMP more likely activates calcium-independent STING signalling, 
TMEM203 obtains a high potential to link calcium transients to the type I interferon 
activation, opening an area to explore in relation to STING activation and trafficking in 
ligand-free conditions. 
 
An alternative hypothesis for TMEM203-enhanced STING activation relates to with the 
confirmation change of the receptor. Several groups have reported the change of 3D 
structure of STING when in contact with different ligands [285–287]. STING 
conformation is switched between the “open-inactive” and a “close-active” forms. The 
contact of ligands with the dimeric ligand binding pocket alters the open structure to a 
closed conformation which enabled the rearrangement of C-terminal cytoplasmic tail 
to expose the docking sites for TBK1 and IRF3 [286, 288]. The “lid” region of STING 
aa 224 - 244 positions adjacent to the ligand binding site, and it was predominantly 
tightened by ligand recognition and highly affected by the different affinities of ligand 
binding [288]. This is why DMXAA can activate mouse but not human STING, and the 
mutation G230I renders hSTING sensitive to DMXAA binding [286]. However, ligand-
independent activation of STING was observed in Sendai virus (a RNA virus) infection 
where activated RIG-I induce mitochondrial elongation which translates to the nearby 
ER membranes and promotes ER de-reticulation, a mechanism found to induce 
STING-mediated antiviral response [212]. The study of natural STING mutants 
revealed a further ligand-free activation mechanism through mutations in-between the 
transmembrane domains and the “lid” region. Four gain-of-function mutations, V147L, 
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N154S, V155M, and V155R, showed significantly enhanced ability to sustain the 
“close-active” conformation of STING dimer and they are constitutively phosphorylated 
by TBK1, promoting type I interferon signalling in the absence of ligand challenge [120]. 
Moreover, further cGAMP stimulation does not induce or alter the existing interferon 
signalling, suggesting that a conformational change is sufficient to activate STING. A 
prevalent loss-of-function STING variant was also identified in 20.4% human 
population [289]. This HAQ mutant, R71H-G230A-R293Q, showed a lower intrinsic 
NF-κB promoter activity and a reduced IFN-I response to bacterial cyclic dinucleotides. 
These three mutations individually lie within the transmembrane domain, “lid” region, 
and the ligand binding domain, was proposed to alter C-terminal conformation that 
clamps c-di-GMP, thus incurring the impaired interferon signalling functions. All the 
evidence supports the idea that conformation change critically regulates STING 
activation, and the specific STING ligands can induce such changes.  
 
To address how TMEM203 may impact on this STING activation, our protein 
complementary assays and co-immunoprecipitation experiments shown in Chapter 2, 
Fig. 6E and 6H have demonstrated a strong association between TMEM203 and the 
N-terminal domain of STING. The addition of STING’s dimerisation domains (DD) to 
its transmembrane domains (TM) enhanced its interaction with TMEM203 even though 
the protein level of STING is impaired. As described above, this region is involved in 
the reorganisation of the cytoplasmic domains and STING activation. It is speculated 
that our over-expansion of TMEM203 could be facilitating the “close-active” 
conformation of STING. Nonetheless overexpression of TMEM203 alone did not 
induce type I interferon activation (Chapter 2, Fig. 3G & 5D), we believe that it is more 
likely to help stabilise ligand-bound STING, and thus sustain and prolongate the 
downstream interferon activation. On the other hand, reduced TMEM203 level may 
affect STING structural stability which does not abolish the type I interferon expression 
but significantly impaired the amplitude (Chapter 2, Fig. 4), and potentially also incurs 
early signalling attenuation.  
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3.2 Future work 
Our work has demonstrated that STING-dependent type I interferon expression is 
regulated by the novel proinflammatory mediator TMEM203. The function of 
TMEM203 was previous reported to relate to calcium signalling, while our data strongly 
support a previously unidentified immune regulatory role. As my project mainly 
investigated the role for TMEM203 and STING IFN-I induction, a number of areas 
could be explored regarding the additional functions of TMEM203. 
 
One area to expand is the LPS-induced TMEM203 upregulation, initially discovered in 
the cDNA functional screen in RAW 264.7 cells. As the project evolved, STING 
became the priority area of research, but questions remain as to how TMEM203 
expression is upregulated by LPS stimulation and whether TMEM203 acts as the 
intermediate platform for crosstalk between LPS/TLR and STING pathways. There is 
a lack of strong evidence for STING and TLR signalling communication, although an 
intact microbe presents multiple PAMPs that can be recognised by several PRRs. For 
example, the bacterium Brucella abortus is able to activate both TLR/MyD88 and RNA 
polymerase III/STING pathways [290]. Further experiments could explore the function 
of TMEM203 in the context of LPS-induced inflammation and address the mechanistic 
pathways of STING regulation. This area is of significant interest to link complex 
antimicrobial immune signalling between STING and TLR. 
 
Commercial purified STING ligands (Invitrogen) were used throughout experiments as 
the focus was to identify and monitor the interaction between TMEM203 and STING, 
and thus the use of complex microorganism was not required. However, human 
physiology almost never encounters clean bacterial molecules, but rather as 
biologically active organisms that can change and interact with host system. It is yet 
unclear whether complex immune stimuli may induce alternative TMEM203 activation 
other than pathway via STING. The aspect of TMEM203-dependent chemokine 
upregulation by LPS challenge was under-addressed, and questions arise as whether 
TMEM203 can switch between signalling routes in response to different immune 
challenges. Furthermore, the mechanism underlying re-localisation of TMEM203 
induced by LPS was unclear (Chapter 2, Fig. 3A-B). Whether LPS or other bacterial 
196 
 
ligands could promote TMEM203 translocation to lysosomes and thus potentiates 
STING activation will require further investigation.  
 
In Chapter 2, we have extensively investigated the localisation and translocation of 
TMEM203 and TMEM203-STING complex to provide reason for their interaction in 
immune activation. However, limited by the little cytosolic exposed region in TMEM203, 
our investigation on TMEM203 relies solely on the expression of fusion plasmids which 
inevitably resulted in the overexpression of this gene. Overexpression of ER proteins 
has been implicated in unfolded protein stress response which disturbs the 
physiological condition of the organelle, creating an additional variable in the 
experiment system [291, 292]. To eliminate the possibility, we have measured the 
transcriptional splicing of XBP1 as an indicator of ER stress unfolded protein response 
(UPR), and little stress event was detected (Chapter 2, Fig. S4). Despite this, 
TMEM203 upregulation could possibly induce calcium perturbation and showed an 
intracellular localisation pattern of its post-activated state [132]. A specific anti-
TMEM203 antibody will be required to solve this problem, as well as to quantify the 
protein levels in TMEM203 knockdown experiments in human monocyte-derived 
macrophages (Chapter 2, Fig. 4A-B). More importantly, the time and spatial regulation 
of TMEM203 will be better characterised with antibody labelling which may reveal 
differential trafficking strategies to various immune challenges. 
 
Protein complementation assay was frequently used in this project to investigate 
protein-protein interaction. This technique shown in Chapter 2 Fig. 6A-C has helped 
us to quantify molecular interaction in living cells. Although cells are monitored in a 
short 30-minute period under restricted CO2-free condition, we were able to capture 
the association of proteins at 2.5 to 5-minute time points. Such assays can be 
developed into tools for in vitro drug screen [293, 294]. The advantage of this 
experiment was to compensate the unspecific false positive protein interactions reveal 
by a protein-only screen test, as live-cell drug screen ensures that proteins are 
available in the native cellular environment with all potential influence of natural 
inhibitors and scaffolding proteins, and it also assesses the permeability of drugs 
across the plasma membrane. Combining this live-cell assay with hi-throughput 
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analysis [294] can be both effective and accurate in validating pharmacological 
influence on protein association in a real physiological setting. Similar live-cell based 
PCA has already been used to screen protein interactions using the reporter of 
dihydrofolate reductase (DHFR) to reflect protein interactions by yeast growth under 
different chemical conditions [295]. In comparison, our system is superior in rapid 
detection of protein interactions via luciferase reporter, and hence it can precisely 
distinguish both the strength and duration of interaction.  
 
Although the interaction and functional relevance between STING and TMEM203 has 
been established, we have to acknowledge that much is unknown about the activities 
of TMEM203 in regulating inflammation. It is still unclear whether TMEM203 is a 
stabiliser of STING dimerisation and functional conformation, whether TMEM203 also 
couples to additional receptors or ion channels (most likely calcium channels), and 
whether TMEM203-STING interaction is a promising therapeutic target for STING 
deficiency or over-activation. Although we have analysed the level of TMEM203, 
STING and MAVS in T cells isolated from a cohort of treatment naïve patients, it still 
remains unclear how these genes contribute to or affected by this pathology, or if there 
are other cell types that can better represent the roles of these interferon regulators. 
Particularly, patient-derived T cells were activated by PHA (phytohaemagglutinin) prior 
to TMEM203 and STING mRNA measurement, and its potentially impact to T cell 
characteristics and interferon response should be addressed in future. Although we 
have demonstrated the role for TMEM203 and STING in a variety of macrophage 
models, it is crucial to ascertain whether they have similar functions in other type I 
interferon-producing cells, particularly T cells which largely contribute to SLE [139]. 
Furthermore, a loss-of-function STING HAQ (R71H-G230A-R293Q) variant has been 
identified to show 90% reduction in the ability to activate IFN-β signal in response to 
Legionella pneumophila and bacterial STING ligands [296]. The series of mutations 
occurs in the transmembrane domain and ligand binding domain of STING which 
impairs but not completely abolishes STING’s ability to become activated. Thus, the 
HAQ mutant would likely alter STING’s ability to dimerise and interact with TMEM203. 
Questions also remain to the potential of single nucleotide polymorphisms (SNPs) in 
TMEM203 gene, nevertheless there was none discovered at present, this would be 
worth investigating in future.  
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Particularly, since STING overactivation can cause autoimmunity and its deficiency 
increases infection susceptibility, the challenge for targeting STING therapeutically is 
to identify the fine balance for its activation and inactivation. Based on our evidence, 
TMEM203 has the potential to be a surrogate for STING intervention because of its 
ability to alter but not complete abolish STING signalling. This can ideally prevent 
excessively immunodeficiency and renders the host certain ability to exhibit interferon 
response. Further studies on the human and mouse STING orthologues can also 
inform us how the TMEM203-dependent regulation in these two species will likely be 
comparable or distinct in antiviral response. In general, the discovery of TMEM203 
has widened our knowledge on inflammatory signalling and has added a substantial 
piece of evidence to address the importance of STING-regulated immunity. 
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Abstract: 
Dengue virus (DENV) is a member of the family Flaviviridae which poses major health threats. 
The signalling by the DNA sensor cGAS and adaptor Stimulator of Interferon Genes (STING) 
is critical for the host antiviral response against DENV, notably via the production of type I 
interferon (IFN) and IFN stimulated genes (ISG). Nonetheless, this signalling is targeted by 
the viral proteases, leading to immune evasion. Zika virus (ZIKV) is an emerging flavivirus that 
causes neurological disorders in foetus and adults. As ZIKV and DENV are genetically closely 
related, ZIKV is predicted to share similarities with DENV for its interaction with host factors. 
ZIKV can infect placental tissue macrophages and this greatly contributes to in utero 
transmission and foetus disease. Thus, we investigated whether ZIKV and DENV infect human 
primary monocyte-derived macrophages and addressed the potential involvement of STING. 
Our results revealed that active viral replication of both viruses induces a potent type I IFN/ISG 
response and that the level of STING can impact the degree of virus-mediated ISG 
upregulation.  
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Introduction: 
Members of the Flavivirus including Zika virus (ZIKV) and Dengue virus (DENV) cause human 
pathologies globally. These genetically closely related viruses belong to the flavivirus genus 
and are both transmitted by mosquito bites. In its severe form, DENV induces severe 
hemorrhagic fever and shock syndrome. In contrast, ZIKV infection was thought to be primarily 
asymptomatic; however, recent epidemics have led to foetal demise and detrimental 
neurological development, i.e., microcephaly in newborns and Guillain–Barré syndrome in 
adults (rapid-onset of muscle weakness caused by immunological damage on the peripheral 
nerve system) [1–3]. Seeking mechanisms of protection against these viral infections is of 
significant medical demand.  
 
Type I interferons (IFNs) are potent antiviral host effectors against viral infections [4]. 
Stimulator of Interferon Genes (STING) and its downstream effectors TANK-binding kinase 
(TBK1) and interferon regulatory factor 3 (IRF3) form a key antiviral signalling cascade that 
notably regulates type I IFN response [5–7]. The upstream DNA sensor cyclic GMP-AMP 
synthase (cGAS) and STING mediate an immune response dependent on the recognition of 
mitochondrial DNA released in the cytosol upon DENV infection [8]. Nonetheless, DENV has 
evolved mechanisms to inhibit and evade this host response, including the proteolytic 
cleavage of STING and cGAS by the viral NS2B/3 protease complex, leading to blunted type 
I IFN induction [9, 10]. STING inactivation is critical to ensure viral replication in the host cells 
[9, 10] and might contribute to host species restriction [11]. Reversing or blocking STING 
inhibition could, therefore, offer a potential therapeutic approach to combat DENV and other 
related flavivirus infections. 
 
Interestingly, the cGAS/STING pathway is known as a critical antiviral signalling mechanism 
in monocytes/macrophages [11–15]. Previous reports suggested that placental tissue 
macrophages contribute to ZIKV transmission from mother to foetus [12, 16]. Owing to the 
high level of sequence homology between DENV and ZIKV genome, their known interactions 
with host factors and the viral replication cycle also display high similarities [17–19]. Along this 
line, a recent report demonstrated that ZIKV cleaves STING in fibroblasts in a species-
restricted manner [20]. This study has also pointed out the conservation between ZIKV and 
DENV in the cleavage target of human STING and the mechanism of action of their NS2B/3 
protease complexes, suggested it was logical to compare ZIKV with DENV in virus research.  
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Abundant recent research on Dengue virus have focused on its infectivity and regulation in 
primary human T cells, dendritic cells (DC) and plasmacytoid DCs [21–23] whereas few has 
investigeted how human macrophages contribute to viral pathology. This is potentially due to 
that macrophages produce less interferons than the previously mentioned cell types [22]. 
Macrophages are also plastic cells that show heterogeneous response to stimuli when they 
are in different tissue environments. The most well described M1 and M2 phenotypes 
distinguish macrophage subsets into the “pro-inflammatory” or the “pro-resolution” states, 
respectively, which often impact differently on the cellular response to microbial infections [24, 
25]. In contrast to various of macrophage differentiation techniques, macrophage colony-
stimulating factor (M-CSF) is most well-known for its role in consistent monocyte-macrophage 
differentiation in vitro compared to that by granulocyte-macrophage colony-stimulating factor 
(GM-CSF) [26, 27]. Differentiation by these two cytokines does not clearly polarise the cells to 
a well-defined M1 or M2 phenotype. Whilst it has been discovered that both growth factors 
cause similar level of type I interferon secretion in DENV-infected cells, GM-CSF can 
additionally activate potent inflammasome-mediated interleukin-1 response [27, 28]. Although 
GM-CSF promotes macrophage sensitivity to Dengue virus, it also causes more complex 
immune crosstalk between macrophages and multiple cytokine-stimulating pathways are 
involved in the regulatory process. For an accurate characterisation of the role of type I 
interferon signalling in Dengue-infected human macrophages, M-CSF has the advantage of 
creating a simple cell model that best depicts this biological event. 
 
Therefore, we here investigated the importance of ZIKV-induced host response in human 
monocyte-derived macrophages differentiated by M-CSF. We aim to define the potential 
interplay between ZIKV and the cGAS/STING-induced antiviral response that shapes viral 
replication in this cell model. We will also address the susceptibility of M-CSF -MDMs to DENV 
and ZIKV infection and to compare and contrast the infection-induced type I interferon 
stimulated response. These assessments will be used to understand the antiviral activation of 
cGAS/STING signalling against these viral infections.  
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Results: 
ZIKV/DENV infection in human monocyte-derived macrophages (MDMs) induce a 
potent ISG response 
Myeloid cells / monocytes are known to efficiently respond to different viruses and other stimuli 
via the cGAS/STING pathway [11–15, 33, 34] and they represent key cellular targets for 
ZIKV/DENV infection. We thus first aimed to validate a cell system for infection by ZIKV and 
DENV and for subsequent assessment of host responses (Fig. 1A). Human blood isolated 
monocytes were cultured ex vivo in the presence of M-CSF, which is known to induce their 
differentiation to macrophages (MDMs). These naïve macrophages do not exhibit clearly 
defined M1/M2 phenotypes in the absence of IFN-γ and IL-4 [35]; although literature shows 
that M-CSF derived macrophages become IFN promoting [36, 37] and display cGAS/STING 
activation upon human cytomegalovirus infection [38]. After 6 days of culture, cells were 
infected by ZIKV at different multiplicity of infections (MOIs). Our results demonstrate that ZIKV 
RNA levels increased over-time in MDMs, thus reflecting viral replication (Fig. 1B). The levels 
of ZIKV RNA amplification were in keeping with the MOI applied. Interestingly, ISG15 and MxA 
expression was potently induced upon ZIKV infection, as detected as early as 24 hpi and 
persisting at 72 hpi. (Fig. 1C-D).  
 
Next, we compared the viral infectivity and the host response to ZIKV versus DENV infection 
(MOI of 1) and assessed the level of ISG expression in a 3 day-kinetic analysis post-infection. 
For this donor, ZIKV and DENV replication levels in MDMs were similar (Fig. 1E-F) with a peak 
of viral RNA detected at 24 hours and decreased at 72 hpi. However, the kinetics of viral 
replication in this donor (Fig. 1B-C) were different from that detected in the previous donor 
(Fig. 1E-F at MOI of 1), the difference was likely due to the variation of infection susceptibility 
between different primary macrophages. Nonetheless, marked ISG induction was consistently 
observed upon ZIKV and DENV infection in MDMs and maintained over time despite the 
decrease of viral RNA load observed at 72 hpi (Fig. 1G-H). M-CSF differentiated human 
macrophages have been reported to exhibit a potent interferon response to Dengue infection 
[39] whereas other macrophage cultures were less permissive for Dengue [9, 10]. Together 
our results suggest that this cell model is susceptible to ZIKV and DENV infections and 
constitute a stable human cell model to study type I interferon-mediated ISG induction in 
primary human macrophages due to these viral infections. 
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Figure 1: ZIKV/DENV infections in human monocyte-derived macrophages (MDMs) 
induce a strong ISG response.  
A. Schematic representation of experiment timeline.  
B. At day 6 post isolation from a healthy donor, MDMs were infected or not with ZIKV at 
multiplicity of infection (MOI) of 0.2, 1 and 2, and cells were assessed for ZIKV intracellular 
RNA levels by RT-qPCR at 2, 24 and 72 hours post infection (hpi).  
C, D. Interferon-stimulated genes (ISG) ISG15 (B) and MxA (C) induction was assessed in 
MDMs upon ZIKV infection at the indicated MOIs and times post-infection. The mRNA 
expressions were compared to the uninfected control cells. Gene mRNA expression levels 
were assessed by RT-qPCR and presented as in A.  
E, F. MDMs isolated from a healthy donor were mock infected or infected with ZIKV (E) or 
DENV (F) at MOI of 1 and viral RNA levels were assessed by RT-qPCR at 2, 24 and 72 hpi.  
G, H. MDMs were infected as in Fig. 1E&F and ISG15 (G) and MxA (H) mRNA levels were 
assessed in ZIKV and DENV infected MDMs at 2, 24 and 72 hpi by RT-qPCR. ISGs mRNA 
expressions were compared to the uninfected control cells. Data is presented as Genome 
equivalent (GE) per µg of total RNA. All figures were plotted from n=1 donor, 2 technical 
repeats, mean±SD. 
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ISG activation in MDMs is induced upon replication of ZIKV/DENV.  
Since previous reports indicated that the cGAS/STING/JAK/STAT axis is induced upon 
modification of the mitochondria [8, 40], we next asked whether active viral replication is 
required to induce antiviral responses in MDMs. Human macrophages were infected with 
active or UV-inactivated ZIKV/DENV (Fig. 2A). UV radiation is widely used to abolish viral 
activities by permanently and chemically damage their genome [41].  As expected, UV-
inactivated ZIKV and DENV viruses have demonstrated limited ability to replicate (Fig. 2 B-C) 
and were unable to induce ISG expressions in MDMs compared to the replication competent 
viruses (Fig. 2D-E). Therefore, this study reveals that the replication of ZIKV and DENV is 
required for the stimulation of type I interferon–mediated response in MDMs, in agreement 
with the proposed activation mechanism of cGAS/STING signalling. 
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Figure 2. The induction of ISG is dependent on viral replication.  
A. Schematic representation of experiment timeline.  
B, C. MDMs isolated from a healthy donor were infected with mock, UV-inactivated or 
replication-active ZIKV (B) and DENV (C) at MOI of 2 for 2 h and viral replication was assessed 
by RT-qPCR at 24 hpi.  
D, E. MDMs were infected with ZIKV or DENV as above and the mRNA inductions was 
assessed for ISG15 (D) and MxA (E) by RT-qPCR at 24 hpi. Data is presented as Genome 
equivalent (GE) per µg of total RNA. All figures were plotted from n=1 donor, 2 technical 
repeats, mean±SD. 
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ZIKV/DENV infection does not impair STING activation by cGAMP 
Given the previous evidence indicating that the DENV-secreted NS2B/3 protease complex 
targets the STING-cGAS axis and thus type I interferon signalling [9, 10], we next addressed 
whether ZIKV, similar to DENV, inhibits STING-activated ISG expression in primary 
macrophages. We infected MDMs with ZIKV for 24 hours followed by 6 hours of STING 
stimulation with 2’3’-cGAMP (Fig. 3A), the level of viral replication and ISG induction were 
assessed by RT-qPCR. Upon ascertaining the replication of ZIKV (Fig. 3B), STING-dependent 
ISG expression was found not impaired by the prior ZIKV infection (Fig. 3C-D). Nonetheless, 
2’3’-cGAMP was able to promote ISG expression to a seemingly saturated level, which could 
potentially cover/outcompete the underlying viral antagonism of the interferon response. This 
result was validated in MDMs isolated from a different donor to that of the DENV infection (Fig. 
3E-J). After assessing the same parameters, we reached the same conclusion that the 
competent replication of both ZIKV/DENV (Fig. 3E&H) did not result in suppression of cGAMP-
STING –mediated ISG expression (Fig. 3F-G & I-J). We therefore suggest that STING 
activation in M-CSF-treated macrophages was unaffected by pre-infection of ZIKV and DENV, 
at this time point post-infection. Possibly, the absence of virus-mediated STING antagonism 
could be due to an insufficient infection establishing period, and/or a restricted number of 
infected cells in the total MDM population or alternatively due to an alternative ISG signalling 
mechanism being activated by 2’3’-cGAMP. 
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Figure 3: The activation of ISG expression by cGAMP was not inhibited by ZIKV and 
DENV infection.  
A. Schematic representation of experiment timeline.  
B. MDMs isolated from a healthy donor were mock infected or infected with ZIKV at MOI of 2 
for 24 h and further treated with 4 µg/ml 2’3’-cGAMP for 6 h before being assessed for ZIKV 
replication by RT-qPCR at 30 hpi.  
C, D. MDMs were treated as in Fig. 3A and ISG15 (B) and MxA (C) mRNA levels were 
assessed by RT-qPCR post treatment.  
E-G. In another donor, MDMs were treated as in Fig. 3A and the gene level of ZIKV (E), ISG15 
(F) and MxA (G) levels were assessed by RT-qPCR post treatment Data is presented as 
Mean±SD, n=2.  
H-J. MDMs isolated from a healthy donor (same as in Fig. 3E) were mock infected or infected 
with DENV at MOI of 2 for 24 h and further treated with 4 µg/ml 2’3’-cGAMP for 6 h before 
being assessed for DENV replication by RT-qPCR at 30 hpi (H). ISG15 (I) and MxA (J) mRNA 
inductions were assessed by RT-qPCR. Data is presented as Genome equivalent (GE) per 
µg of total RNA. All figures were plotted from n=1 donor, 2 technical repeats, mean±SD. 
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STING regulated ZIKV/DENV infection in MDMs 
Next, we investigated how STING contributes to the regulation of virus-induced ISG response. 
To address this, MDMs derived from two donors were transfected with STING suppressing 
siRNA (or control siRNA) followed by 24 h and 72 h of infection with either ZIKV or DENV virus 
(Fig. 4A). Due to the 48 h extension to the culture time for the siRNA treatment, an ISG 
response stimulated by 2’3’-cGAMP was tested in MDMs as a positive comparison to ascertain 
the induction of interferon response and the efficiency of siSTING (Supplementary Fig. 1A-B). 
Both ISG15 and MxA mRNA levels were induced by the ligand and were inhibited by STING 
downregulation, indicating that MDMs at day 8 post M-CSF incubation remain responsive to 
immune stimuli. Next, we investigated how siSTING impacts ISG expression. From our 
observation, we revealed that the downregulation of STING suppressed ISG expression of 
virus-infected macrophages in Donor 1 (Fig. 4B-C) but not in the donor 2 (Fig. 4D-E). This 
result suggests that cGAS/STING signalling might contribute to the induction of ISG response 
upon ZIKV/DENV infection, yet other pathways may still have a role depending on the donor 
and/or differentiation state of the MDMs and/or the level of viral replication. Moreover, 
consistent responses were found between the two viruses in terms of the induction of STING-
ISG axis and the response to STING downregulation, indicating that these two viruses might 
similarly induce the antiviral host pathway.  
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Figure 4: STING regulated ZIKV/DENV infection in MDMs. 
A. Schematic representation of experiment timeline.  
B, C. MDMs isolated from Donor 1 were transfected with Control or siSTING and then mock 
infected or infected with ZIKV/DENV at MOI of 1 and ISG15 (B) and MxA (C) were assessed 
by RT-qPCR at 24 hpi and 72 hpi.  
D, E. MDMs isolated from Donor 2 were transfected with Control or siSTING and then mock 
infected or infected with ZIKV/DENV at MOI of 1 and ISG15 (B) and MxA (C) were assessed 
by RT-qPCR at 24 hpi and 72 hpi. Data is presented as Genome equivalent (GE) per µg of 
total RNA. All figures were plotted from n=1 donor, 2 technical repeats, mean±SD. 
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Discussion: 
Species of the Flavivirus family pose a major infectious threat to the tropical world. Unlike 
Dengue and Yellow fever viruses, Zika virus is an emerging member of the family that came 
to the center of research due to its ability to uniquely invade the nerve system and to transmit 
in utero. From literature, type I interferons are critical for innate immune protection against 
viral infection, which are induced by the cytoplasmic sensing mechanism of viral nucleic acids 
or mis-localised host DNAs (in the context of cGAS/STING) [5–8]. Notably, the type I 
interferons (IFN-I) response acts against virtually all viruses and is often inhibited/manipulated 
by viruses to enhance their replication. One of the critical type I interferon-inducing pathway 
is mediated by the adaptor protein Stimulator of Interferon genes (STING) and its upstream 
cytosolic DNA sensor GMP-AMP synthase (cGAS). Since DENV is known to evade host 
response by targeting cGAS-STING for degradation, it is logical to assess whether the related 
Zika virus also regulates or is being regulated by STING activities.  
 
DENV is known to infect a variety of myeloid cells, especially monocytes and T cells, whereas 
little was studied on ZIKV’s infectivity in haematopoietic cells, except that it was discovered to 
invade human placental macrophages [16]. A number of DENV infection model adopt 
differentiation method using GM-CSF to enable macrophages to be more permissive to virus 
infection [9, 10, 27, 42]. However, the complexion of type I interferon and inflammasome 
signaling in this cell model [27, 28] can potentially influence with each other and thus interfere 
our analysis of STING activation and ISG response. In contrast, M-CSF is critical for the 
homeostasis of macrophage functions and it maintains the resting state of macrophages until 
immune challenge [26, 27]. Most importantly, M-CSF regulation is at the heart of maintaining 
placental development and the formation of immune defense by the local macrophages [43–
45]. Therefore, to best address the role of STING regulation in DENV/ZIKV infected human 
macrophages, M-CSF has the superiority over the GM-CSF culture condition to address this 
question. 
 
Given that M-CSF differentiated macrophages were used in few DENV studies [28], our work 
first aimed to characterise that these cells are permissive and sensitive to DENV and ZIKV 
infections, and they elicit considerable amount of type I interferon stimulated genes. We tested 
the dose and time upon which ZIKV infects MDMs and showed that the viral replication has 
rapidly occurred within 24 hours post infection. Resolution of infection was observed at 72 hpi 
but a high ISG mRNA level was maintained over this period. However, our observation of a 
potent induction of ISG expression was contradictory to previous research that suggested 
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STING inhibition by DENV [9, 10], still the MDM culture conditions by the different colony 
stimulating factor could largely influence the cells’ ability to respond to virus infections. Thus, 
our method seemed to render macrophages DENV/ZIKV susceptibility for a longer period of 
time compared to Aguirre’s model [9].  
 
Secondly, we identified that the activation of ISG response by both ZIKV and DENV 
predominantly depends on active replication. Aguirre and Yu have reported that DENV 
antagonizes and evades STING and the subsequent type I interferon signaling [9, 10, 46] 
whilst other groups also showed that Dengue virus can induce the interferon axis in 
macrophages [27, 47].  In our study, at 24 hpi, neither ZIKV and DENV were able to intercept 
STING activation by its endogenous ligands, and consequently the ISG production remained 
significant with or without viral infection. Again, these observations contradicted to the STING 
cleavage model by DENV infection [9, 10] and thus confirmed that our M-CSF / MDM model 
has allowed the macrophages to be immune responsive to both virus infections. Additionally, 
evidence suggests that DENV and ZIKV block multiple components of the cGAS/STING/IFN 
cascade [9, 10, 20, 48–50], potentially because a single inhibition can be easily overcome by 
our immune amplification. Our challenge with cGAMP is a precise and potent activation 
mechanism of STING which bypasses the viral protease degradation of cGAS, which may 
thus counteract the prior viral antagonism. As a result, STING ligands is a highly effective tool 
of viral protection. However, degradation of STING by ZIKV may still occur at the protein level, 
which could be assessed as viral load establishes further. 
 
Thirdly, our testing on STING downregulation in virus-infected MDMs showed a difference in 
donor responses to viral treatment as assessed by ISG expression. This difference may 
potentially be technical as a result of different efficiency of siSTING transfection or virus 
infection. Alternatively, evidence shows that a number of Toll-like receptors [51–53] and the 
RIG-I like receptor [54, 55] also interact and respond to Dengue virus, implying that immune 
signaling crosstalk and alternative interferon activation could give rise to this donor-variable 
interferon response. Nonetheless, this experiment has indicated that STING has a potential 
role in regulating ISG response to DENV and ZIKV, and that these two closely-related species 
are highly similar in their kinetics of immune activation. This may inform further investigations 
to compare their mechanisms of interaction with the host immunity.   
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In summary, even though our study has presented seemingly contradictory results to the 
report of DENV-mediated inhibition of STING-interferon signalling, we were pioneering in 
testing ZIKV and DENV infections in a M-CSF-cultured primary macrophage model. The 
observations showed a surprising activation of ISG response in MDMs stimulated by 
ZIKV/DENV viral nucleic acids. Following our work, two groups have published that non-
structural proteins of ZIKV target cGAS, STING, TBK1, and Jak1-STAT pathways in multiple 
cell types [20, 50, 56]. These reports imply that both Dengue and Zika viruses induce STING-
dependent interferon / ISG response, and possibly employ a conserved STING evasion 
strategy. Our research has revealed a basic similarity between ZIKV and DENV pathogenesis 
in the M-CSF –differentiated macrophages. This cell model has shown the advantage of 
displaying potent interferon-activated characteristics and thus could be expanded to study 
flavivirus infectivity and host-pathogen response in a wider donor population. The question of 
whether STING is similarly antagonized by ZIKV infection should also be address in future 
studies. 
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Material and Methods: 
Cell cultures 
Cytapheresis units from healthy adult human volunteers were obtained according to 
procedures approved by the “Etablissement Français du sang” (EFS) Committee. Peripheral 
blood mononuclear cells (PBMCs) were isolated from blood using Ficoll-PagueTM density 
centrifugation method (GE Healthcare). Human CD14+ monocytes were isolated by positive 
selection using CD14+ microbeads (Miltenyi Biotech) according to the manufacturer’s 
guideline. CD14+ monocytes were differentiated into macrophages in complete RPMI 1640 
(1% Pen-Strep, 1% L-glutamine, 10% low endotoxin fetal bovine serum) supplemented with 
100 ng/ml human recombinant macrophage-colony stimulating factor (hr M-CSF, Peprotech) 
for 6 days.  
Transfection & stimulation 
Post M-CSF incubation, MDMs were transfected with hSTING ON-TARGETplus SMARTPool 
siRNA (Dharmacon #L-024333) to suppress STING expression, or with non-targeting siRNA 
pool (Dharmacon #L-001810) as negative control. 12.5 nM siRNA were delivered to MDMs 
using Viromer green (Lipocalyx, Germany) according to the manufacturer’s protocol.  48 hours 
post transfection, cells were further treated or harvested for gene expression assessment by 
RT-qPCR. MDMs were stimulated with 2’3’-cGAMP at 4 μg/ml in MDM culture medium to 
compare to the unstimulated control. Medium for MDMs was changed before each treatment. 
Virus Preparation and Infection 
Viral stocks of DENV-2 New Guinea C (NGC) strain (AF038403) [29] were produced as 
previously described [30].  The clinical isolate of epidemic strains of ZIKV including from Brazil 
(PE243_KX197192) [31] was kindly provided Alain Kohn (MRC-University of Glasgow Centre 
for Virus Research, UK) and Rafael Freitas de Oliveira Franca (FIOCRUZ, Recife, Brazil) and 
amplified using Vero cells (ATCC) by Décembre E using the same method as DENV-NGC 
[30]. All people involved in virus infection work have vaccine protection against various 
flavivirus species and virus stocks were kept in contained and isolated freezers to avoid 
damage to laboratory staffs. 
Viruses were inactivated by UV radiation (4.75 J/cm2) for 10 mins at a distance of 10 cm. 
Inactivation of viruses was carried out by Grass V. Monolayer of MDMs were infected with 
either DENV or ZIKV (active or UV-inactivated as indicated) for 2 hours at the indicated 
multiplicity of infection (MOI) in RPMI medium before being washed with PBS. MDMs were re-
supplied with fresh culture medium and left for the indicated culture periods. For these 
experiments, mock control cells were replaced with fresh RPMI medium. By the end of 
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experiments, MDMs were washed twice with PBS and cells were harvested in guanidinium 
thiocyanate citrate (GTC) buffer for gene expression analysis as described below.  
RNA, standard and Real-Time quantitative PCR 
At the end of treatment, cells were washed with PBS and were lysed in guanidinium 
thiocyanate citrate (GTC) buffer for RNA isolation using the phenol/chloroform RNA isolation 
method [32]. 100 ng RNA was used to synthesis cDNA in 20 µl reaction volume using dNTPs 
and reverse transcriptase (life technologies). ZIKV, DENV, ISG15, MxA and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRNA levels were determined by RT-qPCR using a 
Real-Time PCR SYBR Green Master Mix (Life Technologies). mRNA levels were normalised 
to GAPDH levels. The sequences of primers used in RT-qPCR are detailed below: 
Genes Primers (Forward / Reverse) 
GAPDH 5’-AGGTGAAGGTCGGAGTCAACG-3’ 
5’-TGGAAGATGGTGATGGGATTTC-3’ 
ISG15 5’-GACAAATGCGACGAACCTCT-3’ 
5’-CGGCCCTTGTTATTCCTCA-3’ 
MxA 5’-ACAGGACCATCGGAATCTTG-3’ 
5’-CCCTTCTTCAGGTGGAACAC-3’ 
ZIKV-Brazil 5’-ATTGTTGGTGCAACACGACG-3’ 
5’-CCTAGTGGAATGGGAGGGGA-3’ 
DENV-NGC 5’-ACCTGGGAAGAGTGATGGTTATGG-3’ 
5’-ATGGTCTCTGGTATGGTGCTCTGG-3’ 
 
To calculate Genome equivalent (GE) number of mRNA expression, a stock of calibrator 
plasmid DNA at 10E9 copies per l was diluted multiple times by ten folds to 10E8, 10E7, 
10E6, 10E5, 10E4, 10E3, 10E2 and 10 copies per l concentration. These standard DNA 
samples contain specific sites for each primer pairs to bind to and they were reacted in the 
same plate as the experiment samples. Each diluted standard DNA generates a Ct value 
which can form a linear relationship to calculate the copy number of genes in samples with a 
qPCR Ct value. GE is calculated as 2 copies (6.6 pg) /l for a diploid genome. 
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Supplementary figure 1: STING knockdown impairs 2’3’-cGAMP –induced ISG 
expressions. 
A.&B. ISG15 (A) and MxA (B) inductions were assessed in control or siSTING transfected 
MDMs treated with +/- 6 h of 2’3’-cGAMP stimulation. Gene mRNA expression levels were 
assessed by RT-qPCR. Data is presented as Genome equivalent (GE) per µg of total RNA. 
All figures were plotted from n=2 donors, mean±SD. 
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Chapter 5: Discussion and future work for STING 
regulation in response to Zika and Dengue virus 
infection. 
 
Type I interferons, by name, have the primary function in interfering virus [134]. Most, 
if not all, viruses induce type I interferon response upon detection of their nucleic acid 
by the cytosolic sensors [233, 234, 281, 297–300]. These genetic materials are 
important for viruses to establish virulence in the host, and the survival and infectivity 
of a virus highly relies on its ability to minimise and block host immune reactions [301].  
 
Members of the Flaviviridae family are a major threat to human health mainly due to 
their strong infectivity through mosquitos [302] and their widely known ability to evade 
immune defence via STING [232, 234, 300] and other antiviral adaptors [97, 303]. 
Dengue virus (DENV) is one of the most well-studies species of this family. Only 
humans and a few primates are susceptible to DENV infections whereas most rodents 
and primates can resist this virus predominantly because of the variations in the 
adaptor protein STING [232, 234, 304]. A mutation that resides in the third 
transmembrane domain of human STING is uniquely targeted by DENV-released non-
structural (NS) protein/protease complex NS2B/3 [232, 305]. Particularly, the NS 
proteins are a potent weapon for flaviviruses to combat against human immune 
machineries. Flaviviruses release a variety of NS proteins to degrade multiple factors 
along the type I signalling axis, and these mechanisms of antagonism have been 
summarised in Chapter 1.5 [119]. Despite that these viruses have their specialties in 
infection, they share similarities in their interaction with the host and thus hypothesis 
can be made to research novel flavivirus species according to the knowledge of 
previous known viruses.  
 
Zika virus (ZIKV) is a recently emerged flavivirus with its discovery in the 1940s and a 
notable outbreak after 2007 [306]. ZIKV is genetically close-related to DENV despite 
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that their symptoms of infection are different [236, 307]. DENV-infected patients are 
characterised by the flu-like “Dengue fever” [308] whereas ZIKV usually causes a self-
resolving mild flu that will soon become asymptomatic [309]. However, ZIKV can 
reside in the host for more profound influence where it has been shown that the 
infection in pregnant women can transmit the virus to the foetus, which are often born 
with severe neurological defects such as microcephaly (reduced head circumference) 
and the Guillain–Barré syndrome (immune attack on the peripheral nerve system that 
causes rapid-onset of muscle weakness) [310–312]. Current research urgently seeks 
to identify host factors that respond to ZIKV establishment and in utero transmission. 
Due to the close relationship between ZIKV and DENV, a logical approach was to 
compare and contrast the infection machineries between these two flaviviruses, which 
may reveal some conserved targets for therapeutic design. 
 
ZIKV is unique in its ability to transmit from mother to child during pregnancy [ref] 
potentially due to its long dormancy in the host to allow virulence to build up in the 
placental tissues. This also reflects that the virus can reside silently in certain cells and 
tissues without being detected. Quicke and colleagues [313] have reported that the 
placental tissue macrophages are the major target and niche for ZIKV to invade the 
foetus, although these cells were not previously identified as highly susceptible to 
flavivirus infection. One potential reason could be that the other flaviviruses such as 
DENV are more reactive to circulating dendritic cells and plasmacytoid cells [314–316], 
whereas ZIKV are more likely to “hide” longer to infect tissue-resident and resting 
immune cells like macrophages. Still, these two viruses may nonetheless induce the 
same immune regulator on initial encounter of host immunity and later inhibit it. As it 
is known that STING is a major regulator and degradation target of DENV [232, 234, 
304], we thus wonder if it is the same for ZIKV, and most importantly whether such 
reaction occurs in macrophages. 
 
Since live virus infection in human macrophages were analysed at 24h and days post 
infection, the first spike of type I interferon cannot be observed, and thus we have used 
type I interferon genes MxA and ISG15 as experimental readouts. Both genes are 
potently induced by virus-induced interferon signal and ISG15 is particularly known to 
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maintain the expression and functioning period of other ISG, such as RIG-I, PKR and 
MxA [317]. In our study, both ZIKV and DENV infects human primary macrophages at 
low MOI (multiplicity of infection = 1) and the replication could be detected as early as 
24 hpi (hour post infection) (Paper 3 Fig. 1). This was in contrast to the result of Aguirre 
et al., [232] which not only showed that DENV induced little IFN-α production in their 
GM-CSF – macrophages but also the cleavage of STING protein at 48 hpi in STING-
transfected HEK 293T cells. Although our study lacks a large population size and the 
result could be only representative of a single donor, still the major difference of 
interferon activation between our experiments could be the outcome of the culture 
conditions of macrophage differentiation. The growth factor GM-CSF (granulocyte-
macrophage colony-stimulating factor) was used by Aguirre’s group [232] in contrast 
to the M-CSF (macrophage colony-stimulating factor) condition used in our 
macrophage differentiation was a possible reason for this distinct result of virus-
induced immune activation. The reason we have chosen M-CSF over GM-CSF in 
research was due to the fact that GM-CSF primes macrophages to activate both type 
I interferons and inflammasome-interleukin 1 pathways, whereas M-CSF – cultured 
macrophages predominantly release type I interferons upon viral challenges [28, 29]. 
Additionally, M-CSF tends to produce a more uniform and stable population of resting 
macrophages whereas GM-CSF (together with IL-4) is also used in differentiation of 
monocytes to dendritic cells [318, 319].  
 
The effect of macrophage differentiation protocol should be investigated in future virus 
study with a large population size. This limitation of our study subject was mainly 
because that the white blood cells were eluted from 500 ml of blood donated in a 
hospital which was acquired only once each week. Thus, the small n number was 
inevitable in this time-limited project. In contrast, MDMs used in Paper 2 were isolated 
from 80 ml of whole blood from each donor so the isolation process can accommodate 
up to 3 donors a day. Therefore, a study population must be increased to understand 
the role of STING and MDMs in DENV/ZIKV infections. 
 
In this preliminary study, we have also observed another distinction to the previous 
literature, the absence of ISG antagonism by DENV infection [232]. Again, this 
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difference is found in a single donor and it would not accurately represent the MDMs 
response in a large population. Additionally, we have tested virus infection for up to 72 
h and it is likely that a longer period may be required by the viruses to establish STING 
antagonism. Although the reduction of ISG was not immediately seen at our designed 
time points, degradation of STING, or even cGAS, might still occur at the protein level.  
 
Taken together, our M-CSF differentiated primary macrophage model presents a novel 
system in virus infection research due to its ability to show potent ISG inductions. 
Although our research was conducted in a limited population, we have observed a 
clear ISG response in macrophages infected with ZIKV and DENV, and that STING 
cleavage or ISG inhibition reported in previous research was absent in our studies. All 
these results should be repeated in more donors, and since ZIKV tend to reside in the 
host for a longer period of time, further time points could be looked into using our 
macrophage model. As viruses tend to induce type I interferons rapidly upon infection, 
a lower infection MOI (perhaps MOI=0.1) may potentially facilitate ZIKV/DENV to 
evade immune response and establish virulence better in cells. In addition to STING 
degradation, its upstream sensors (such as cGAS) and the downstream effectors 
(TBK1 and STAT) are also likely to be targeted by flaviviral proteases [304, 320, 321]. 
Even though macrophages are not as highly interferon-inducing to viruses as dendritic 
and plasmacytoid cells [322, 323], their signalling pathways are active and are perhaps 
even crucial for ZIKV to interact with to enable its survival in the host. 
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Chapter 6: Main conclusions 
6.1 Paper 2: TMEM203 regulates the innate immune Type I interferon 
response via STING.  
The novel proinflammatory mediator TMEM203 is a critical co-regulator of STING-
activated type I interferon expression in human and mouse primary macrophages and 
murine macrophage cell lines. TMEM203 overexpression promotes STING 
translocation to lysosomes which resembles its active states. TMEM203 trafficking to 
lysosome membranes is likely to potentiate and promote ligand-independent STING 
translocation and activation. TMEM203 directly interacts with the N-terminal 
transmembrane domains of STING and such association can be further strengthened 
by STING’s dimerization domain. TMEM203 selectively regulates cGAMP but not 
DMXAA -induced STING activity and these two ligands can distinctly alter TMEM203-
STING association. Future research should aim to address the potential involvement 
of calcium signalling in the regulation of STING- type I interferon response via 
TMEM203. Additionally, LPS-induced TMEM203 signalling and TMEM203 
polymorphism are areas to expand. 
 
6.2 Paper 3: STING regulates type I interferon stimulated gene 
expression upon infection of Zika virus (ZIKV) and Dengue virus 
(DENV) in human monocyte-derived macrophages. 
In our preliminary study, Zika virus and Dengue virus induce potent ISG expression in 
M-CSF differentiated human primary monocyte-derived macrophages. ISG induction 
in MDMs were viral replication dependent. Prior infection of ZIKV/DENV cannot impair 
cGAMP-induced STING activation at the tested dose and time, although STING-
downregulation was associated with ISG reduction in ZIKV/DENV infected MDMs 
isolated from one donor. 
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Appendix 1: Supplementary data for Paper 2 
A1.1 Relative mRNA expression levels of TMEM203, STING, and 
MAVS in human monocyte-derived macrophages (A-C); Linear 
correlation was discovered between STING vs TMEM203 but not 
between MAVS vs TMEM203. 
 
  
Figure A1. A strong correlation of mRNA levels was identified between TMEM203 and 
STING but not TMEM203 and MAVS in primary monocyte-derived macrophages. Basal 
mRNA expression level of TMEM203 (A), STING (B), and MAVS (C) in primary human 
monocyte-derived macrophages isolated from 9 donors (letter coded identities). Spearman 
correlation coefficient of STING mRNA expression (D) and MAVS mRNA expression (E) were 
measured against TMEM203 mRNA expression in donors (95% confidence interval: dash 
lines). Sample macrophages isolated from each donor were analysed by qPCR in duplicates. 
Data is presented as mean ± SD, n=2 technical replicates.  
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A1.2 siRNA transfection does not activate IFN-β and IL-8 mRNA 
upregulation 
 
Figure A2. Control siRNA transfection does not induce significant inflammatory 
activation in primary monocyte-derived macrophages. MDMs were left untransfected or 
transfected with scrambled siRNA sequences at 12.5 nM using Viromer green transfection 
method. 48 hours post transfection mRNA expressions of IFN-β and Cxcl8 (IL-8) were 
assessed by RT-qPCR. Data is presented as mean ± SEM with n=7 donors.   
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A1.3 Optimising siRNA-directed knockdown in human MDMs 
 
 
Figure A3. Assessment of cell viability and siRNA transfection efficiency in primary 
monocyte-derived macrophages. The lowest dose of siRNA transfection showed consistent 
siGlo signal in cells and no significantly reduction of cell numbers. Representative images 
were taken 48 hrs post-transfection of green transfection indicator siGlo in MDMs isolated 
from Donor #94, and visualised under green fluorescent microscope (magnification x20). 
Concentration of siRNA for each transfection was indicated below each graph. Scale bar 25μm.  
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A1.4 Site-directed mutagenesis for the generation of STING 
mutants 
 
 
Figure A4. Sequence confirmation of Sting mutagenesis. Site-directed mutagenesis of 
Sting truncations at (A) 141A, (B) 184L, (C) 243V, and (D) 344A were confirmed by both 
forward and reverse Sanger sequencing. Amino acid residues were replaced with a stop 
codon in the sense transcription strand to result in truncations.   
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A1.5 Optimising ER staining in HeLa cells. 
 
Figure A5. ER staining in HeLa cells. Adherent HeLa cells were stained with ER Cytopainter 
dyes (Abcam) reconstituted in staining buffer according to the manufacturer’s protocol. The 
staining reagent was further diluted by mixing the recommended dose with 1xPBS. Hoechst 
33342 was mixed with ER staining buffer at 1:1000 dilution to counterstain the nuclei, and the 
control was incubated with dye-free staining buffer diluted 1:4 with PBS. Cells were imaged 
under the Leica AFI6000 Time-Lapse microscopy at 40X magnification. Scale bar is 50 µm.  
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A1.6 Optimising lysosome staining in HeLa cells. 
 
Figure A6. Lysosome staining in HeLa cells. Adherent HeLa cells were stained with 
Lysosome Cytopainter dyes (Abcam) reconstituted in staining buffer according to the 
manufacturer’s protocol. The staining reagent is further diluted by mixing 1:3 with 1xPBS and 
this concentration was tested by Bukhari A to be the optimal dose for lysosome visualisation. 
Hoechst 33342 was mixed with lysosome staining buffer at 1:1000 dilution to counterstain the 
nuclei, and the control was incubated with dye-free staining buffer diluted 1:3 with PBS. Cells 
were imaged under the Leica AFI6000 Time-Lapse microscopy at 63X magnification. Scale 
bar is 25 µm.  
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A1.7 Optimising co-transfection of protein complementation 
fluorescence for confocal imaging. 
 
Figure A7. Protein complementation transfection in HeLa cells. Adherent HeLa cells were 
(co) transfected with plasmids designed for V1 and V2 reporter protein complementation assay 
for Tmem203 and Sting interaction. The total amount of V1_Sting and V2_Tmem203 plasmids 
transfected into 20,000 cells in 100 µl culture medium were indicated. The negative control 
was transfected with 100 ng of V2_Tmem203 plasmid only. 24 hours post transfection, HeLa 
cells were stained with Hoechst 33342 (1:1000) and were imaged under the Leica AFI6000 
Time-Lapse microscopy at 40X magnification. Scale bar is 50 µm. 
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A1.8 Summary of assay development 
The following work has helped to develop assays to complete the work presented in 
paper 2, although these did not produce displayable data. 
1. Adjusting voltage for analysing HEK293 and monocyte population by FACS. 
Testing TOPRO-3 staining concentration to indicate cell viability. 
2. Adjusting cell concentration for HeLa cells imaging using 10mm/35mm glass 
bottom culture dish. We tested cell density from 300,000 / 100 µl to 150,000 / 
100 µl and the best concentration was the highest, which gives a monolayer of 
HeLa cells for microscopy after plasmid DNA transfection.  
3. Testing concentrations for DMXAA, 3’-3’ cGAMP and 2’-3’ cGAMP stimulation 
in primary macrophages. We tested 2’-3’ cGAMP at 1 µg/ml, 2 µg/ml and 4 
µg/ml and the highest concentration gave the maximal IFNβ response. 3’-3’ 
cGAMP was used at 1 µg/ml in consistent to our colleagues in Singapore. 
DMXAA was used at 4 µg/ml and 10 µg/ml and the high concentration gave the 
optimal response. 
4. Testing transfection method for 3’-3’ cGAMP stimulation in MDMs. Digitonin-
permeabilization buffer was used to incubate MDMs with and without 3’-3’ 
cGAMP for 15 mins to 30 mins. Incubation longer than 20 mins gives excessive 
cell death.  
5. Optimising the annealing temperature (Tm) for each site-directed mutagenesis. 
Tm for each PCR reaction is determined by the predicted Tm of each primer 
pair.  
6. Optimising antibody concentration for protein detection in Western blots. 
7. Testing and optimising NonBIT live cell luciferase assay system (Promega), 
including substrate concentrations, 1.1/2.1 gene tagging orientations 
(1.1_Tmem203 + 1.2_Sting, 1.1_Tmem203 + Sting_1.2, Tmem203_1.1 + 
1.2_Sting, and Tmem203_1.1 + Sting_1.2), Hoechst 33342 staining 
concentration, and plating strategy. Katherine Pye was also involved in the 
optimisation process. 
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Appendix 2: Materials for Paper 2 
A2.1 List of Reagents 
Reagent Catalog Number Company 
Agarose 1.01236 Sigma Aldrich 
ATP (Adenosine 5’-triphosphate 
disodium salt hydrate) 
A26209 Sigma Aldrich 
Anhydrous Ampicillin A9393 Sigma Aldrich 
Anhydrous DMSO 276855 Sigma Aldrich 
Bovine Serum Albumin A7906 Sigma Aldrich 
CD14 Microbeads, human 130-050-201 Miltenyl Biotec 
CytoPainter ER staining kit – 
red fluorescence 
Ab139482 Abcam 
CytoPainter Lysosomal staining 
kit – red fluorescence 
Ab112137 Abcam 
DAPI (4’,6-Diamidino-2-
2Phenylindole, Dihydrochloride) 
D1306 Thermo Fisher 
DharmaFECT 1 Transfection 
Reagent 
T-2001-03 Dharmacon, Horizon - 
Discovery 
Digitonin Ab141501 Abcam 
DMXAA (5,6-
dimethylxanthenone-4-acetic 
acid) 
tlrl-dmx Sigma Aldrich 
DTT (DL-Dithiothreitol) 3154 Tocris 
ECL Select Western Blotting 
detection reagent 
RPN2235 GE-Healthcare 
EDTA (Ethylenediamine 
Tetraacetate acid) 
BP2482-500 Thermo Fisher 
Ethidium Bromide 46067 Sigma Aldrich 
FBS (Fetal Bovine Serum) 10500 Life Technologies 
FBS Ultralow endotoxin S1860-500 VWR 
Ficoll-Pague PLUS 17-1440-03 GE Healthcare 
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GatewayTM LR ClonaseTM II 
Enzyme mix 
11791100 Thermo Fisher 
GenEluteTM Plasmid Miniprep kit PLN350-1KIT Sigma Aldrich 
GenEluteTM HP Plasmid 
Midiprep kit 
NA0200 Sigma Aldrich 
GeneRuler 100bp plus DNA 
ladder 
SM0321 Thermo Fisher 
Glycerol G5516 Sigma Aldrich 
GTP (Guanosine 5’-
trophosphate sodium salt 
hydrate) 
G8877 Sigma Aldrich 
Hoechst 33342 Trihydrochloride 
nuclear stain 
H3570 Thermo Fisher 
iScript cDNA Synthesis kit 170-8891 Biorad 
Kanamycin sulfate 60615 Sigma Aldrich 
L-glutamine BE17-605E Lonza 
LipofectamineTM 3000 
Transfection reagent 
L3000008 Thermo Fisher 
LPS from E.coli, Serotype R515 ALX-581-007-L002 Enzo 
LS columns 130-042-401 Miltenyl Biotec 
MEM Non-essential amino acids 
solution (100X) 
1114050 Thermo Fisher 
Nano-Glo® Live Cell Assay 
System 
N2012 Promega 
NEB 5-alpha Competent E.coli 
(High Efficiency) 
C2987/ Lot 205 New England Biolabs 
NuPAGETM Antioxidant NP0005 Life Technologies 
NuPAGE MES running buffer 
(20X) 
NP0002 Life Technologies 
NuPAGE Transfer buffer (20X)  NP0006-1 Life Technologies 
NuPAGE® Novex® 4-12% Bio-
Tris Protein Gels, 1.0mm, 10 
well 
NP0321BOX Life Technologies 
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ON-TARGETplus Non-targeting 
Pool control siRNA 
D-001810-10 Dharmacon 
ON-TARGETplus SMARTpool 
TMEM173 (STING) siRNA  
L-024333-02 Dharmacon 
ON-TARGETplus SMARTpool 
Tmem173 (mouse Sting) siRNA 
L-055528-00 Dharmacon 
ON-TARGETplus SMARTpool 
TMEM203 siRNA 
L-015191-01 Dharmacon 
ON-TARGETplus SMARTpool 
Tmem203 (mouse) siRNA 
L-057116-01 Dharmacon 
Penicillin / Streptomycin 15140-122 Life Technologies 
PierceTM BCA Protein Assay kit 23227 Life Technologies 
PolyFECT Transfection reagent 301105 Qiagen 
PrecisionPLUS SYBR 
mastermix 
PrecisionPLUS-iC-SY Primerdesign 
Protease inhibitor cocktail 
(100X) 
P8340 Sigma Aldrich 
QuikChange II Site-Directed 
Mutagenesis kit 
200523 Agilent 
ReBlot Plus Strong Antibody 
Stripping Solution, 10X 
2504 Merk Millipore 
Recombinant human M-CSF 300-25 Peprotech 
ReliaPrepTM RNA Minoprep 
system 
Z6012 Promega 
RIPA Lysis buffer R0278 Sigma Aldrich 
Restriction Endonucleases NA Promega 
Restriction buffers NA Promega 
RPMI-1640 media 31870-025 Life Technologies 
siGLO Green Transfection 
indicator 
D-001630 Thermo Fisher 
Thapsigargin T9033 Sigma Aldrich 
TO-PRO®-3 Iodide T3605 Life Technologies 
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Tris Acetate-EDTA (TAE) Buffer 
50X concentrate 
SRE0033 Sigma Aldrich 
Triton X-100 T8787 Sigma Aldrich 
Trypsin-EDTA 25200056 Life Technologies 
Viromer Green Transfection 
reagent 
VG-01LB-01 Lipocalyx 
Β-mercaptoethanol M3701 Sigma Aldrich 
2’-3’ cGAMP tlrl-nacga23 Invivogen 
3’-3’ cGAMP tlrl-nacga Invivogen 
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A2.2 List of Antibodies 
Antibody Target / Clone Catalog number Company 
CD3 monoclonal antibody, 
PE 
SK7 12-0036-42 eBioscienceTM 
CD14 anti-human Alexa 
Fluor®700  
61D3 56-0149 Affymetrix 
eBioscience 
CD14 anti-human FITC  M5E2 301803 BioLegend 
CD19 monoclonal 
antibody, PE-Cyanine7 
HIB19 25-0199-41 eBioscienceTM 
CD62L (L-Selectin) anti-
human APC  
DREG56 17-0629 Affymetrix 
eBioscience 
CD68 monoclonal antibody 
unconjugated  
PG-M1 MA5-12407 eBioscienceTM 
TMEM173 anti-human 
rabbit monoclonal 
unconjugated  
TMEM173 aa 
250 to the C-
terminus 
Ab181125/ 
EPR13130 
Abcam 
GFP/YFP mouse 
monoclonal antibody 
unconjugated 
Whole protein CSB-MA000283 Cusabio 
PDHX (E3BP) mouse 
monoclonal antibody 
unconjugated 
H-6 Sc-377255 Santa Cruz 
Polyclonal goat anti-mouse 
IgG-HRP 
NA P0447 Dako 
Polyclonal goat anti-rabbit 
IgG-HRP 
NA P0448 Dako 
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A2.3 List of plasmid DNA 
The list below describes plasmid DNA used by the primary author (myself). Additional 
plasmid DNA used in paper 2 can be found in the new manuscript in PNAS, 2019. 
Site-directed mutagenesis were carried out by myself using gene-carrying entry 
vectors as input backbones. After mutation, genes were gateway cloned into 
pcDNA3.1-DEST vectors or NonBIT Renilla vectors containing either N or C terminal 
tags. 
Vector Source 
pcDNA3.1 
gateway 
destination vector 
Empty vector acquired from Invitrogen. Split Venus tag and YFP 
tag insertions at the N or C terminal of attR cloning sites were 
produced by E. Kiss-Toth. The WT Tmem203 and Sting were 
inserted into V1, V2, YFP tagged pcDNA3.1 vector by E. Kiss-
Toth. Gateway cloning of mutant Sting insertions into these 
vectors were made by myself. 
pENTR/D 
entry vector 
Empty vector acquired from Invitrogen. The WT Tmem203 and 
Sting insertions were produced by D. Wyllie. pE-Sting mutants 
were made by myself. 
1.1/2.1 BIT Empty vector acquired from Promega, NonBIT PPI system, by E. 
Kiss-Toth. The WT or mutant Tmem203 and Sting insertion 
between the attR sites were produced by myself and with help 
from Vera Kiss-Toth. 
pEGFP-N2 Plasmid DNA acquired by E. Kiss-Toth. 
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Appendix 3: Methodology for Chapter 2 
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A3.1 Bioinformatics 
Nucleotide sequences for TMEM203 (human), TMEM173 (human STING), Tmem203 
(mouse), Tmem173 (mouse STING) and Tbk1 (mouse TANK-binding kinase, mTBK1) 
were obtained from GeneBank, NCBI (National Center for Biotechnology Information).  
Gene and protein accession numbers were obtained from Ensembl and Uniprot, 
respectively. DNASTAR® Lasergene 14 SeqBuilder was used to create gene maps, 
predict amino acid sequences, identifying endonuclease restriction sites and design 
primers for single amino acid mutations. The program SeqMan Pro 14 was used to 
align nucleotide sequences to verify mutations of plasmids. Uniprot was used to 
identify the predicted molecular weight of proteins. Genes are listed below in Table 1. 
 
Table 1. List of genes. 
Gene Species Gene ID mRNA ID Protein ID 
TMEM203 Human ENSG00000187713 NP_444273.1 Q969S6 
TMEM173 / 
STING 
(Canonical) 
Human ENSG00000184584 NP_938023.1 Q86WV6 
Tmem203 Mouse ENSMUSG00000078201 NP_796318.2 Q8R235 
Tmem173 / 
Sting 
(Canonical) 
Mouse ENSMUSG00000024349 NP_082537.1 Q3TBT3 
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A3.2 Established cell line cultures 
RAW 264.7 mouse macrophage cell line is maintained in Dulbecco’s Modified Eagle 
medium (DMEM) supplied with 1% Penicillin-Streptomycin (100 U/ml, P-S), 1% L-
Glutamine ( 0.05 mM, L-G), 10% low endotoxin heat-inactivated fetal bovine serum 
(LE-HI-FBS); HeLa human cervical cancer cell line is maintained in DMEM supplied 
with 1% P-S, 1% L-G and 10% HI-FBS; HEK293 T human embryonic kidney cell line 
is maintained in DMEM supplied with 1% PS, 1% nonessential amino acids (NEAA) 
and 10% HI-FBS; immortalised bone marrow derived macrophage (iBMDM) cell line 
is maintained in DMEM supplied with 1% PS, 1% L-G and 10% LE-HI-FBS. All cells 
lines were purchased from ATCC except for the iBMDM cell line (C57BL/6 background) 
which was generated as described in [324] and kindly given by David Brough’s lab 
(University of Manchester). All cell lines were maintained in a 37℃ incubator with 5% 
CO2. Cells were plated at densities listed below (Table 2) on the day before 
transfection or treatment to allow attachment. 
 
Table 2. Cell plating format. 
Cell line Cell density Volume of medium (ml) Plate format 
RAW 264.7 
HeLa 
HEK293 T 
500,000 2 6 
250,000 1 12 
125,000 0.5 24 
25,000 0.1 96 
iBMDM 200,000 2 6 
100,000 1 12 
50,000 0.5 24 
10,000 0.1 96 
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A3.3 Human primary cell isolation and culture 
 
A 3.3.1 Isolation of PBMC 
Healthy and unrelated adult donors (aged 20 to 50 years old) were recruited to provide 
blood for isolation of peripheral blood mononuclear cells (PBMCs). All blood donors 
were given written and informed consent under regulation stated in the ethical 
approval SMBRER310 and in accordance to the Declaration of Helsinki.  
 
PBMC and CD14+ monocyte isolation protocol follows method stated by Hadadi E 
(PhD Thesis submitted in 2015, University of Sheffield). In essence, blood was 
collected in 50ml tubes with sterile sodium citrate in a ratio of 9:1 to prevent clotting, 
and was then carefully transferred into 50 ml tube in 2:1 ratio to and on top of Ficoll-
PagueTM Plus (GE Healthcare, Life Sciences). Overlaid blood-Ficoll gradient was 
centrifuged for 20 min at 900 x g with low acceleration and deceleration rates to 
separate PBMC layer by buoyancy. The PBMC layer which appears just below the top 
plasma layer was collected into a clean 50 ml tube and washed with 50 ml cold 1x 
phosphate-buffered saline (PBS)-ethylenediaminetetraacetic acid (EDTA, 2 mM) 
(PBS-EDTA; PBSE). The cells were centrifuged (5 mins 1500 rpm) and the pellet was 
resuspended and incubated for 5 mins at room temperature in 10 ml 1x red blood cell 
(RBC) lysis buffer (155 mM NH4Cl, 10 mM KHCO3 and 0.1 mM EDTA) to lyse the 
erythrocytes by hypotonic pressure. After incubation, cells were washed in 50 ml 1x 
PBSE and centrifuged for 5 mins at 1500 rpm. The supernatants containing RBC 
debris was removed and the cells were resuspended in 30 ml 1 x PBSE. Cell number 
was counted using a haemocytometer (C-Chip, Digital Bio) and the cells were then 
centrifuged for 5 mins at 1500 rpm to acquire the PBMC pellet for further purification 
steps. 
 
A3.3.2 Isolation of CD14 positive (+) monocytes 
CD14 proteins are abundantly expressed on the cellular surface and are vital for the 
activation of innate immune responses in mammalian myeloid cells typically 
monocytes. Thus, they are often used as selection markers for monocyte purification. 
To isolate monocytes from PBMCs, positive selection was used to tag CD14-
expressing monocytes with magnetic microbeads (Miltenyi Biotec). To do so, every 10 
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million pelleted PBMCs were resuspended in 90 μl magnetic cell sorting (MACS) buffer 
(1 x PBS, 2% (w/v) low endotoxin bovine serum albumin (BSA), 2 mM EDTA) 
supplemented with 10 μl CD14 microbeads (Miltenyi Biotech), and incubated for 15 
mins at 4 °C to allow microbeads binding to CD14+ cells. The PBMCs were washed 
in 2 ml additional MACS buffer, centrifuged (5 mins at 1200 rpm), and resuspended in 
500 μl MACS buffer to be added to pre-washed (3ml MACS buffer) LS column (Miltenyi 
Biotec). For magnetic selection, the column was washed with 3 x 3 ml MACS buffer to 
remove non-magnetic bound cells, and the microbeads-bound cells were immediately 
flushed down the column with 5 ml cold MACS buffer into a clean collection tube. Cell 
number was counted again using a haemocytometer and spun down (5 mins 1500 
rpm) to acquire a cell pellet for further experimental purposes. 
 
A3.3.3 Determine monocyte purity and viability by FACS 
To assess the purity of CD14+ monocytes after isolating all CD14+ cells, samples 
were prepared in MACS buffer. A sample of 750,000 cells was taken for analysis by 
fluorescence-activated cell sorting (FACS) using a LSR II flow cytometer (BD 
Bioscience), and data was analysed by FlowJo_V10 software. Both pre-purified PBMC 
samples and post-purified CD14+ selected cells were prepared as described in Table 
3. Pre-purification PBMCs were singly stained with anti-human CD3-PE (, clone SK7), 
anti-human CD19-PECyanine7 (eBioscience, clone HIB19), or anti-human CD14-
Alexa Fluor®700 (eBioscience, clone 61D3), For each sample, 10,000 cell events 
were recorded on an arbitrary gate created on a bivariate scatterplot of forward (FSC) 
vs. side (SSC) to separate cells by sizes and granularities, respectively. The forward 
and side scattered lights were both adjusted to 275 volts to allow best display of 
subpopulations of CD14+ cells. Gates were drawn around the subpopulations close to 
the population boundaries and monocyte population was identified according to gating 
strategies suggested by Hadadi E (PhD Thesis submitted in 2015, University of 
Sheffield). An average of over 90% monocytes were identified in total CD14+ 
population with minor proportions of cell debris, lymphocytes, granulocytes and 
CD14+ monocyte doublets (Fig. 13). Monocyte responsiveness to immune challenge 
was tested by phorbol 12-myristate 13-acetate (PMA) treatment which indicates the 
ability to become active and induce shedding of L-selection (Fig. 14) [325]. 
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Table 3. PBMC and monocyte staining. 
Samples Staining Antibodies Clone Fluorophore 
Figure 13/ Monocyte purity assay 
Total population Unstained N/A N/A 
Dead cells Hoechst 33342 N/A Hoechst 33342 
T lymphocytes Anti-CD3 SK7 PE 
B lymphocytes Anti-CD19 HIB19 PE- Cyanine7 
Canonical 
monocytes 
Anti-CD14 61D3 Alexa Fluro® 700 
Figure 14/ Monocyte activation assay 
Total population Unstained N/A N/A 
Dead cells Hoechst 33342 N/A Hoechst 33342 
Canonical 
monocytes 
Anti-CD14 M5E2 FITC 
L-selectin Anti-CD62L 
(L-selectin) 
DREG56 APC 
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Figure A8. Monocyte identification in peripheral blood mononuclear cells (PBMCs). 
PBMCs pre (A) and post (B) CD14 positive column selection were analysed by flow cytometry 
to indicate monocyte purity. PBMCs were left unstained or stained with Hoechst 33342 
(UV_450nm activated) to indicate cell death. Hoechst negative (viable) cells were stained with 
fluorescence-conjugated antibodies against CD14, CD19 and CD3 to identify populations of 
monocytes, B lymphocytes and T lymphocytes, respectively. Green colour indicates the 
monocyte population in the forward (FSC) and side (SSC) scatter plot. (C) Frequency of 
subpopulation of cells were calculated and a reduced ratio of T and B lymphocyte in PBMCs 
has resulted in over 90% of monocyte purity post CD14 selection. Experiments conducted in 
monocytes isolated from two donors and the result is representative from a healthy Donor. 
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Figure A9. PMA-activated human primary monocytes.   
Post CD14 selection, viable monocytes (Hoechst negative) were tested by CD62L (L-selectin) 
shedding to indicate the ability of activation. (A) Fluorescence minus one (FMO) control: 
Fluorescence-conjugated CD14 antibodies (Yellow) identifies the total monocyte population 
(Red) which is CD62L negative (unstained). (B) Total monocyte population (Red) was stained 
with anti-CD62L (Dark Blue) before PMA treatment; PMA stimulation was able to induce 
CD62L shedding/reduction in monocytes (Dark Blue to Light Blue), suggesting monocyte 
activation post CD14 column selection. Experiment conducted in collaboration with Kajus 
Baidzajevas using monocytes isolated from two donors and the result is representative from 
a healthy Donor.  
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A3.3.4 Monocyte maintenance and macrophage differentiation 
Primary CD14+ monocytes were temporarily cultured in complete RPMI-1640 medium 
supplemented with 10% (v/v) LE-HI-FBS (Biowest), 1% PS (Gibco) and 1% L-
glutamine before differentiation. Primary monocytes were seeded in 12 well plates at 
250,000 ± 5% cells (1.5 ml) per well density to be differentiated into monocyte-derived 
macrophages (MDMs). Monocytes were differentiated into human monocyte-derived 
macrophages (MDMs) with RPMI-1640 monocyte medium supplied with 100 ng/ml 
human recombinant macrophage-colony stimulating factor (hrM-CSF; PeproTech) for 
7 days (medium was not changed during incubation). Fresh medium was supplied 
before further cell treatment. 
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A3.4 Mouse primary cell isolation and culture 
WT and Tmem203 knockout (-/-) C57BL/6 mice were generated by Harwell Institute 
(Oxford) by CrispR-Cas9 method, and the hind limbs were given to our lab. Genome 
of Tmem203 was confirmed by Sanger sequencing indicated by MRC Harwell 
(indicated in Paper 2, Fig. S2F). Femur and Tibia of mouse hind limbs were cleared 
out from muscles and were truncated at both end so that bone marrow can be eluted 
and collected using RPMI (10% LE-HI-FBS and 1% P-S) without Phenol Red for 
visualising in the tube. Bone marrow was centrifuged and replaced with fresh complete 
DMEM medium (10% LE-HI-FBS, 1% P-S and 10% L929 conditioned medium) to grow 
for 5 days in T75 flasks in a humid 37 ℃ incubator containing 5% CO2. Bone marrow-
derived macrophages were re-seeded in cell culture plates containing fresh medium 
before further treatments. BMDMs were seeded at a density of 100,000 cells in 1 ml 
medium in 12 well plates. Experiments were conducted in duplicate or triplicate wells. 
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A3.5 STING stimulation 
 
A3.5.1 2’-3’ cGAMP 
The endogenous STING ligand 2’-3’ cGAMP was reconstituted in 1xPBS to a 
concentration of 1µg/µl. Stimulation was performed by mixing the indicated 
concentrations of ligand with fresh cell culture medium and incubate for indicated 
periods. Unstimulated control was replaced with fresh medium without 2’-3’ cGAMP.  
 
A3.5.2 3’-3’ cGAMP 
the bacterial STING ligand 3’-3’ cGAMP was reconstituted in 1xPBS to a concentration 
of 1µg/µl. Bacterial cyclic dinucleotides carry two negatively-charged phosphate 
groups that reduce their ability to penetrate the plasma membrane [326], and thus 3’-
3’ cGAMP was aided with the previously suggested Digitonin-permeabilisation method 
[120, 286, 289, 327]. Stimulation procedure was performed according to Woodward 
JJ. et al [328]. Post differentiation, macrophages were washed twice with ice-cold PBS 
and pre-incubated with 10 x Digitonin permeabilisation buffer (50 mM HEPES pH 7.0, 
100 mM KCl, 3 mM MgCl2, 0.1 mM DTT, 85 mM sucrose, 0.2% BSA, 1 mM ATP, 0.1 
mM GTP, with or without 10 μg/ml digitonin) with or without 1 μg/ml 3’-3’ cGAMP for 
15-20 mins. Digitonin buffer was thoroughly washed twice with PBS and cells were 
then supplemented with fresh complete medium and incubated for indicated period of 
time since initial addition of ligand. Incubation of cells was always at 37°C with 5% 
CO2. 
 
A3.5.3 DMXAA 
The synthetic STING ligand DMXAA was reconstituted by mixing 10 mg DMXAA in 1 
ml solvent 100% dimethyl sulfoxide (DMSO). Stimulation was performed by mixing 
DMXAA/DMSO in complete cell culture medium and apply to cells. Unstimulated 
control was replaced with fresh medium containing only DMSO at the same dose as 
DMXAA stimulation complex.  
 
  
293 
 
A3.6 Transfection and stimulation 
Each cell type transfection was performed by a specific protocol which has been 
optimised by our precious laboratory members or myself.  
 
A3.6.1 siRNA Transfection into MDMs and iBMDMs  
As STING is an anti-viral adaptor protein, all the virus-derived transfection methods 
can likely induce STING-dependent antiviral response prior to our investigations, we 
therefore choose non-microbial derived delivery method that is potent nucleic acid 
vehicle and is less likely to induce type I interferon response. Delivery of small-
interfering RNA (siRNA) into MDMs uses the transfection reagent Viromer Green 
(Lipocalyx) according to the manufacturer’s guidelines. For optimisation of siRNA 
transfection, siGlo green transfection indicator (Dharmacon, #D-001620-01) was used 
at the indicated concentrations (Chapter 2 Fig. 4 & Appendix 1.3, page 270). ON-
TARGETplus smartpool control non-targeting siRNA and siRNA against human and 
mouse TMEM203 / Tmem203 and STING (TMEM173 / Tmem203) were purchased 
from Dharmacon. siRNA was diluted to 20µM before being used to transfect cells. For 
optimised siRNA transfection in MDMs and iBMDMs the concentration was 12.5 nM. 
For this, 1.4 µl siRNA (20 µM) was mixed with 8.6 µl and added to Viomer green 
mixture (Buffer green 90 µl added to Viromer green 1 µl) and incubated for 15 mins at 
room temperature. The transfection complex was applied to 1 well of 2 ml cell culture 
in 6 well format and the transfected cells are maintained at 37°C in humid 5% CO2 
incubator for 48 hrs before being used in further experiments. 
 
A3.6.2 RAW 264.7 cells 
RAW 264.7 macrophages were transfected with plasmids or siRNA using 
DharmaFECT reagent according to the manufacturer’s guidelines. 0.4 µl of 
DharmaFECT was required to deliver 100 ng plasmid DNA into 25,000 cells in 100 µl 
transfection volume in a 96 well plate format.  The same protocol delivers 20 µM siRNA 
into RAW 264.7 cells. 
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A3.6.3 HEK293 cells 
HEK 293 cells were transfected with plasmids using PolyFECT reagent according to 
the manufacturer’s guidelines. 1 µl of PolyFECT was required per 100 ng plasmids for 
transfection into 25,000 cells in 100 µl transfection volume in a 96 well plate format.   
 
A3.6.4 HeLa cells 
HeLa cells were seeded in the centre of glass-bottom imaging dish (35 mm diameter, 
glass area 10 mm diameter) at 300,000 cells in 100 µl DMEM medium (10% LE-HI-
FBS and 1% P-S) and incubated for 1 h to allow adherence. After this, cells were 
further supplied with 1.5 ml complete medium and leave overnight before transfection. 
A total of 1.5 µg of plasmid DNA was resuspended in 490 µl of serum-free medium 
and incubated with 10 µl P3000 and 3 µl 3000 Reagent, provided in 
Lipofectamine3000 transfection kit, for 30 mins at room temperature. The mixture was 
supplied with 1 ml complete medium to transfect HeLa cells for 24 hrs before further 
studies.  
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A3.7 Gene expression analysis 
 
A3.7.1 RNA isolation 
Total RNA isolation from cells was preformed using ReliaPrepTM RNA Cell miniprep 
system (Promega). Post treatment, cell medium was aspirated and cells were washed 
twice with PBS before being lysed with BL-TG buffer and isolated according to the 
manufacturer’s protocols. RNA concentrations were determined using NanoDropTM 
1000 microvolume Spectrometer (Thermo Fisher).  
 
A3.7.2 Complementary (c)DNA synthesis 
Complementary DNA was produced from total RNA using iScriptTM cDNA synthesis 
kit (Biorad).  500 ng total RNA was mixed with 1 µl Reverse Transcriptase and 4 µl 
reaction master mix in a total volume of 25 µl. The mixture was reacted on a Bioer 
LifeECOTM PCR Thermal Cycler at 25℃ for 5 mins, 46℃ for 20 mins, 95℃ for 1 min 
and maintained at 4℃ until it is used for further treatment. 
 
A3.7.3 Quantitative Real-Time Polymerase Chain Reaction (qPCR) 
Quantitative PCR was performed in triplicate wells and quantified in CFX384 TouchTM real-
time PCR iCycler (Biorad). Reaction mixture contains 4.4 μl cDNA (0.5 ng/ml), 5 μl 
mastermix, 0.3 μl forward primer (10 µM) and 0.3 μl reverse primer (10 µM).  Mixture was 
reacted with hot start (95℃ 2 mins) followed by 40 cycles of amplification (95℃ 10 secs + 
60℃ 60 secs), and a final melt curve was determined by an additional amplification 
process. The primer sequences used for mRNA level quantification were shown in Table 
4. Primers are designed with Blast primer design tool (NCBI) and all sequences were 
generated by Sigma-Aldrich unless otherwise specifies.  
 
For analysis of relative gene expressions, Ct values of interest genes were normalised to 
the Ct values (expression levels) of β-actin and were calculated using the 2(-Ct) method. 
Gene expressions were compared to the indicated control group designed for each 
experiment. Analysis of gene expression by genome equivalent method is described in 
Chapter 4, Material and Methods, RNA, standard and Real-Time quantitative PCR.  
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Table 4. List of primers used in qPCR reaction. 
Human Gene  Primer sequences 
β-ACTIN Forward 5’ - GGATGACAGAAGGAGATCACT G – 3’ 
Reverse 5’ - CGATCCACACGGAGTACTTG – 3’ 
Cxcl8 (IL-8 
gene) 
Forward 5’ - TGCCAAGGAGTGCTAAAG – 3’ 
Reverse 5’ - CTCCACAACCCTCTGCAC – 3’ 
IFN- β Forward 5’ - AAGCAGCAATTTTCAGTGTCAGA – 3’  
Reverse 5’ - CCTCAGGGATGTCAAAGTTCA – 3’ 
TMEM203 Forward 5’ - GTCTTCGAGATGCTGTTGTGC – 3’ 
Reverse 5’ - ACGTAATGAGGCCGAACCAG – 3’ 
STING Forward 5’ - TCTCGCAGGCACTGAACATC – 3’ 
Reverse 5’ - GGGCCACGTTGAAATTCCCT – 3’ 
MAVS Forward 5’ - TGCCTCACAGCAAGAGACCA – 3’ 
Reverse 5’ - CCGCTGAAGGGTATTGAAGAGA – 3’ 
 
Mouse Gene Primer Sequences 
β-actin Forward 5’ - GGGACCTGACAGACTACCTCATG - 3’ 
Reverse 5’ – GTCACGCACGATTTCCCTCTCAGC – 3’ 
Tmem203 Forward 5’ – CCCTGTTGGTGTTCTCCGTA - 3’ 
Reverse 5’ – GCACAAAGACGTTCCACCAG - 3’ 
Sting Forward 5’ – GCTGGCATCAAGAATCGGGT - 3’ 
Reverse 5’ – TACTCCAGGATACAGACGCC - 3’ 
Ifnb1 Forward 5’ – TGTCCTCAACTGCTCTCCAC - 3’ 
Reverse 5’ – CATCCAGGCGTAGCTGTTGT - 3’ 
Cxcl2 Forward 5’ – ATCCAGAGCTTGAGTGTGACG - 3’ 
Reverse 5’ – TTTGACCGCCCTTGAGAGTG - 3’ 
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A3.8 Western blot 
 
A3.8.1 BCA protein concentration assay 
To prepare protein samples, cells were washed with 1x PBS and lysed with RIPA 
buffer (Sigma Aldrich) containing 10% protease inhibitor. Every 250,000 cells were 
then lysed by 200µl RIPA-protease inhibitor mixture on ice for >30 mins with multiple 
vigorous vortexing, and 15 min sonication. Samples were centrifuged for 10 mins 
(14,000 rpm at 4℃) to remove membrane debris and supernatants were collected for 
protein assay. Pierce BCA protein assay (Thermofisher) was performed to determine 
protein concentration in the lysate according to the manufacturer’s guideline. Lysates 
were diluted to a concentration of 5 µg per 10 µl with 1x Laemmli buffer (4% SDS, 10% 
2-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 0.125 M Tris-HCl, pH 
6.8).  
 
A3.8.2 SDS-PAGE 
Total protein separation was performed by SDS-PAGE (Sodium Dodecyl Sulfate 
PolyAcrilamide Gel Electrophoresis). 5 µg (in 10 µl) of each protein sample or 5 ul of 
protein ladder was loaded into each well of the pre-cast NuPAGE 4%-12% Bis-Tris 
Protein Gels, 1.0 mm, 12-well (Thermo Fisher). Empty wells were filled with 10 µl of 
1x Laemmli buffer. The gel was transferred to the electrophoresis tank filled with 1x 
NuPAGE MES SDS Running Buffer to run for 1.5 - 2 h at 150-200 V. 
 
A3.8.3 Western blot 
Following electrophoresis, proteins were transferred to methanol-activated positively 
charged PVDF nylon membrane followed by antibody detextion. Protein-blot transfer 
sandwich (negative electrode – 2 sponges / 2 filer papers / Gel / PVDF membrane / 2 
filter papers / 5 sponges – positive electrode) was placed in the Western blot tank filled 
with 1x NuPAGE Transfer Buffer supplemented with 10% (v/v) methanol and 1 ml 
NuPAGE antioxidant. Proteins were transfer for 1 h at 40 V.  
 
To blot for specific proteins, membranes were rinsed with 1X Tris buffered saline (TBS) 
– 0.1% (v/v) Tween-20 (TBST) and then blocked with 10% (w/v) skimmed milk in TBST 
for 1 h at room temperature. Post blocking, membrane was rinsed 4 times with TBST 
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for 5 mins and then incubated with primary antibodies diluted in 5% milk-TBST on 4°C 
overnight. Primary antibodies were rinse off the next day with 5 mins – 4 times TBST, 
and the HRP conjugated secondary antibodies were applied in 5% milk-TBST to 
incubate the membrane at room temperature for 1 h. At the end, secondary antibodies 
were rinsed by 5 mins - 4 times with TBST. Antibody concentrations were listed in 
Table 5. 
 
To detect proteins, the membrane was incubated for 2 mins with chemiluminescence 
followed by visualisation under a C-DiGit ® Western Blot Scanner (LI-COR). Signal of 
secondary antibodies can be strapped off by incubation in 1x ReBlot Plus Strong 
antibody stripping solution (Merk Millipore) for 10 mins at room temperature. The 
membrane can be re-blocked and blotted with another primary and secondary 
antibody to detect different proteins. Protein bands were quantified using Image Studio 
Digit Version 5. Data were normalised to the loading control. 
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Table 5. Antibody concentrations used in Western blotting. 
Antibody Concentration 
GFP/YFP mouse monoclonal antibody 
unconjugated 
1:4000 
PDHX (E3BP) mouse monoclonal 
antibody unconjugated 
1:8000 
Polyclonal goat anti-mouse IgG-HRP 
For YFP detection 
1:2000 
Polyclonal goat anti-mouse IgG-HRP 
For PDHX detection 
1:4000 
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A3.9 Molecular cloning 
 
A3.9.1 Site-directed mutagenesis 
Single-amino acid mutation was performed using QuikChange II Site-Directed 
Mutagenesis kit (Agilent) following the manufacturer’s protocol. The Wildtype gene 
has already been cloned into pENTR/D-TOPO® vector (Thermo Fisher) between the 
attL1/attL2 region. The entry clone also contains Kanamycin resistance gene for 
bacterial selection. In brief, each mutagenesis was reacted with 100 ng entry plasmid 
vector, 125 ng of each oligonucleotide primer, and the rest of the reagents provided 
by the kit. Forward and reverse primers were designed for each mutation with the tri-
nucleotide substitution in the middle to change single amino acid, and 15-nucleotide 
long sequence at each side of mutation (total 33 bp in length). Primers were generated 
by Sigma Aldrich and were used at the recommended concentration as according to 
the Mutagenesis kit protocol. Primer sequences for Sting truncation mutants were 
stated in Chapter 2 Materials and Methods: Site-directed Mutagenesis and molecular 
cloning. Polymerase chain reaction (PCR) cycling condition is detailed in Table 6 
(modified from the manufacturer’s protocol). The resulting plasmid products were 
transformed into XL10-Gold ultra-competent cells following the manufacturer’s 
instructions (Agilent). Mutations of Sting was confirmed by Sanger sequencing as 
shown in Appendix 1.4 (page 271). 
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Table 6. Agilent site-directed mutagenesis guideline protocol for polymerase chain 
reaction. 
 
Segment Cycles Temperature Time 
1 1 95℃ 2 mins 
2 25-30 95℃ 20 sec 
60℃ 10 sec 
68℃ 1 min/ kb of plasmid length* 
3 1 68℃ 5 mins 
 
*For example, a 5 kb plasmid requires 5 mins per cycle at 68℃. The temperature of 
this step can be optimised to help the amplification of desired plasmids. 
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A3.9.2 Ligase recombination  
Mutated genes inside the Gateway Entry clones were further cloned into a Gateway 
Destination vector [329] containing split Venus tag, or Yellow Fluorescence Protein 
(YFP) tag [330], or split Renilla BIT tags (modified from the commercially available BIT 
system, Promega) which are later used for expression in mammalian cells. Ligase 
recombination of gene cloning into Gateway Destination vectors uses GatewayTM LR 
ClonaseTM II Enzyme Mix (Invitrogen). Reaction was performed according to the 
manufacturer’s protocol. In brief, 10 ng (1 µl) of entry clone plasmid carrying the 
designed gene was mixed with 100 ng (1 µl) Gateway Destination vector and 0.5 µl of 
LR Clonase II to incubate for 1 h at 25 °C. Reaction was terminated by mixing with 1 
µl proteinase K and incubating for 10 mins at 37 °C. Destination vectors were 
transformed into one vial of 45 µl of NEB 5-alpha Competent E. coli (High Efficiency) 
(New England Biolabs) according to the manufacturer’s (New England Biolabs) 
protocol.  
 
A3.9.3 Bacteria transformation and plasmid preparation 
To transform Gateway Entry Clones into XL10-Gold ultracompetent cells, a vial of 45 
µl E.coli was taken out of -80°C freezer and immediately and gently thawed on ice. 
Cells were treated with 2 µl of β-mercaptoethanol (provided with the kit) for 10 mins, 
and were further added 2 µl of Dpn I-treated plasmid products (enzyme provided with 
the kit, 1µl Dpn I was used to digest 1 tube of PCR reaction for 15 mins at 37 °C). 
Mixture was gently swirled and incubated on ice for 30 mins followed by an exact 30 
sec heat-shock at 42°C before being recovered on ice for 2 mins. Mixture was then 
transferred to a 15 ml Falcon tube containing 0.5 ml of warm SOC growth medium 
(Super Optimal Broth, Invitrogen) and incubated at 37 °C for 1 hour with shaking at 
240 rpm. By the end, 100 µl of bacterial culture was plated onto a warm LB-Kanamycin 
(50 µg/ml) agar plate and incubated upside down (to avoid drying the agar by water 
evapouration) at 37 °C for a further 16-20 hours before colonies were selected for 
further use.  
 
To transform Gateway Destination clones into NEB 5-alpha Competent E.coli (High 
Efficiency), plasmids were mixed and incubated with one unit (45 µl) of bacteria pre-
thawed on ice. This is followed by exactly 30 sec of heat-shock at 42 °C and 2-5 mins 
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recovery on ice. Cells were then supplemented with 1 ml warm SOC growth medium 
and cultured at 30℃ for 90 mins. 150 µl of bacteria were evenly spread on a warm LB-
Ampicillin agar plate (100 µg/ml) and incubated upside down at 30 °C for 16 – 20 hours 
before bacteria colonies were selected for further use. 
 
Post transformation, six colonies per mutation were selected for amplification in 3 ml 
SOB broth (Super Optimal broth, 32 g Tryptone + 20 g Yeast extract+ 5 g NaCl heat-
dissolved in 1 L ddH2O) containing the appropriate antibiotics) at 30 °C for 18-24 hours 
to obtain enough cells for plasmid isolation (Sigma Aldrich).  
 
A3.9.4 Plasmid sequence verification 
To ascertain the correct plasmids were amplified, plasmid DNA was digested with 
restriction endonucleases (Promega) in the suggested digestion buffer for 1 to 1.5 
hours at 37 °C. Briefly, 5 µl of plasmids (over 500 ng) were used in each digestion with 
1 or multiple enzymes at a total volume of 10 µl or 15 µl according to the 
manufacturer’s suggestions. Plasmid digestion was checked by DNA gel 
electrophoresis. Plasmid samples were diluted 1:5 with sample loading dye (0.25% 
bromophenol blue, 30% glycerol in ddH2O) and loaded into the wells of a 10% agarose 
gel (1:50 ddH2O diluted 50x TAE (Tris Acetate-EDTA) with 10% w/v agarose powder, 
both Sigma Aldrich) containing 0.5 µg/ml ethidium bromide, with 1x TAE as the running 
buffer. The GeneRuler 100bp plus DNA ladder was used to indicate the size of the 
digested DNA products. DNA was separated at 80-90 V for 40 to 50 mins and the gel 
was visualised and captured under the UV lamp in InGenius3 gel imaging and analysis 
system (SYNGENE). Once DNA fragments were confirmed at the expected lengths, 
plasmid samples were sent for sequence confirmation at Sanger sequencing labs of 
Source Bioscience (Nottingham). Reaction primers were provided by the sequencing 
lab according to the construct. Specific primers designed for plasmids constructed for 
split-Renilla protein complementary assay were purchased from Sigma Aldrich.  
 
Primer used for sequencing genes in the Entry Clones were (5’-3’): 
Forward: M13F, TGT AAA ACG ACG GCC AGT 
Reverse: M13R, CAG GAA ACA GCT ATG ACC 
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Primers used for sequencing genes in the V1 and YFP fusion Destination Clones were 
(5’-3’): 
Forward: CMVF_pCDNA3, CAA CGG GAC TTT CCA AAA TG 
Reverse: BGH Reverse, TAG AAG GCA CAG TCG AGG 
 
Primers used for sequencing genes in the BIT fusion Destination clones were (5’-3’): 
Forward: CCC TGT TGG TGT TCT CCG TA 
Reverse: GCA CAA AGA CGT TCC ACC AG 
 
One correct Entry Clone per mutation was selected for further cloning process and 
one correct Destination Clone per mutation was selected for transformation and 
amplification. 
 
A3.9.5 Bacteria amplification and stock 
To maintain bacteria culture for further use, 0.5 ml of overnight bacteria culture is 
thoroughly mixed with 40% glycerol and kept at -80 °C for later use. 
 
To amplify plasmids, bacteria colonies or glycerol stock (20% glycerol in growth 
medium) were added to 3-5 ml SB buffer for small quantity plasmids preparation or to 
50 ml LB buffer (10 g Tryptone + 5 g Yeast extract + 5 g NaCl heat-dissolve in 1 L 
ddH2O) for medium quantity plasmid preparation. All bacteria cultures were supplied 
with 50 µg / ml Kanamycin or 100 µg / ml Ampicillin according to the plasmid antibiotics 
selection condition and cells were incubated at 30℃ for 18 – 24 h.  
 
A3.9.6 Plasmid isolation 
Small quantity plasmid purification was carried out using GenEluteTM plasmid Miniprep 
kit and medium quantity plasmid purification was carried out using GenEluteTM HP 
Plasmid Midiprep kit, both from Sigma Aldrich. Plasmid concentration was determined 
using NanoDropTM 1000 microvolume Spectrometer (Thermo Fisher) and were at least 
80 ng/ml. 
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A3.9.7 Plasmid maps 
Plasmid maps are shown in Figure 15. The split Renilla fusion plasmids were constructed 
using NanoBiT ® PPI MCS Starter system vectors (Promega, UK) which allowed the 
Tmem203 and Sting genes in the entry clones to recombine into the multiple cloning sites by 
LR Recombinase reaction (Invitrogen), creating either the N terminal or C terminal fusion of 
LgBiT (2.1) or SmBiT (1.1). The plasmids were selected on 100 µg / ml Ampicillin according 
to the manufacturer’s protocol.  
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Figure A10. Circular map for (A) pENTR/D-TOPO1 clone and (B) Venus and Yellow 
fluorescence protein fusion Gateway Destination clones.  
Desired genes such as Tmem203 and Sting are cloned from pENTR/D vectors into the 
pENTR/D insertion site in the Gateway Destination vector.  
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A3.10 Protein complementation assay (PCA) 
 
A3.10.1 Split Venus fluorescence system 
Venus protein is a derivative of Green Fluorescent Protein (GFP) with enhanced 
fluorescence. The Venus is split into a large part V1 and a small part V2. Each tag was 
expressed in the Gateway Destination vectors which are clones with the desirable 
genes to create fusion proteins. For Venus-reporter PCA, HEK293 T cells were plated 
and transfected with the indicated methods described in Appendix 3.6.3. Cells were 
transfected with the recommended amount of a single plasmid per well, or half amount 
of each plasmid for co-transfections. A single transfection of V1 fusion protein was 
used as control transfection. 18 - 24 h post transfection, cells were washed with 1x 
PBS before further treatment.  
 
Flow cytometry was performed to identify Venus fluorescence-positive cell population. 
Post treatment, HEK293 cells were gently and thoroughly washed with PBS and 
detached by resuspending in 0.5 ml FACS buffer (5% (v/v) FBS in PBS). Samples 
were maintained on ice until process. Samples were run on a bivariate forward (FSC) 
vs. side (SSC) scatterplot using BDTM LSRII Flow Cytometer (BD Bioscience). After 
identifying the major cell population, 2 µl of the nuclear dye TO PRO-3 (0.2mM, Red 
660nm laser, Thermo Fisher) was added to 0.5 ml cells to identify cell death (TO PRO-
3 positivity). Blue 530nm laser was used to excite Venus fluorescence expressed in 
cells. Successful interaction between proteins would result in the formation of GFP 
signal from V1 and V2 tags, and should result in a positive shift of GFP signal in the 
histogram. 10,000 cell events were recorded for each sample. Geometric mean for the 
histogram of GFP expression was used to determine signal strength. 
 
Venus PCA transfected into HeLa cells for imaging Tmem203-Sting localisation on 
intracellular organelles were transfected as described in Appendix 2.6.4, and the 
images were acquired and analysed by confocal microscopy as described below 
(Appendix 3.11.2). 
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A3.10.2 Split Renilla luciferase reporter system 
Renilla signal is split into a large part named 2.1 and a small part named 1.1. For split 
Renilla-reporter PCA, HEK293 T cells were seeded at a density of 25,000 cells per 
100 µl in 96 well plates the day before transfection to allow attachment. Cells were 
transfected with a total of 100 ng of plasmid DNA per well, or 50ng each for co-
transfections using PolyFECT transfection method as described in Appendix 3.6.3. 
Empty vector Nano-BIT was used as negative control plasmid. 2.1 N RelA and 1.1 C 
IκBα was transfected as positive control. Cells were used in experiments 18 - 24 h 
post transfection.  
 
To assess protein interaction from Renilla PCA, old medium was aspirated from the 
cell culture and the plate was washed with 50 µl of PBS. Each well was detached by 
resuspension in 50 µl of colourless sterile trypsin-EDTA (0.25% in PBS) and were 
transferred to a non-transparent white 96 well plate. Plate was sealed and centrifuged 
at 1000 rpm for 3 mins, and PBS was replaced with 50 µl colourless DMEM (10% HI-
FBS) to attach cells to the bottom. To measure Renilla activity, 25 µl of Renilla 
substrate mixture (1:19 Substrate to buffer ratio as suggested by Nano-Glo live assay 
system, Promega) was added to each well with 5 mins incubation at 37℃ prior to 
stimulation and luciferase assessment. Renilla-catalysed substrate breakdown and 
luminescence was measured by 37℃ -controlled Varioskan plate reader (Thermo 
Fisher, version: 4.00.53) in the absence of ligands and were measured repeatedly with 
stimulations at the indicated times. DMXAA and 2’-3’cGAMP were added in 5 µl 
volume per well to achieve the total concentration of 50 µg/ml and 10 µg/ml, 
respectively. Interaction between 2.1 N RelA and 1.1 C IκBα was measured at the time 
points to indicate the rate of signal deterioration. By the end, cells were stained with 
Hoechst 33342 (0.002 nM) for 5 min to indicate cell numbers, which is used for Renilla 
normalisation. Measurement lasts a maximum of 30 mins to prevent extensive cell 
death.  
 
To calculate Renilla luciferase activity of each well: 
Renilla luciferase activity =  
(luminescence of treatment − luminescence of NanoBIT)
(Hoechst of treatment − Hoechst of unstained cells)
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A3.11 Fluorescent microscopy 
 
A3.11.1 Fluorescent imaging for human macrophages 
To determine green indicator siGlo transfection efficiency into human primary 
monocyte-derived macrophages (MDM), macrophages were transfected with the 
indicated amount of siGlo (Dharmacon, GE Healthcare) using Viromer Green 
transfection reagent as instructed by the manufacturer (Lipocalyx). 48 hours post 
transfection, culture medium was aspirated and replaced with warm colourless RPMI 
(1% PS and 10% LE-FBS). MDMs were imaged using a Leica AF6000 time lapse 
fluorescent microscope with 37℃ temperature control. 
 
To identify macrophage marker CD68 expression, primary monocytes were seeded in 
8 well chamber slides at a density of 200,000 cells per 400μl RPMI-1640 (1% PS and 
10% LE-FBS) and differentiated into macrophages with 100 ng/ml human recombinant 
M-CSF as described previously. Differentiated MDMs were washed twice with PBS 
and fixed with 4% formalin for 30 mins at 37℃. Cells were again washed three times 
with PBS and permeabilised with 0.1% Triton x100 in PBS for 15 mins. Cells were 
washed five times with 1x PBS to thoroughly remove Triton, and then blocked with 2% 
BSA-PBS for 45 mins at room temperature. After blocking, macrophages were 
changed into 1% BSA-PBS mixed with either 2 μg/ml primary mouse anti-CD68 (Dako) 
for specific binding, or 2 μg/ml anti-CD68 isotype (Dako) for non-specific binding 
control, or 1% BSA-PBS only for secondary antibody only control. Macrophages were 
incubated at 4℃ overnight. On the next day, cells were washed 3 times with PBS and 
incubated with 2 μg/ml goat anti-mouse secondary antibodies in 1% BSA-PBS for 1 h 
at room temperature. Macrophages were washed five times with PBS, mounted with 
vector shield containing DAPI, and dried at room temperature in dark for at least 30 
mins before imaging. Samples were imaged under Leica AF6000 time lapse 
fluorescent microscope. 
 
Images of each experiment were acquired at the indicated and consistent 
magnification, light exposure, gain and intensity. 
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A3.11.2 Imaging for protein complementation assay 
For organelle staining, HeLa cells were plated into glass-bottom petri dish and 
transfected with plasmids as stated in Appendix 3.6.4. Post transfection, cells were 
washed three times with PBS and incubated with either CytoPainter ER staining kit – 
red fluorescence (Abcam) or CytoPainter Lysosomal staining kit – red fluorescence 
(Abcam) for 10 min at 1:5 and 1:3 dilutions (with 1x PBS), respectively. Cells were 
then washed three times with PBS and recovered at 37℃ for 30 mins in warm 
colourless DMEM (1% PS and 10% HI-FBS). Control cells were maintained in warm 
colourless DMEM until imaging. Cells were then imaged with confocal microscopy on 
a Zeiss LSM 510 META with 40X inverted water-lens (Molecular Probes) with 30℃ 
temperature control. Both ER and lysosomal staining were excited at light wavelength 
of 565/615 nm, and Venus fluorescence obtained from Tmem203-Sting interaction 
PCA expression was excited at 500/520 nm. 
 
To image Tmem203-Sting localisation on the ER and lysosomes, HeLa cells were 
attached, transfected with plasmids, and stained with organelle dyes as described in 
Appendix 3.6.4 and 3.10.1. HeLa cells were imaged with confocal microscopy on a 
Zeiss LSM 510 META with 40X inverted water-lens (Molecular Probes) with 30℃ 
temperature control. A tilescan of GFP signal (Venus reconstitution) was produced for 
each sample so that 12 to 15 areas could be selected for better analysis (a 
demonstration of a tilescan is shown in Figure 16). Fifteen images were captured per 
sample and two independent experiments were carried for each condition. Images 
were analysed with Fiji_ImageJ [331]. Individual cells were analysed as shown in 
Figure 17. 
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Figure A11. Area selection for confocal microscopy of split Venus protein 
complementation assay of Sting - Tmem203 interaction.  
Glass-bottom culture dish with HeLa cells was scaned under a Zeiss confocal microscope. A 
5x5 area was selected for tilescan to produce a map of cells with weak but clear GFP signal. 
Transmission light phase was omitted to avoid fluorescence bleaching for later steps. Little 
and non-specific GFP signal shown in a. demonstrates a negative V1_Sting single transfection 
whereas positive GFP generated from V1_Sting and V2_Tmem203 interaction was shown in 
b. To prevent bias of result interpretation, 12 – 15 non-overlaping areas per dish were selected 
to be analysed in higher magnifications and resolutions, such as in c. Each selection area 
provides a view of 10-20 HeLa cells (although some were on the edge of view) which were 
captured for image analysis as shown in Figure 17. Scale bar is 100 µm.  
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Figure A12. Demonstration of imaging analysis using Fiji.  
① After acquiring images, the transmission (Cell), green (Tmem203-Sting), red (Lysosome) 
and the merged images were created. Convert the green and red channels to Black/White for 
analysis. ② Calculate the common (Both) pixels of the green and red channels. ③ Analyse 
cells individually. Select the region of interest (ROI) around the boundary of green 
fluorescence (Tmem203-Sting co-expression) of a cell and add the selection to ROI manager. 
④ Calculate the number of pixels for each channel and the Both pixels in the ROI. ⑤ 
Calculate the ratio of Tmem203-Sting expression on the lysosome (Both)) over the detection 
of lysosome to obtain the percentage of lysosomal expression of Tmem203-Sting. Only the 
whole-bodied cells were analysed to avoid generation of false-positive results and over-
calculation. 
